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ABSTRACT 
 
Updating the Rulebook: Sustainable Methods for the Construction and Functionalization of 
Small Molecules Utilizing Micellar Catalysis 
by 
 
Christopher Michael Gabriel 
 
Over the past two centuries, the field of organic chemistry has expanded to facilitate 
transformations for the synthesis of complex molecular scaffolds of increasing variability. 
With these advancements, however, the dependence on organic solvents as reaction medium 
remains. This research describes a general alternative to organic solvents by employing the 
designer surfactant, TPGS-750-M, under aqueous conditions, which spontaneously 
assembles to form micellar aggregates (nanoreactors) providing conditions under which 
organic transformations favorably take place. Key features of this technology include: low 
reaction temperatures, the ability to recycle the reaction medium (and often the catalyst), as 
well as low production of organic waste as quantified by Sheldon’s E Factors. 
Under micellar catalysis conditions it was discovered that nanoparticle-catalyzed 
reactions are especially well suited to take place including the Z-selective semi-reductions of 
alkynes as well as nitro-group reductions that take place at room temperature with 
exceptional yields and selectivity. Both systems undergo reduction by the use of borohydride 
salts as the hydride source allowing these procedures to take place under ambient conditions. 
An environmentally responsible method for amide and peptide bond synthesis is also 
described, not only replacing egregious organic solvents such as DCM and DMF, but also 
  xi 
eliminating the need for explosive HOBt by incorporation of an oxime activator, Oxyma, in 
the form of uronium coupling reagent COMU. 
Furthermore, as an ultimate goal of this chemistry is to minimize potential waste on 
scale, procedural modifications are described by the incorporation of minimal co-solvents 
for a survey of reaction types. These modifications investigated impact on reaction yield, 
rate, and physical aspects of a reaction mixture such that technology developed in lab can 
reach its highest potential when considered on an industrial scale.  
  1 
I. Going Green 
1.1 Micellar Catalysis  
“Going Green” has become such a common idea in the past few decades that it is now 
somewhat of a cliché. Global warming is now appreciated and accepted in the scientific 
community as it graduates from its status as a theory into the role of unstoppable force. The 
more that we understand about climate change the more we humans begin to recognize our 
impact. It is no hidden fact that current atmospheric levels of CO2 are astronomically higher 
than levels prior to the industrial revolution. The impact of CFC’s on the ozone layer is yet 
another instance of how efficiently humans are destroying the environment. Government 
intervention on our ability to pollute and produce waste is surprisingly minimal as many of 
those in seats of high power still refuse to submit to the overwhelming amount of data that 
suggests that a major change is needed to take place in order for the earth to continue as a 
beautiful and habitable planet. It is then up to us, the citizens of the world to make the 
change.  
One area specifically which requires change is that of molecular synthesis. In the 21st 
century, western medicine is trusted, proven, and expected often in the form of prescription 
or over-the-counter pharmaceuticals. The major feedstock of the hydrocarbon based or 
“organic” active pharmaceutical ingredients (API) is crude oil. The past two centuries have 
led to discoveries and developments for the purification of chemical species from crude oil 
from which biologically important molecular scaffolds can be constructed. It is not simply 
the chemical entity which is generally constructed from this non-renewable feedstock, but 
also the organic solvents which are usually required for their synthesis. After one use of an 
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organic solvent in a chemical process, the waste is incinerated, further depleting our 
resources and generating pollution in the atmosphere. The alarming dependence of western 
culture on crude oil seems impossible to overcome, however by recognizing outlets for 
hampering the use of the diminishing resources, we can prolong the lifetime of the Earth’s 
supply while slowing the rate at which waste is produced.  
Several advances have been made in the area of sustainable or “Green Chemistry,” such 
as the use of biomass derived feedstocks often by the conversion of carbohydrates into 
higher value fine chemicals.1 This is a significant step in the right direction, however 
minimal effort has been made to replace organic solvents with a renewable or even 
recyclable feedstock. While the use of “green solvents” such as ethanol, isopropanol, acetic 
acid, ethyl acetate, and 2-methyltetrahydrofuran serve as valuable alternatives to traditional 
organic solvents,2 their virtues are more greatly attributed to the associated cost, handling, 
and disposal; yet rarely are these solvents recycled. Water as a solvent for organic 
transformations is commonly disregarded due to its highly polar nature and inability to 
dissolve reaction components, yet is frequently employed as a means to enrich products upon 
reaction completion by the removal of polar reagents or by-products. In terms of feedstock, 
water is a renewable resource which is available in amounts larger than what would ever be 
required. It literally falls from the sky. Water is also clearly safer from the user’s perspective 
in comparison to even the safest organic solvents such as ethanol in that it is non-flammable 
and completely non-toxic.  
Until recently, the use of water as a solvent has generally been utilized either as a 
biphasic mixture with organic solvent or in the presence of a phase transfer catalyst with 
very few methods using water alone for “on-water” reactions.3 Surfactants provide a non-
canonical approach to utilize water as a solvent by solubilizing reaction components by 
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means of micellar aggregates. This technology has been used widely for solubilizing organic 
material in water for thousands of years and is most easily recognized in our daily lives in 
the form of soap, however is sparingly used in the arena of organic chemistry.4  
In 2008, the use of nonionic tocopherol based surfactant PTS-6005 was exploited for the 
first time for the use in olefin-cross metathesis in water (Figure 1).6 This methodology was 
the seminal publication from our group for synthesis by means of micellar catalysis by the 
use of a benign-by-design surfactant yielding exceptional results for neutral organic reactants 
in the absence of organic solvent at room temperature. Since the initial disclosure of this 
work, the scope of aqueous micellar catalysis utilizing PTS-600 has expanded to a large 
array of transformations including: ring-closing-metathesis, transition metal cross-couplings 
(ie. Heck,6 Suzuki-Miyaura,7 Miyuara Borylations,9 Sonogashira,10 Buchwald-Hartwig,11 
Negishi,12 and C-H activation.13 These works later gave rise to surfactants as a catalyst 
support within the lipophilic region of ubiquinol based designer surfactant PQS effecting 
Ru-catalyzed cross/ring-closing-metatheses,14 Rh-catalyzed asymmetric 1,4-additions,15 as 
well as organocatalysis.16 Modifications to PTS-600 were later made by shortening the 
diester chain, extending the PEG portion, and capping the PEG chain with a methyl group 
leading to the development of the next generation surfactant TPGS-750-M.17 This surfactant 
was found to outperform PTS-600 for a variety of transformations on the basis of product 
yield which is proposed to be the consequence of the increased particle size of the micelle 
(PTS-600 = 24 nm; TPGS-750-M = 53 nm). Since the advent of TPGS-750-M, our group 
has utilized this surfactant as a staple for developing sustainable methods under micellar 
catalysis conditions, expanding the scope of transformations to include reductions,18 
oxidations,19 nucleophilic aromatic substitutions,20 and nanoparticle catalyzed 
processes.18c,g,h,21,22 Additionally, our library of benign surfactants has been extended to 
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include newly developed “Nok” based on a β-sitosterol core, parrellaleing the applications of 
TPGS-750-M, but from a more renewable feedstock.23 
 
 
 
Figure 1. Lipshutz Group designer surfactants. 
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The use of aqueous micellar catalysis for the synthesis and functionalization of organic 
scaffolds is the focus of the work presented within this dissertation. The use of this 
technology extends past the ability to utilize water as the gross reaction medium, by 
considering the amount of waste generated by these methods measuring Sheldon’s E 
Factor24 in comparison to traditional methods in organic solvent, as well as leveraging the 
aqueous nature of the reaction mixture for in-flask work-ups and recycling capabilities. My 
work specifically has been focused on “updating” traditional methods, some older than a 
century, where classical procedures have unmet environmental concerns especially on the 
basis of solvent usage, waste generated, recyclability, and safety. Some of the methods 
include: the Z-selective semi-reduction of alkynes (Chapter II), amide and peptide bond 
formation (Chapter III), reduction of nitroarenes (Chapter V) and the Fisher indole 
Ssynthesis (Chapter VI), all taking place under aqueous micellar catalysis conditions. While 
it may be convenient to view these methods as a simple solvent switch, many additional 
parameters must be considered in an aqueous environment and experience in these 
techniques has led to significant advancements in the field by considering the influence of 
salts,18a,c pH,25 and miscibility18h,26 on reaction yields and selectivity; all concepts which are 
presented within this work (vide infra).   
Furthermore, it should be noted that while my efforts in the field of organic synthesis 
have been highly focused on developing methods in aqueous media, the theme of 
constructing methodologies that have minimal environmental impact as the highest priority 
has impacted my outlook on organic synthesis as a whole beyond the scope of 
transformations in water. Much of what is done in our labs which may be termed “Green 
Chemistry” translates in industrial processes as good process chemistry. What is meant by 
this is that these are considerations which need to be commonplace in organic synthesis by 
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looking closely at safety, reagent availability, ease of preparation and purification, waste 
generation, and cost; many of parameters highlighted as the “12 Principles of Green 
Chemistry.” These themes are presented herein for projects that I have either led18h,25,26 or 
collaborated on.18c 
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II. Stereoselective Semi-Reduction of Alkynes in Water at Room 
Temperature 
2.1 Introduction 
Stereo-defined alkenes represent a functionality found ubiquitously in synthesis both in 
terms of target molecules such as drugs and natural products (Figure 1) as well as versatile 
intermediates in organic synthesis. The geometry of an alkene not only influences the 
properties of a molecule but can also greatly influence molecular geometry in further 
transformations.1 Access to stereo-defined alkenes has long been an area of intense research 
and while many methods exist for the synthesis of E-alkenes, the less thermodynamically 
favorable Z-alkene remains a challenge to this day.2,3 In addition to the relative 
thermodynamic stability of E-alkenes over Z-alkenes, challenges for this transformation are 
met on the basis of generality, harsh reaction conditions, chemo-selectivity, and waste 
generation.  
  9 
 
 
 
Figure 1. Representative examples of important drugs and natural products containing 
stereo-defined alkenes. 
 
Z-Alkenes can be accessed by a number of ways with the most common strategies 
including: 1) Wittig olefination,4 2) olefin metathesis,5 3) cross coupling,6 and 4) semi-
reduction of alkynes.2,7-15 This chapter focuses on the development of methodology for the 
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semi-reduction of alkynes, but it is certainly well placed to note other important milestones 
for this synthesis of this important moiety. 
First reported in 1954,4 the Wittig olefination is still used as a powerful method for 
accessing Z-olefins. The installation of the olefin goes by means of substitution of a 
phosphine ylide onto an aldehyde often affording high selectivity for the Z-geometry as the 
result of the steric bulk of the phosphine group. The phosphine ylide is often generated from 
the corresponding triaryl- or trialkylphosphine and an alkyl halide with subsequent 
deprotonation under basic conditions. This transformation is highly regarded by the synthetic 
community with Georg Wittig receiving the Nobel Prize for his work in 1979. Furthermore, 
the Wittig olefination has been used extensively for the synthesis of natural products 
including Petrosiol E,16 Cermizine D,17 (−)-Maoecrystal V,18 and Palhinine A & D.19 An 
excellent example of how this transformation has been leveraged is represented by the 
synthesis of (+)-discodermolide by Smith and coworkers (Scheme 1).20 
 
 
 
Scheme 1. Wittig reaction en route to (+)-discodermolide. 
 
Mechanistically similar to the Wittig olefination is the Horner Wadsworth Emmons 
olefination (HWE) which generally affords the E-geometry from aldehydes.21 In comparison 
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to the Wittig olefination, electron deficient alkyl phosphonate esters are used in place of the 
triaryl- or trialkylphosphonium ylides, selectively favoring the thermodynamic E-olefin. Still 
and Gennari modified this procedure by the use of bis(trifluoroalkyl)phosphonoesters and 
trifluoroethanol favoring the Z-olefin with high selectivity.22  The Still-Gennari modification 
of the HWE olefination gives rise to α,β-unsaturated ketones, esters, and cyanides, and has 
been used in the total synthesis of spinosyn A by Roush and coworkers. (Scheme 2).23 
 
 
Scheme 2. Use of the Still-Gennari modification of the HWE olefination en route to 
spinosyn A. 
 
Tremendous synthetic advancements have been made for Z-selective olefin methathesis 
as well. This transformation is not generally sought after as products from cross-metathesis 
often lead to the E-isomer and the Z-geometry usually only occurs for ring closing 
metathesis (RCM) because the E-olefinic product would cause too much strain for small 
sized rings. One of the first reports of Z-alkenes via olefin metathesis was exemplified by 
means of ring opening cross-metathesis (ROCM) from a cyclobutene substrate, showing 
only moderate selectivity as the result of minimizing steric interaction between the substrate 
and the ligands of Grubbs’ first generation catalyst.24 Another report with much higher 
selectivities utilized Hoveyda-Grubbs second generation catalyst and a related pyridine 
coordinated analogue offered selectivities up to Z:E = 96:4 when cross methathesis was 
carried out on enyne substrates.25 This example was particularly interesting, showing 
orthogonality to alkyne substrates which would be reduced under semi-reduction conditions.  
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Mo and W have also been proven to offer selective access to Z-alkenes.26,27 An early 
example was reported by Crowe and coworkers for Mo-catalyzed cross metathesis of 
acrylonitriles with Shrock catalyst, however selectivities were moderate with in the best case 
achieving Z:E = 9:1.26a  Much better selectivities (Z:E > 98:2) have been reported with Mo-
MAP for ROCM where the catalyst possesses a highly bulky biaryl framework which was 
proposed to effect stereo-retention of cyclic alkenes to Z-defined styrenes.26b This same 
catalyst has been shown to deliver exceptional Z-selectivity for the cross-metathesis of vinyl 
ethers and was used as a key step in the synthesis of plasmalogen C16:0.26c A similar 
example was reported for the highly Z-selective (Z:E > 98:2) ring-opening metathesis 
polymerization (ROMP) to afford polymers bearing a cis-syndiotactic configuration from 
substituted bicyclo[2.2.1]hepta-2,5-dienes which was catalyzed by a Mo complex containing 
the bulky hexaisopropyltriphenoxide (HIPTO) ligand.26d Catalysts of W bearing many 
similarities to their Mo counterparts have also been shown to afford Z-alkenes selectively, 
where W-MAP catalyzed cross-metathesis yields the homo-coupled product with Z:E > 
98:2.27a W catalysts bearing the HIPTO ligand have also shown success producing Z-alkenes 
by cross metathesis with vinylic alcohols and sulfonamides to afford homo-coupled products 
with reasonable selectivities (Z:E = 91:9).27b 
Cross-coupling offers the advantage of retaining stereochemistry from the partner 
undergoing the coupling event, however Z-selectivity of a prior functionalization step is 
required. An excellent example of the utility of this reaction is the total synthesis of 
oximidine II by Molander and coworkers.28  In this report, Pd-catalyzed Suzuki-Miyaura 
(SM) cross coupling was used as the ring closing step from an E-configured alkene bearing 
BF3K, which was coupled with a Z-alkene with a terminal bromide. This example shows the 
applicability of this reaction to both alkene configurations maintaing stereo-chemistry. A 
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more recent report by the Trost group described the total synthesis of Leustroducsin B where 
a Hiyama cross coupling event was used to access a Z,Z-diene.29 In 2012, our group 
investigated SM couplings from various vinyl halides, unveiling a direct correlation between 
stereo-retention and catalyst structure.30 It was found that Pd(PtBu3)2 and PdCl2(AmPhos)2 
led to significant, and in some cases near complete, isomerization to afford the undesired E-
styrene product while catalysts such as Pd(P(o-Tol)3)2 and PdCl2(PPh3)2 afforded Z-styrenyl 
products with high stereo-retention up to Z:E = 99:1 in many cases.  
One of the most common methods for accessing Z-alkenes is by the semi-reduction of 
alkynes.2 A widely utilized system for the partial hydrogenation of alkynes is the Lindlar 
reduction. First introduced in the early 1950’s, the Lindlar reduction remains as the 
fundamental approach presented in organic chemistry textbooks for this transformation.31 
Though Lindlar’s catalyst comes in many forms, this type of heterogeneous catalysis stems 
from the use of supported Pd(0), typically on BaSO4 or CaCO3 with variable amounts of 
other additives such as Pb(OAc)2. Quinoline is often used to “poison” the catalyst in order to 
achieve higher Z-olefin selectivities and suppress over-reduction. In addition, a sacrificial 
oxidant such as cyclohexene may be used and may be reduced in place of the desired alkene 
product to further suppress over-reduction.32  The use of such “deactivators”, “poisons”, and 
“sacrificial oxidants” is crucial for this catalyst as alkene isomerization to the more 
thermodynamically more stable E-olefin may readily occur, along with reduction of either 
configuration of the product olefin to the corresponding alkane. Furthermore, additive 
stoichiometry optimization is commonplace depending on the nature of the alkyne and 
careful reaction progress monitoring (by either H2 consumption or reaction conversion) are 
critical for a high yielding and selective transformation. An impressive example of how the 
Lindlar reduction can be exploited is represented by the total synthesis of (-)-Laulimalide by 
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Ghosh and coworkers where the semi-hydrogenation was employed late-stage following a 
Yamaguchi macrolactonization (Scheme 3).33 Due to the many challenges that may arise 
when optimizing conditions to a specific substrate, the Lindlar reduction lacks generality, 
both in terms of alkyne type and functional tolerance, and reaction monitoring is 
operationally tedious.  
 
 
Scheme 3. Use of the Lindlar reduction en route to (-)-Laulimalide. 
 
Another system which is similar in nature to the developed method to be presented in 
this chapter is use of P2-Ni (Brown’s Catalyst), developed during World War II.34 The 
heterogenous nickel-boride catalyst synthesized from Ni(OAc)2.4H2O and NaBH4 in EtOH. 
The catalyst has been used as an alternative to Lindlar’s catalyst as net semi-reduction occurs 
via a hydrogenation pathway. Selectivity improves by the use of ethylenediamine (eda) as an 
additive.35 This system benefits from its functional group compatibility, tolerating alkenes, 
amides, acetals, oxazoles, benzyl ethers, silyl ethers, and free hydroxyl groups.2 While this 
classical system shows many advantages even over some of the more recent 
communications, drawbacks include the requirement for H2 as reductant and instability of 
the catalyst (very sensitive to oxygen), requiring synthesis of P2-Ni immediately before 
alkyne reduction.  
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To circumvent many of the associated drawbacks with semi-hydrogenation either by 
Lindlar’s catalyst and related platanoid supported catalyst systems under hydrogenation 
conditions, much focus has been geared toward effecting the partial reduction via hydride 
transfer.2 This approach takes advantage of stoichiometric control by solid or liquid hydride 
sources as opposed to H2. In addition, highly pressurized systems are not required for this 
approach in most cases often lending these procedures as safer and operationally simpler 
alternatives. While many examples of alkyne semi-reduction to Z-alkenes exist in the 
literature, this section will focus mainly on examples that relate to the scope of this chapter.  
The first known report of homogeneous catalytic hydride transfer for the reduction of 
alkynes was reported in 1989 by Trost and coworkers.36 The conditions employed 
Pd2dba3.CHCl3 and P(o-Tol)3 with acetic acid and TMHDS as the cooperative hydride 
source. While only poor selectivity was achieved, with the best reported selectivity being 
Z:E = 2.6:1 this work set the stage for an entire field of chemistry. Notable features of these 
conditions are the relatively short reaction times (1 to 20 minutes) and compatibility with 
substrates bearing alkenes, nitro groups, and esters. This method was later used by the same 
group for the total synthesis of (−)-Ushikulide A, where good selectivity of the Z-enone was 
achieved (Z:E >20:1) from the corresponding ynone in the presence of an alkene, silyl ether, 
and a PMB ether (Scheme 4).37  This same reduction was attempted under Lindlar’s 
conditions however, the spectator alkene was completely reduced. 
 
 
Scheme 4. Trost’s selective Pd-catalyzed hydride transfer en route to (−)-Ushikulide A. 
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In a later communication by Sato and coworkers, milder conditions were employed for 
the highly Z-selective Pd-catalyzed semi reduction of alkenes via hydride transfer from 
HCO2H-Et3N.38  In this report, the more bulk and electron rich ligand P(tBu)3 was used with 
Pd2dba3.CHCl3 to afford selectivities as high as Z:E = 98:2 for several examples. Functional 
compatibility was shown for substrates bearing esters, free alcohols, silyl ethers, and PMB 
ethers, however extended reaction times favor isomerization to the undesired E-alkene. 
Another important example of hydride transfer via Pd(0) catalysis was reported by 
Elsevier and coworkers which showed an intriguing correlation between solvent and 
selectivity.39 The catalyst for this system relies on Pd(IMes)(MA) which is generated in situ 
from Pd(tBuDAB)(MA), 1,3-bis(mesityl)imidazolium chloride, and potassium t-butoxide. 
Excellent selectivity for the Z-alkene as achieved in many cases (up to Z:E = 98:2) when the 
reaction was conducted in MeCN, however a complete selectivity switch was observed for 
some aliphatic alkynes when THF was used as solvent. Mechanistic studies showed that 
coordination of MeCN to the active Pd catalyst liberates the Z-alkene, preventing 
isomerization and over reduction for many electron rich systems. This method is limited by 
the poor functional group compatibility, although ketones and esters survive these 
conditions. Interestingly, Wu and coworkers noticed a pronounced decrease in selectivity 
when MeOH was used in place of THF for the reduction of various phenylacetylene 
derivatives under conditions employing Pd(OAc)2 and NaOMe.40 
One of the more impressive systems for this transformation was the work reported by 
Shen et. al which describes a hydride transfer system which could be tuned to effect high 
selectivity  for both Z and E isomers as well as the fully saturated alkane product (Scheme 
5).41 The scope of this methodology seemed to be limited to the synthesis of various styrene 
analogues, however several functional groups were tolerated including boronic esters, 
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pyridine, esters, aryl halides, nitroarenes, and benzyl ethers. The key to selectivity in this 
case was the use of Pd2dba3/dppb with formic acid either under anhydrous conditions to 
afford the Z-alkene or in the presence of water to selectively afford the E-isomer, while the 
fully saturated product was acquired from a ligand switch to PCy3. The change in selectivity 
was proposed to be due to isomerization of the alkenylpallaladium species prior to 
decarboxylation and subsequent reductive elimination, however the role of water was not 
mentioned (Scheme 6). The increased reducing abilities of the system incorporating PCy3 as 
ligand was explained on the basis of this catalysts poor ability to facilitate β-hydride 
elimination, thus allowing further a decarboxylation/hydride insertion sequence to take place 
readily prior to reductive elimination. This work was an excellent example of the capabilities 
of heterogeneous Pd catalysis for hydride transfer, yet some notable drawbacks of this 
system are the requirement of high temperatures in 1,4-dioxane which is a highly toxic 
solvent.42 
 
 
Scheme 5. Effects of water and ligand on reduction selectivity. 
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Scheme 6. Mechanism described by Shen et. al. 
 
With the impressive developments made in this field it seems that selectivity is so highly 
regarded as an important objective, that the use of high temperatures and egregious solvents 
is not taken into consideration. While selectivity is of utmost importance for developing 
suitable conditions for the synthesis of Z-alkenes, other parameters are certainly worth 
exploring especially on the basis of sustainability. One of the premier factors that would 
constitute a method as environmentally responsible is the amount and nature of waste 
generated for a given process. So the question is, how green are these methods? It is no 
question that waste generation by the use of stoichiometric reagents would generate at least 
stoichiometric waste as is the case with olefination via the Wittig and HWE reactions. In 
fact, the waste generated by these reactions is comparable to some of the catalytic methods, 
due to the lack of recyclability of the organic solvents and the catalysts being employed. As 
mentioned previously, many of these transformations require some of the more dangerous 
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solvents such as MeCN and 1,4-dioxane. Not only are these solvents toxic,42  but their high 
miscibility in water requires more complicated work up procedures for the isolation of 
products. Also, many of these procedures require temperatures well outside of room 
temperature which requires additional energy, where HWE reactions require cooling, many 
of the hydride transfer chemistries require high temperatures. Furthermore, hydrogenation in 
many cases requires high pressures of flammable H2 which is certainly a concern in terms of 
safety and operational simplicity. It seems then, that in order to meet many of the criteria 
which defines a sustainable process, many of these tremendous advancements have 
fundamental limitations.  
From the perspective of green chemisty, these drawbacks can be addressed by first 
installing parameters for the method followed by the development of the chemistry itself. 
That is, the reaction should take place using benign solvents, offer the potential for 
recyclability, reduce waste, minimize energy (in the form of heating and cooling), and with 
operationally simplicity and safety.43 
2.2 Previous Work 
In order to address many of the environmental concerns associated with current alkyne 
semi-reduction methods, the parameters were set in place that a general and highly selective 
procedure would utilize aqueous micellar catalysis at room temperature. Our efforts towards 
the goal of developing such a method came serendipitously, however, with the initial focus 
on delivering a tandem process for an unrelated transformation. In fact, the early work on 
semi-reductions in the Lipshutz group was to selectively access the E-allylic phenyl ethers 
and alcohols from their corresponding propargyl precursors. The strategy was intended to 
supplement earlier work from our group, where allylic ethers and alcohols were found as 
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excellent electrophiles for Pd(0) cross coupling with boronic acids, amines, and disilanes 
(Scheme 7A).44   From this precedent, it was well understood that highest selectivity to the 
linear-brached product resulted from pure trans-disubstituted alkenes (Scheme 7B). 
Furthermore, it was found that methyl formate greatly increased the reaction rate for these 
transformations. Initial experiments towards a one-pot procedure from propargylic materials 
to allylic substitution products came by means of a modified procedure from Shen et. al 
under aqueous micellar conditions, where methyl formate was used in place of formic acid.41  
Based on these prior findings, we believed that it was feasible that high selectivity could be 
achieved for the E-alkene product based on the aqueous environment. Furthermore, both the 
reduction and substitution methods utilize the same catalyst, so it was perceived that this 
approach was certainly possible. Initial attempts at the semi-reduction gave low conversion, 
yet interestingly, when Pd(PCy3)2 was screened enrichment of the Z-isomer was observed 
(Scheme 8). In stark contrast with the method that this reduction was based on,41 the project 
shifted focus to further increasing the Z-selectivity of the semi-reduced product as very few 
methods exist for the Z-selective semi-reduction of alkynes under aqueous conditions.  
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Scheme 7. A. Allylic alcohol/phenylether cross coupling in micellar catalysis conditions;   
B. Cross coupling selectivity from stereo-defined allylic phenylethers 
 
 
 
Scheme 8. Initial discovery of Z-selective semi-reduction of alkynes. 
 
To date, very few methods for the Z-selective semi-reduction of alkynes under aqueous 
conditions exists, the most common of which is the use of activated zinc.45 Many 
preparations of activated zinc have been reported and these reductions are generally run in a 
mixture of MeOH and water. The use of this method is highlighted by its ability to reduce 
conjugated polyenes. An example of its use is represented by the synthesis of 3-
hydroxyleukotriene B4, where a conjugated alkyne underwent semi-reduction in the 
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presence of both cis and trans-disubstituted alkenes (Scheme 9).46 Some of the drawbacks of 
this method include the use of super-stoichiometric Zn as well as isomerization, over 
reduction, and polymerization with extended reaction times. In addition, use of activated Zn 
for semi-reduction is not generally compatible with substrates bearing esters, ketones, 
nitriles, alkyl halides.2,45 
 
 
Scheme 9. Active Zn-mediated Z-selective semi-reduction en route to 
3-hydroxyleukotriene B4. 
 
Furthermore, the opportunity for catalyst and solvent recycling is a rare occurrence for 
this transformation. In 2013, Mitsudome et. al reported a Pd nanocomposite catalyst that 
offered good selectivity for the reduction phenylacetylenes and simple aliphatic alkynes and 
showed that the catalyst could be recovered and reused for a subsequent reduction.47 While 
this was a step in the right direction, the only report to our knowledge where both the 
catalyst and solvent were recycled was a communication by Chandrasekhar and coworkers. 
Chandrasekhar’s work showed that PEG-400 could be used for Lindlar reductions allowing 
for catalyst and solvent reuse by extraction of the product alkene with diethyl ether. This 
work parallels some of the capabilities of the method which will soon be described (vide 
infra). As previously described, drawbacks of this method include limitations in terms of 
generality and the use of H2 as the stoichiometric reductant.  
2.3 Results and Discussion 
Initial screening consisted of an exhaustive survey of Pd sources and ligand with 1.2 
equivalents of formic acid. From these experiments it was realized that while formic 
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acid/Pd(0) system did result in enrichment of the Z-alkene, selectivity was moderate and 
conversion was poor even with extended reaction times and increased reductant loading. The 
best of these systems came from the use of ligands such as DMPP with Pd2dba3 at 5 mol % 
loading which afforded the product in only 32% conversion with Z:E = 12:1 over 40 hours 
(Scheme 10A). Further screening efforts found that NaBH4 gave much higher conversion 
and selectivity, delivering 51% conversion and Z:E = 98:2 for a system catalyzed by 
QPhosPd(allyl)Cl (5%) after 24h (Scheme 10B).  
 
 
Scheme 10. Initial optimization of Z-selective semi-reduction of phenylacetylene under 
homogeneous Pd-H transfer conditions.  
 
Over the course of further catalyst evaluation, the method was plagued once again by low 
conversion. While screening conditions, an observation was made that some of the more 
successful systems appeared to generate small amounts of Pd aggregates suggesting that this 
system may be catalyzed by Pd nanoparticles. To investigate this possibility, intentional 
generation of Pd nanoparticles from various palladium sources with NaBH4 in the absence of 
a ligand was carried out, not unlike the synthesis of Brown’s catalyst. The conditions 
screened included A: metal salt/complex under H2 atmosphere; B: hydrogenation in the 
presence of nanoparticles synthesized with five equivalents NaBH4 relative to metal; and C: 
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use of NaBH4 as the stoichiometric t reductant after first generating the nanoparticles in situ 
(procedures represented in the Experimental Section of this chapter). 
Under these conditions, quantitative conversion could be achieved for the reduction of 4-
octyne showing nearly perfect selectivity when Pd(OAc)2 and PdI2 were employed with 
NaBH4 as reductant (Table 1, entries 10 & 13), yet interestingly over-reduction to the 
corresponding alkane was observed for PdCl2 under all conditions. Other group 10 metal 
salts or complexes (e.g., NiCl2, Ni(OAc)2, Pd2(dba)3) were either inactive or led to mixtures 
of E- and Z-alkenes. Alternatively, a similar outcome can be realized using a balloon of 
hydrogen gas in place after prior reduction of Pd(OAc)2 with NaBH4 (entry 9), however 
activation of the catalyst (nanoparticle synthesis) was appear to be necessary for optimal 
conversion and selectivity. 
 
 
Table 1. Metal salt/complex screening for heterogeneous semi-reduction of 1. 
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The use of NaBH4 with the nanoparticles generated from Pd(OAc)2 then became the 
optimal system for investigation on an expanded substrate scope. This system was decided 
upon as suitable conditions to meet some of the environmental concerns associated with 
preexisting methods. Environmental and safety drawbacks associated with hydrogenation 
conditions are met by the use of sub-stoichiometric NaBH4 which provides access to a 
system in which the equivalence of H2 can easily be controlled and directed towards the 
alkyne substrate alleviating the need for excess reagent and high pressures. The catalyst is 
easily prepared by use of relatively inexpensive and readily available Pd(OAc)2 (1 mol %) 
admixed with NaBH4 (0.05 equiv) via sonication, followed by the addition of water 
containing 2 wt % TPGS-750-M. Upon stirring at ambient temperature, a black suspension 
(“black water”) is obtained (Figure 2A).  It should be noted that this catalyst suspension can 
be generated in situ or as a bulk suspension for the use over several reactions. Prepared as a 
bulk suspension, the black water shows no loss in catalytic activity over several weeks, 
however the mixture should be stirred under and atmosphere of Ar. A cryo-TEM image of 
nanoparticles generated from Pd(OAc)2 shows an interesting phenomenon, where micelles 
aggregate around the particles using the PEG chain of the surfactant as a ligand48 to bring the 
catalyst close to the reaction site and allow for uniform dispersion of the mixture. (Figure 
2B).  
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Figure 2. A. Bulk catalyst suspension in 2 wt % TPGS-750-M/H2O “Black Water”;  
B. Cryo-TEM image of nanoparticle-nanomicelle interaction. 
 
Upon investigation of the scope this method, it was soon realized that functionalized 
alkynes such as propargylic alcohols, had diminished selectivities and in fact over reduction 
of the alkyne was observed once again. It was hypothesized that the polar functionality could 
coordinate to the Pd and its close proximity to the reduced Z-alkene would facilitate further 
modifications to the product such as isomerization and reduction to the alkane. To address 
this, several salt additives were considered and it was discovered that incorporation of LiCl 
(2 equiv) led to high Z-selectivity and conversions once more (Table 2). Other lithium salts 
such as LiBr and LiOH did show some improvement over the control, while interestingly 
Li2CO3 was found to further diminish selectivity. NaCl had no effect on the outcome of the 
reaction. Since the development of this method, a similar system was developed by our 
group utilizing Pd(OAc)2 doped Fe nanoparticles to catalyze nitro group reductions in 
aqueous TPGS-750-M solution with NaBH4.49 Based on the findings presented by Table 2, 
several salts were screened concluding that KCl (1.0 equiv) improves the rate and overall 
conversion of nitro group reduction, and in fact KBH4 could be used to arrive at the same 
results (Chapter V).50 The similar findings for orthogonal transformations suggests that the 
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reactivity of NaBH4 may in fact be hampered by the use of the added LiCl leading to a 
system less prone to over-reduction. Furthermore, Guella and coworkers investigated the 
catalytic hydrolysis of NaBH4 by Pd/C, a similar system to these optimized conditions, 
which suggested Pd-BH3- species as a key intermediate in the generation of the active 
palladium hydride.51Adapting this model to our systems, it is possible that the Li+ counterion 
may be playing a significant role in effecting the hydrolysis of the palladium boride.  
 
 
Table 2. Additive screening on Black Water reduction. 
 
Attention was then brought to the effect of solvent. As our goal was to provide a system 
incorporating water as the gross reaction medium, several surfactants were screened under 
the newly optimized conditions (Table 3). It was found that the choice of TPGS-750-M as 
surfactant was critical (entries 7 & 9), while the corresponding hydrogenation “on water”52 
(i.e., in the absence of the surfactant) afforded mostly the over-reduced, saturated product 
(entry 1). In fact, replacement of TPGS-750-M with other commercially available surfactants 
led to decreased selectivity and varying amounts of over reduction were apparent in all cases. 
When our conditions were carried out in organic solvent, poor conversion resulted, yet 
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selectivity was retained, and in fact improved by the use of MeCN (entry 13). While organic 
solvents screened may not be useful under these conditions, the selectivity observed may 
explain the superior performance of TPGS-750-M. When compared to SPGS-550-M 
(“Nok”),53 TPGS-750-M is very structurally similar, with both surfactants bearing a 
methylated PEG chain linked by succinate diester to a polycyclic lipophilic scaffold, 
however the tocopherol core of TPGS-750-M contains a benzopyran (Chapter I). It is 
believed that the oxygen of this benzopyran may play a role in coordination to the catalyst, 
similar to the results reported by Elsevier and coworkers where coordination of MeCN was 
shown to greatly influence Z-selectivity.39 
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Table 3. Surfactant and organic solvent screening for the semi-reduction of 4. 
 
With the optimized conditions in hand, the scope of this transformation was examined 
for various alkynes including unsymmetrically disubstituted, terminal, and conjugated 
systems (Figure 4). Additional examples of propargylic and homopropargylic alcohols and 
their ester derivatives led to excellent Z-selectivity under the general conditions (entries 1-5), 
as did the corresponding acetal (entry 6). A conjugated aryl alkyl alkyne (entry 7) afforded 
the corresponding styrenyl array with Z:E = 95:5 showing applicability to substrates bearing 
anilines. As expected, free hydroxyl groups (entries 1, 4, 5, & 15) afforded quantitative 
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conversion in most cases, with exceptional selectivity. A major highlight of these conditions 
is the ability to obtain Z-α,β-unsaturated esters, a major limitation of many semi-reduction 
methods.2 Interestingly, a ketone (entry 10) and an epoxide (entry 11) survived the 
conditions, affording high conversions without effecting these sensitive functionalities. 
However, the ketone was reduced in the absence of Pd. Terminal cases (entries 12-15) 
reacted to afford the targeted mono-substituted alkenes without over reduction, yet some 
reduction of the olefin in an acrylate was observed leading to the drop in yield (entry 12). 
Even under these basic conditions stereo-defined α-amino acids such as proline and alanine 
derivatives (entries 13, 14) showed no epimerization. Benzyl ethers and N-Cbz groups 
remained fully intact, which are generally not suitable under standard Pd(0) catalyzed 
hydrogenation conditions such as Pd/C.54 A representative TMS-acetylene showed 
absolutely no conversion under these conditions which could be used as a protection strategy 
for terminal alkynes in the presence of an alkyne undergoing semi-reduction (entry 16). In all 
cases, reductions were complete within 45 minutes. 
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Figure 4. Representative example of Z-selective semi-reduction in Black Water. 
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As mentioned previously, one parameter of the system that was sought after when 
developing this method was the potential for recycling the catalyst and aqueous solvent. 
Upon reaction completion, an in-flask extraction may be used for isolation of the alkene 
product. The choices of extraction solvent are those of low polarity such as hydrocarbons 
(e.g., hexanes) or ethereal solvents (Et2O or MTBE). The use of these solvents is preferred 
over  EtOAc, as leaching of the Pd into the organic phase is observed, thus removing 
recyclable catalyst from the reaction mixture and complicating subsequent purification. The 
partition between MTBE and the active catalyst mixture is shown in Figure 5. TPGS-750-M 
is essentially insoluble in all extraction solvents described, including EtOAc.  
 
 
Figure 5. Extraction of product with MTBE from Black Water. 
 
After isolation of the crude product via extraction, the remaining water, surfactant, LiCl, 
and palladium catalyst can be reused for subsequent reactions with the addition of fresh 
NaBH4 (0.5 equiv) and substrate. The catalyst was found to be sensitive to air, and thus the 
extraction/recycle process is conducted under an inert atmosphere of Ar. This is easily 
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achieved by the use of cylindrical reaction vessels fitted with a septum, such as a microwave 
vial, with extracts being removed via syringe. Using this process, it was observed that the 
mixture could be recycled up to five times without effecting yield or stereo-chemical 
outcome (Table 3). In terms of organic waste, the minimal amount of solvent required for 
isolation results in an especially low E Factor55  of 3.4, about five times lower than typical 
values of 25-100 associated with pharmaceutical processes. The flexibility of our recycling 
efforts can be further exploited by using the reaction mixture for various starting materials 
affording the expected results of high conversion and selectivity (Scheme 11). 
 
 
Table 3. Recycle of surfactant, H2O, LiCl, and Pd catalyst for the semi-reduction of 5 over 
six reactions.  
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Scheme 11. Recycling Black Water with varying substrates. 
 
Mechanistically, heterogeneous catalysis is often regarded as a “black box” as much is 
yet to be understood about the composition, structure, and pathway by which substrates are 
reduced. Initially, we had considered that the semi-reduction goes by means of a 
hydrogenation pathway, where the catalytic hydrolysis of NaBH4 generates H2 in situ which 
seeks preferential dissolution into the micellar core. This hypothesis was considered on the 
basis that the dissolution of gases, including H2, is far greater in hydrocarbon solvent than in 
water (Table 4).56 In addition, it is possible that H2 is absorbed onto the surface of the 
catalyst. This hypothesis was further supported by deuterium studies on substrate 11. Under 
otherwise standard conditions D2O was used in place of H2O showing only moderate site 
selectivity for hydride incorporation, with essentially a 1:2 ratio of enoate products 
containing one alkenyl deuterium (Scheme 12A). Electronically the β-carbon of the ynoate 
would be preferred under a Pd-H mechanism, and the lack of site preference supports the 
scrambling of H-D on the surface of the catalyst followed by a cis-mode of addition. These 
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results were intriguing, as the reduction procedure is conducted under flow of argon, which 
should purge the system of any residual H2. Furthermore, it should be noted that during 
catalyst activation rapid evolution of gas is observed, while no effervescence is observed 
upon addition of the NaBH4 to the reaction in the presence of the alkyne starting material. 
This reduction pathway is further complicated by additional deuterium studies on the non-
conjugated alkyne 4 under the same conditions. Interestingly, no deuterium incorporation 
was observed (Scheme 12B), suggesting that both hydrides were delivered from NaBH4 
without participation by water, supporting a Pd-H mechanism. Under conditions where 
NaBD4 was employed with H2O, complete deuteron incorporation was observed (Scheme 
12C). Thus, it is likely that two pathways for this semi-reduction may be possible, which is 
remarkable considering the exceptional Z-selectivity found for both substrates.  
 
Table 4. Solubility of H2 and O2 in water and organic solvents. 
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Scheme 12. A. Semi-reduction of 11 in D2O; B. Semi-reduction of 5 in D2O; C. Semi-
reduction of 5 with NaBD4. 
 
The developed method addresses many of the safety and environmental concerns 
associated with hydrogenation by considering parameters such as benign solvents, relatively 
inexpensive and readily available catalyst materials, recycling capabilities of the majority of 
the reaction components, and operational simplicity while delivering exceptional Z-
selectivity in excellent yields within short reaction times at room temperature. The advances 
made by this newly developed method are highly general, yet limitations have been 
observed. For example, carboxylic acids have been shown to completely shut down 
reactivity of the catalyst. In one case, it was observed that a trace acid impurity present in a 
starting material (6) led to no conversion whatsoever, while the pure material yielded the Z-
alkene nearly quantitatively (Scheme 13). Poor chemoselectivity was also noted for ynones 
as well as substrates bearing nitroarenes which give a complex mixture of products under 
these conditions. 
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Scheme 13. Acid sensitivity of Black Water semi-reductions. 
2.4 Summary and Conclusions 
In conclusion, a heterogeneous catalyst has been developed from Pd(OAc)2 and NaBH4 
for the highly selective and general semi-reduction of alkynes under aqueous micellar 
catalysis conditions.57 To our knowledge, this is the first report of a semi-reduction in the 
absence of organic solvent, and is a great improvement over some of the most widely used 
egregious solvents associated with this transformation (e.g., 1,4-dioxane, DMF).2 The 
interactions between metal and micellar nanoparticles in water has been used to synthetic 
advantage, enabling development of new technology that provides a broadly applicable 
solution to the problem of alkyne semi-reductions, including disubstituted, terminal, and 
conjugated systems. Major consideration is taken on the basis of environmental 
sustainability which is exemplified by the recyclability of the water, surfactant, catalyst, and 
LiCl additive. Furthermore, organic waste resulting from isolation of the product olefin is 
minimized as proven by the low E Factor of 3.4. 
This work represents the first example of heterogeneous catalysis under aqueous micellar 
conditions in our group and has since led to an expanding portfolio of projects. Since the 
communication of this work in Angewante Chemie (International Edition) in 2014, several 
other methods have been published based on heterogeneous systems including nitro-group 
reductions49,50 and Suzuki-Miyaura cross-couplings.58 Forthcoming work from the Lipshutz 
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group includes aza-click chemistry catalyzed by Cu/Fe nanoparticles as well as several other 
heterogeneous systems for reduction chemistry. 
2.5 Experimental Procedures 
General Information 
A solution of 2 wt % TPGS-750-M/H2O solution was prepared by dissolving TPGS-750-
M in degassed HPLC grade water and was stored under argon. TPGS-750-M was made as 
previously described59 and is available from Sigma-Aldrich (catalog #733857). All 
commercially available reagents were used without further purification. Thin layer 
chromatography (TLC) was done using Silica Gel 60 F254 plates (Merck, 0.25 mm thick). 
Flash chromatography was done in glass columns using Silica Gel 60 (EMD, 40-63 μm). 
GC-MS data was recorded on a 5975C Mass Selective Detector coupled with a 7890A Gas 
Chromatograph (Agilent Technologies). A capillary column (HP-5MS cross-linked 5% 
phenylmethyl-polysiloxanediphenyl, 30 m x 0.250 mm, 0.25 micron, Agilent Technologies) 
was employed. Helium was used as the carrier gas at a constant flow of 1 mL/min. 1H and 
13C NMR were recorded at 22 °C on a Varian UNITY INOVA at 500 MHz. Chemical shifts 
in 1H NMR spectra are reported in parts per million (ppm) on the δ scale from an internal 
standard of residual CDCl3 (7.27 ppm) or the central peak of DMSO-d6 (2.50 ppm). Data are 
reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintet), integration, and coupling constant in Hertz (Hz). Chemical shifts in 
13C chemical spectra are reported in ppm on the δ scale from the central peak of residual 
CDCl3 (77.00 ppm) or the central peak of DMSO-d6 (39.51 ppm). IR data were collected on 
a Perkin Elmer Spectrum Two UATR FT-IR Spectrometer and peaks were described 
according to relative intensity and resolution as follows:  s = strong, m = medium, w = weak, 
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br = broad. Chiral HPLC data were collected using a Shimadzu LC-20AT Prominence liquid 
chromatograph coupled with Shimadzu SPD-M20A Prominence diode array detector. HPLC 
method ran at 1 mL/min using 10% v/v isopropanol/hexanes through a ChiralPAK® AD-H 
column. 
Metal Salt/Complex Screening Conditions 
Condition A: To a H2 purged microwave vial with Teflon coated stir bar, metal salt (1.0 
mol %) was transferred followed by 2 wt % TPGS-750-M/H2O (1.0 mL, 0.5 M) and 4-
octyne (0.5 mmol). The vial was sealed and allowed to stir for ca. 1 h at 23 °C under a 
balloon of H2. 
Condition B: To an Ar purged microwave vial with Teflon coated stir bar, metal salt 
(1.0 mol %) was transferred followed by NaBH4 (0.5 mol %) and the dry mixture was 
allowed to sonicate for 5 min prior to the addition of 2 wt % TPGS-750-M/H2O (0.5 M) and 
4-octyne (0.5 mmol). The vial was sealed and allowed to stir for ca. 1 h at 23 °C under a 
balloon of H2. 
Condition C: To an Ar purged microwave vial with Teflon coated stir bar, metal salt 
(1.0 mol %) was transferred followed by NaBH4 (0.5 mol %) and the dry mixture was 
allowed to sonicate for 5 mins prior to the addition of 2 wt % TPGS-750-M/H2O (0.5 M) and 
4-octyne (0.5 mmol). After stirring for ca. 10 min, the reaction was charged with NaBH4 (1.0 
equiv) and allowed to stir for ca. 1 h at 23 °C under Ar atmosphere. 
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Preparation of Substrates 
 
 
 
Scheme 14. Preparation of undec-4-yn-3-ol, 4. 
 
Undec-4-yn-3-ol (4). To an argon-purged oven-dried 250 mL round bottom flask with 
Teflon coated stir bar, 1-octyne (3.0 mL, 20.0 mmol) and dry THF (50 mL) were transferred. 
The mixture was stirred and maintained at -78 °C as n-butyllithium (2.41 M in hexanes, 8.3 
mL, 20.0 mmol) was added drop-wise. After stirring for 1 h, propionaldehyde (1.5 mL, 20.0 
mmol) was added drop-wise and the reaction was allowed to come to rt. The aqueous phase 
was discarded and the organic phase was washed with NH4Cl saturated water solution (2 x 
50 mL), H2O (50 mL), dried over anhydrous NaSO4, filtered, and evaporated under reduced 
pressure. Impurities were removed by distillation (50 °C, 5 torr) to yield undec-4-yn-3-ol 
(2.61 g, 15.5 mmol) as a colorless oil (78%). 
 
 
Scheme 15. Preparation of undec-4-yn-3-yl acetate, 5. 
 
Undec-4-yn-3-yl acetate (5). To an argon-purged oven-dried 100 mL round bottom 
flask with Teflon coated stir bar, undec-4-yn-3-ol (0.82 g, 4.9 mmol), dry DCM (20 mL), 
DMAP (30.0 mg, 0.2 mmol), and triethylamine (1.4 mL, 9.8 mmol) were transferred. The 
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mixture was stirred and maintained at 0 °C under an argon atmosphere as acetyl chloride 
(0.5 mL, 7.3 mmol) was added drop-wise. The reaction continued to stir at 0 °C for 10 min 
and then at 23 °C for 30 min. The reaction was transferred to a separatory funnel and was 
washed with H2O (3 x 50 mL), dried over anhydrous Na2SO4, filtered and condensed under 
reduced pressure. The crude product was purified by flash chromatography (1:19 
EtOAc/hexanes) to yield undec-4-yn-3-yl acetate (0.77 g, 3.7 mmol) as a colorless oil (75%). 
 
 
Scheme 16. O-TBS protection of 4-pentyn-1-ol. 
 
5-(1-((Tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-ol. To an argon-
purged oven-dried 100 mL round bottom flask with Teflon coated stir bar, 4-pentyn-1-ol 
(1.19 g, 17 mmol) and DCM (50 mL) was syringed to the flask. The cap was removed and to 
the flask DMAP (207 mg, 1.7 mmol) and imidazole (1.39 g, 20.4 mmol) were added. The 
cap and argon were then replaced and this was then cooled to 0 °C. The cap was removed 
and TBSCl (3.07 g, 20.37 mmol) was added to the flask as a solid and the cap and argon 
were replaced. Within 30 min the solution went to a hazy white. This was then allowed to 
warm to rt for 2 h. The crude material was then passed over Celite into a flask and the 
solvent was evaporated in vacuo until insoluble material appeared. This was then transferred 
to a separatory funnel and washed with NH4Cl saturated water solution, extracted with 
hexanes, washed with brine, dried over anhydrous MgSO4, and filtered. The filtrate was then 
concentrated under reduced pressure and purified by a silica plug eluting with hexanes to 
yield t-butyldimethyl(pent-4-yn-1-yloxy)silane (2.81 g, 18.36 mmol) of the desired protected 
alcohol as a colorless oil (90%). 
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Scheme 17. Preparation of alkyne 7. 
 
5-(1-((Tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-ol (7). To an argon-
purged oven-dried 100 mL round bottom flask with Teflon coated stir bar, t-
butyldimethyl(pent-4-yn-1-yloxy)silane (2.5 g, 13.59 mmol) was syringed, followed by THF 
(35 mL). This was cooled to -78 °C and n-butyllithium (5.27 mL, 12.91 mmol, 2.45 M, 0.95 
equiv) was syringed into the flask drop-wise over 10 min. The mixture was stirred at -78 °C 
for 1 h. Cyclopentanone (1.41 g, 12.91 mmol) was then syringed into the flask quickly. The 
solution went to a light yellow. This was allowed to warm to rt overnight, and then worked 
up with NH4Cl saturated water solution, extracted with Et2O, washed with brine, dried of 
anhydrous MgSO4 and filtered. The filtrate was concentrated under reduced pressure and the 
crude material purified by column chromatography with (1:9 EtOAc/hexanes) to yield 1-
(benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-yn-2-ol with sufficient purity for the 
following reaction.  
To an argon-purged oven-dried 100 mL round bottom flask with Teflon coated stir bar, 
impure 1-(benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-yn-2-ol was transferred followed 
by DCM (27 mL). p-Toluenesulfonic acid (26 mg, 0.136 mmol) was then added to this and 
the mixture was cooled to 0 °C. Dihydropyran (2.28 g, 27.16 mmol) was then syringed in as 
one portion and left for 30 min to warm to rt. This was then quenched by a saturated solution 
of NaHCO3, extracted with Et2O, washed with brine, dried over anhydrous MgSO4, filtered, 
and concentrated under reduced pressure. The isolated t-butyldimethyl((5-(1-((tetrahydro-
  43 
2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-yl)oxy)silane as a crude oil was used as is for 
the next step. 
To an argon-purged oven-dried 100 mL round bottom flask with Teflon coated stir bar 
containing t-butyldimethyl((5-(1-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-
yl)oxy)silane, THF (25 mL) was transferred followed by TBAF (4.26 g, 16.31 mmol, 1.2 
equiv). The reaction was stirred for 30 min and then cooled to 0 °C before quenching with a 
few drops of 2 M HCl. This material was then extracted with Et2O, washed with brine, dried 
over anhydrous MgSO4, and filtered. The filtrate was concentrated under reduced pressure 
and then purified by column chromatography (1:4 EtOAc/hexanes) to yield pure 5-(1-
((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-ol (2.0 g, 7.94 mmol) as a colorless 
oil (62% over 3 steps). 
 
 
Scheme 18. Preparation of alkyne 8. 
 
1-(Benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-yn-2-ol (8). To an oven-dried 25 
mL round bottom flask with Teflon coated stir bar, purged with argon, (but-3-yn-1-yloxy)(t-
butyl)dimethylsilane (1.68 g, 9.14 mmol) and THF (5 mL) were transferred. The reaction 
was then cooled to -78 °C and n-butyllithium (2.86 mL, 6.86 mmol, 2.4 M) was added 
followed by 2-((benzyloxy)methyl)oxirane (0.75 g, 4.57 mmol), and then BF3.Et2O (0.644 g, 
4.57 mmol), after which a bright orange color was observed. The reaction continued to stir at 
-78 °C for 1 h and was then allowed to slowly warm to 0 °C and left at 0 °C for 1 h. This 
was then quenched at 0 °C with saturated NH4Cl, extracted with ether, washed by brine, 
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dried over anhydrous MgSO4, and filtered. The filtrate was concentrated under reduced 
pressure and the crude material then purified by flash chromatography (15:85 Et2O/hexanes) 
to yield 1-(benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-yn-2-ol (1.05 g, 2.87 mmol) as a 
colorless oil (63%). 
 
 
Scheme 19. General DCC coupling conditions for preparation of  
substrates 6, 13, 14, 15, 16, and 17. 
 
General procedure for DCC coupling products.60 To an argon-purged oven-dried 25 
mL round bottom flask with Teflon coated stir bar, carboxylic acid (5.0 mmol), dry DCM 
(5.0 mL), alcohol (7.5 mmol), and DMAP (30.5 mg, 0.25 mmol) were transferred. The 
mixture was stirred and maintained at 0 °C as DCC (1.3 g, 6.5 mmol) was added all at once. 
The reaction continued to stir at 0 °C for 5 min and then at 23 °C for 3 h. The contents were 
vacuum filtered and the filtrate was concentrated under reduced pressure. The crude was 
dissolved in DCM (30 mL) and washed with 1 M HCl solution in water (2 x 25 mL), 
NaHCO3 saturated water solution (2 x 30 mL), dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel with a gradient eluent of hexanes and EtOAc. 
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Scheme 20. O-benzyl protection of 4-pentyn-1-ol. 
 
((Pent-4-yn-1-yloxy)methyl)benzene. To an argon-purged, oven-dried 100 mL round 
bottom flask with Teflon coated stir bar, pent-4-yn-1-ol (1.69 g, 20.1 mmol), dry THF (20.0 
mL), and imidazole (2.7 mg, 0.04 mmol) were transferred. The mixture was stirred and 
maintained at 0 °C as NaH (66% dispersion in mineral oil, 2.2 g, 60.4 mmol) was added all 
at once. After stirring for 10 min, benzyl bromide (4.13 g, 24.2 mmol) was added drop-wise. 
The reaction was allowed to come to rt overnight. The reaction was then transferred to a 
separatory funnel, washed with H2O (2 x 50 mL), NH4Cl saturated water solution (2 x 50 
mL), and brine (50 mL), dried over anhydrous NaSO4, filtered, and evaporated under 
reduced pressure. The crude product was purified by flash chromatography (1:99 
EtOAc/hexanes) to yield ((pent-4-yn-1-yloxy)methyl)benzene (3.50 g, 20.1 mmol) as a 
colorless oil (99%). 
 
 
Scheme 21. Synthesis of 9 from ((pent-4-yn-1-yloxy)methyl)benzene. 
 
(((6,6-Diethoxyhex-4-yn-1-yl)oxy)methyl)benzene. To an argon purged oven-dried 250 
mL round bottom flask with Teflon coated stir bar, ((pent-4-yn-1-yloxy)methyl)benzene 
(1.69 g, 9.7 mmol) and dry THF (25 mL) were transferred. The mixture was stirred and 
maintained at -78 °C as n-butyllithium (2.04 M in hexanes, 5.2 mL, 10.7 mmol) was added 
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drop-wise. After stirring for 1 h, DMF (1.5 mL, 19.4 mmol) was added all at once. The 
reaction was allowed to come to rt overnight. The solution was cannulated into a vigorously 
stirring biphasic solution prepared from KH2PO4 (52.5 mL, 38.9 mmol), and MTBE (38.9 
mL) at 0 °C. The aqueous phase was removed and the organic phase was dried over 
anhydrous NaSO4, filtered, and evaporated under reduced pressure.61 The crude product was 
purified by flash chromatography (1:9 EtOAc/hexanes) to yield 6-(benzyloxy)hex-2-ynal 
(1.48 g, 7.3 mmol) as a colorless oil (75%).  
To an argon-purged oven-dried 100 mL round bottom flask with Teflon coated stir bar, 
6-(benzyloxy)hex-2-ynal (1.06 g, 5.2 mmol), ethanol (52.0 mL), triethylorthoformate (1.0 
mL, 6.3 mmol) and p-toluenesulfonic acid monohydrate (0.70 g, 3.7 mmol) were transferred. 
The reaction stirred at 23 °C for 1 h before quenching with 500 mg solid Na2CO3. The 
mixture was then diluted in diethyl ether (50 mL) and washed with H2O (50 mL), Na2CO3 
saturated water solution (2 x 50 mL), and brine (50 mL), dried over anhydrous NaSO4, 
filtered, and evaporated under reduced pressure. The crude product was purified by flash 
chromatography (1:99 EtOAc/hexanes) to yield (((6,6-diethoxyhex-4-yn-1-
yl)oxy)methyl)benzene (1.18 g, 4.3 mmol) as a colorless oil (83%). 
 
 
Scheme 22. Synthesis of 10 by Sonogashira cross coupling. 
 
2-(5-(Benzyloxy)pent-1-yn-1-yl)aniline. To an argon-purged oven-dried 25 mL round 
bottom flask with Teflon coated stir bar, 2-iodoaniline (0.52 g, 2.4 mmol), dry THF (4.8 
mL), ((pent-4-yn-1-yloxy)methyl)benzene (0.46 g. 2.6 mmol), and triethylamine (1.5 mL, 
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23.9 mmol) were transferred. An oven-dried water-jacketed reflux condenser was then 
affixed to the flask and the system was purged with argon several times. Pd(PPh3)4 (55.3 mg, 
0.05 mmol) and CuI (4.6 mg, 0.02 mmol) were added and the reaction was allowed to stir at 
50 °C overnight under an argon atmosphere. The mixture was then diluted with Et2O (20 
mL), washed with H2O (2 x 25 mL) and NaHCO3 saturated water solution (2 x 25 mL), 
dried over anhydrous Na2SO4, filtered, and evaporated under reduced pressure. The crude 
product was purified by flash chromatography (1:9 EtOAc/hexanes) to yield 2-(5-
(benzyloxy)pent-1-yn-1-yl)aniline (0.49 g, 1.8 mmol) as a red oil (78%). 
 
 
Scheme 23. ynoic acid synthesis. 
 
Non-2-ynoic acid.62 To an argon-purged oven-dried 250 mL round bottom flask with 
Teflon coated stir bar, 1-octyne (2.9 mL, 19.8 mol), and dry THF (50 mL) were transferred. 
The mixture was stirred and maintained at -78 °C as n-butyllithium (2.41 M in hexanes, 9.1 
mL, 21.8 mmol) was added drop-wise. After stirring for 1 h, the temperature was increased 
to 0 °C. CO2 was then bubbled through the reaction for 30 min as the flask was slowly 
brought to rt. The reaction was quenched with 1 M HCl solution in water (10 mL) at 0 °C 
and brought to rt. The aqueous phase was discarded and the product was extracted with 1 M 
NaOH solution in water (3 x 50 mL). The aqueous fractions were collected, acidified with 
conc HCl and then extracted with Et2O (3 x 50 mL). The combined organic phase was dried 
over anhydrous NaSO4, filtered, and evaporated under reduced pressure. The crude product 
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was distilled (170 °C, 2 torr) to yield undec-4-yn-3-ol (2.80 g, 18.2 mmol) as a colorless oil 
(92%).  
 
 
Scheme 24. Synthesis of 19. 
 
Trimethyl(oct-1-yn-1-yl)silane (19). To an argon-purged oven-dried 100 mL round 
bottom flask with Teflon coated stir bar, oct-1-yne (1.2 g, 10.9 mmol) and dry THF (27.2 
mL) were transferred. The mixture stirred and maintained at -78 °C as n-butyllithium (2.4 M 
in hexanes, 5.0 mL, 12.0 mmol) was added dropwise. After stirring for 1 h, 
chlorotrimethylsilane (1.7 mL, 13.1 mmol) was added drop-wise and allowed to come to rt 
overnight. The reaction was quenched with NH4Cl saturated water solution (10 mL) at 0 °C 
and brought to rt. The aqueous phase was discarded and the organic phase was washed with 
NH4Cl saturated water solution (2 x 50 mL), dried over anhydrous Na2SO4, filtered, and 
evaporated under reduced pressure. The crude product was purified by flash chromatography 
(hexanes) to yield trimethyl(oct-1-yn-1-yl)silane (1.64 g, 9.0 mmol) as a yellow oil (83%). 
 
 
Scheme 25. Cbz-protection of DL-alanine. 
 
Pent-4-yn-1-yl ((benzyloxy)carbonyl)-DL-alaninate.63 To an argon-purged oven-dried 
50 mL round bottom flask with Teflon coated stir bar, DL-alanine (448.3 mg, 7.5 mmol), 
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H2O (16.8 mL), and Na2CO3 (1.6 g, 15.1 mmol) were transferred. The solution was stirred at 
0 °C as benzyl chloroformate (1.0 g, 6.0 mmol) in 1,4-dioxane (4.8 mL) was transferred 
drop-wise over 30 min. The reaction continued to stir at 0 °C for 1 h and at 23 °C for 3 h. 
The contents were then diluted with diethyl ether (50 mL) and washed with 1 M HCl 
solution in H2O (50 mL). The organic phase was collected and the aqueous solution was 
extracted with Et2O (2 x 50 mL). The organic fractions were combined and were dried over 
anhydrous Na2SO4, filtered, and concentrated under reduced pressure to afford crude 
((benzyloxy)carbonyl)-DL-alanine as white crystals with sufficient purity for the following 
reaction.  
 
 
Scheme 26. Synthesis of 17-rac HPLC standard for epimerization study. 
 
Pent-4-en-1-yl ((benzyloxy)carbonyl)-DL-alaninate (17-rac). To an oven-dried 25 mL 
round bottom flask with Teflon coated stir bar, argon was purged and pent-4-en-1-ol (635 
mg, 7.5 mmol), dry DCM (5.0 mL), ((benzyloxy)carbonyl)-DL-alanine (1.1 g, 5.0 mmol), 
and DMAP (122.17 mg, 0.3 mmol) were transferred. The mixture was stirred and 
maintained at 0 °C as DCC (1.3 g, 6.5 mmol) was added all at once. The reaction was 
continued with stirring at 0 °C for 5 min and then at 23 °C for 3 h. The contents were then 
vacuum filtered and the filtrate was concentrated under reduced pressure. The crude was 
dissolved in DCM (25 mL) and washed with 1 M HCl solution in water (2 x 30 mL), 
NaHCO3 saturated water solution (2 x 30 mL), dried over anhydrous Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash 
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chromatography (1:3 EtOAc/hexanes) to yield pent-4-en-1-yl ((benzyloxy)carbonyl)-DL-
alaninate (1.06 g, 3.7 mmol) as a colorless oil (73%). 
 
 
Scheme 27. Cbz-protection of L-alanine. 
 
Pent-4-en-1-yl ((benzyloxy)carbonyl)-L-alaninate. To an argon-purged oven-dried 50 
mL round bottom flask with Teflon coated stir bar, L-alanine (671.4 mg, 7.5 mmol), H2O 
(25.1 mL), and Na2CO3 (2.4 g, 22.6 mmol) were transferred. The solution was stirred at 0 °C 
as benzyl chloroformate (1.4 g, 8.3 mmol) in 1,4-dioxane (6.6 mL) was transferred dropwise 
over 30 min. The reaction continued to stir at 0 °C for 1 h and at 23 °C for 3 h. The contents 
were then diluted with Et2O (50 mL) and 1 M HCl solution in water (50 mL). The organic 
phase was collected and the aqueous solution was extracted with Et2O (2 x 50 mL). The 
organic fractions were dried over anhydrous Na2SO4, filtered, and concentrated under 
reduced pressure to afford crude ((benzyloxy)carbonyl)-L-alanine as white crystals with 
sufficient purity for the following reaction.  
 
 
Scheme 28. Synthesis of 17a-L HPLC standard for epimerization study. 
 
Pent-4-en-1-yl ((benzyloxy)carbonyl)-L-alaninate (17a-L). To an argon-purged oven-
dried 50 mL round bottom flask with Teflon coated stir bar, pent-4-en-1-ol (0.6 mL, 5.7 
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mmol), dry DCM, ((benzyloxy)carbonyl)-L-alanine (0.85 g, 3.8 mmol), and DMAP (23.3 
mg, 0.2 mmol) were transferred. The mixture was stirred and maintained at 0 °C as DCC 
(1.02 g, 5.0 mmol) was added all at once. The reaction was continued with stirring at 0 °C 
for 5 min and then 23 °C for 3 h. The contents were then vacuum filtered and the filtrate was 
concentrated under reduced pressure. The crude was dissolved in DCM (50 mL) and washed 
with 1 M HCl solution in water (2 x 30 mL), NaHCO3 saturated water solution (2 x 30 mL), 
dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (1:3 EtOAc/hexanes) to yield pent-4-en-1-yl 
((benzyloxy)carbonyl)-L-alaninate (0.78 g, 2.7 mmol) as a colorless oil (71%). 
Semi-Reduction Procedures 
 
 
Scheme 29. General Semi-Reduction Conditions. 
 
Optimized Reduction Procedure: To an oven-dried 20 x 70 mm microwave vial with 
Teflon coated stir bar, purged with argon, was transferred Pd(OAc)2 (1.0 mg, 0.005 mmol) 
and NaBH4 (0.9 mg, 0.025 mmol). The dry mixture was allowed to stir for 20 min after 
which fine black particles were observed. TPGS-750-M (2 wt %) solution in degassed HPLC 
grade water (0.9 mL) was then transferred drop-wise causing gas to evolve from the mixture. 
The mixture was vigorously stirred for an additional 20 min and then centrifuged resulting in 
a black suspension. The vial was then charged with hex-3-yn-2-yl 2,3,4,5,6-
pentafluorobenzoate acetate (133.2 mg, 0.456 mmol) and vigorously stirred for 20 min 
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before the addition of LiCl (42.5 mg, 1.0 mmol) and NaBH4 (9.5 mg, 0.25 mmol). A vent 
needle was then inserted into the septum allowing for argon to circulate over the reaction. 
After stirring 1 h at 23 °C, the reaction was worked up by extraction with EtOAc (3 x 2 mL), 
filtration through a plug of silica, and was concentrated under reduced pressure. The crude 
product was purified by flash chromatography (1:19 EtOAc/hexanes) to yield (Z)-hex-3-en-
2-yl 2,3,4,5,6-pentafluorobenzoate (112.3 mg, 0.436 mmol) as a colorless oil (97%). 
Note:  Best results were obtained when using NaBH4 of very fine particle size, such as 
that obtained from Alfa Aesar (catalog #13432). 
Preparation of Bulk Catalyst Suspension  
To an oven-dried 25 mL round bottom flask with Teflon coated stir bar, purged with 
argon, was transferred Pd(OAc)2 (12.8 mg, 0.057 mmol) followed by NaBH4 (10.8 mg, 0.29 
mmol). The dry mixture was sonicated under a balloon of argon for 60 min and fine black 
particles were observed. 2 wt % TPGS-750-M solution in degassed HPLC grade water (6.0 
mL) was then transferred drop-wise causing gas to evolve from the mixture. Sonication 
continued for 30 min and then the remaining volume of 2 wt % TPGS-750-M solution (5.4 
mL) was added. After 15 min, the mixture was removed from the sonication bath and 
allowed to stir vigorously. The mixture is observed as a black suspension. The catalyst 
suspension remains active for several weeks and should be kept under an inert atmosphere 
while vigorously stirring to retain good mixing. 
Aqueous Surfactant Recycling Procedures 
Reaction A. An Ar-purged, microwave vial with Teflon coated stir bar was charged with 
a premade catalyst suspension (as described previously), undec-4-yn-3-yl acetate 5 (0.5 g, 
2.38 mmol) and LiCl (24 mg, 0.57 mmol). After stirring for 5 min under argon, NaBH4 (46 
mg, 1.19 mmol) was charged to the system and a vent needle was inserted into the septum 
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allowing for argon to circulate over the reaction. After stirring for ca. 1 h, the vent needle 
was removed and the product alkene (Z)-undec-4-en-3-yl acetate (5a) was extracted under 
Ar with 3 x 1.0 mL MTBE, passed through a plug of anhydrous Na2SO4, concentrated under 
reduced pressure, and purified via flash chromatography to yield 458 mg (91%).  
Reaction B (1st Recycle). The remaining aqueous mixture was then charged with 
additional undec-4-yn-3-yl acetate 5 (0.5 g, 2.38 mmol) and LiCl (24 mg, 0.57 mmol). After 
stirring for 5 min under argon, NaBH4 (46 mg, 1.19 mmol) was charged to the system and a 
vent needle was inserted into the septum allowing for argon to circulate over the reaction. 
After stirring for ca. 1 h, the vent needle was removed and the product alkene (Z)-undec-4-
en-3-yl acetate (5a) was extracted under Ar with 3 x 1.0 mL MTBE, passed through a plug 
of anhydrous Na2SO4, concentrated under reduced pressure, and purified via flash 
chromatography to yield 478 mg (95%). 
Reaction C (2nd Recycle). The remaining aqueous mixture was then charged with 
additional undec-4-yn-3-yl acetate 5 (0.5 g, 2.38 mmol) and LiCl (24 mg, 0.57 mmol). After 
stirring for 5 min under argon, NaBH4 (46 mg, 1.19 mmol) was charged to the system and a 
vent needle was inserted into the septum allowing for argon to circulate over the reaction. 
After stirring for ca. 1 h, the vent needle was removed and the product alkene (Z)-undec-4-
en-3-yl acetate (5a) was extracted under Ar with 3 x 1.0 mL MTBE, passed through a plug 
of anhydrous Na2SO4, concentrated under reduced pressure, and purified via flash 
chromatography to yield 464 mg (92%).  
Reaction D (3rd Recycle). The remaining aqueous mixture was then charged with 
additional undec-4-yn-3-yl acetate 5 (0.5 g, 2.38 mmol) and LiCl (24 mg, 0.57 mmol). After 
stirring for 5 min under argon, NaBH4 (46 mg, 1.19 mmol) was charged to the system and a 
vent needle was inserted into the septum allowing for argon to circulate over the reaction. 
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After stirring for ca. 1 h, the vent needle was removed and the product alkene (Z)-undec-4-
en-3-yl acetate (5a) was extracted under Ar with 3 x 1.0 mL MTBE, passed through a plug 
of anhydrous Na2SO4, concentrated under reduced pressure, and purified via flash 
chromatography to yield 494 mg (98%).  
Reaction E (4th Recycle). The remaining aqueous mixture was then charged with 
additional undec-4-yn-3-yl acetate 5 (0.5 g, 2.38 mmol) and LiCl (24 mg, 0.57 mmol). After 
stirring for 5 min under argon, NaBH4 (46 mg, 1.19 mmol) was charged to the system and a 
vent needle was inserted into the septum allowing for argon to circulate over the reaction. 
After stirring for ca. 1 h, the vent needle was removed and the product alkene (Z)-undec-4-
en-3-yl acetate (5a) was extracted under Ar with 3 x 1.0 mL MTBE, passed through a plug 
of anhydrous Na2SO4, concentrated under reduced pressure, and purified via flash 
chromatography to yield 468 mg (93%). 
Reaction F (4th Recycle). The remaining aqueous mixture was then charged with 
additional undec-4-yn-3-yl acetate 5 (0.5 g, 2.38 mmol) and LiCl (24 mg, 0.57 mmol). After 
stirring for 5 min under argon, NaBH4 (46 mg, 1.19 mmol) was charged to the system and a 
vent needle was inserted into the septum allowing for argon to circulate over the reaction. 
After stirring for ca. 1 hour, the vent needle was removed and the product alkene (Z)-undec-
4-en-3-yl acetate (5a) was extracted under Ar with 3 x 1.0 mL MTBE, passed through a plug 
of anhydrous Na2SO4, concentrated under reduced pressure, and purified via flash 
chromatography to yield 480 mg, (95%). 
E Factor Determination Procedure 
An oven-dried, Ar-purged, 10 mL round bottom flask with Teflon coated stir bar was 
charged with Pd(OAc)2 (5.3 mg, 0.024 mmol) and NaBH4 (4 mg, 0.11 mmol). The flask was 
sealed with a septum and a balloon of argon was attached. The dry mixture was stirred for 5 
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min until all of the solids appeared as black aggregates. Degassed 2 wt % TPGS-750-M/H2O 
(3.0 mL) was then charged to the solids and the mixture was allowed to stir for ca. 30 min at 
which point all bubbling had subsided. The remaining 2 wt % TPGS-750-M/H2O (1.76 mL) 
was then added into the flask, washing down the sides of the vial into the black suspension 
mixture. Undec-4-yn-3-yl acetate (500 mg, 2.38 mmol) and LiCl (24 mg, 0.574 mmol) 
where then charged. After stirring for 5 min under argon, NaBH4 (32 mg, 0.86 mmol) was 
charged to the system. The reaction stirred for ca. 1 h and the suspension turned from black 
to light gray. The product alkene (Z)-undec-4-en-3-yl acetate (5a) was then extracted with 3 
x 0.68 mL MTBE, passed through a plug of anhydrous Na2SO4, concentrated under reduced 
pressure, and purified via flash chromatography to yield 446 mg, (89%).  
E Factor Calculations (without water) 
E Factor = (Mass of Organic Waste) / (Mass of Product) 
Mass of Organic Waste = (2.0 mL MTBE) (0.740 g/mL) = 1509.6 mg 
Mass of Product = 446 mg 
E Factor = (1509.6 mg) / (446 mg) = 3.4 
E Factor Calculations (with water) 
E Factor = (Mass of Organic Waste + Aqueous Waste) / (Mass of Product) 
Mass of Water = (4.76 mL) (1.0 g/mL) = 4760 mg 
E Factor = (1509.6 mg + 4760 mg) / (446 mg) = 14.1 
Deuterium Procedures 
A 2 wt % solution of TPGS-750-M was made with D2O in place of HPLC grade water. 
The catalyst solution was prepared according to the general “black water” procedure. To an 
oven-dried microwave vial with a Teflon coated stir bar, Pd(OAc)2 (1.2 mg, 0.006 mmol) 
and NaBH4 (2 mg, 0.053 mmol) were added. The mixture was then capped and an argon 
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balloon was attached. The solids were then stirred for 30 min until the mixture went black. 
To this was added a 2 wt % solution of TPGS-750-M in D2O. This was left for 2 h to stir 
leading to a black homogeneous-looking mixture. The cap was then removed and LiCl (48 
mg, 1.19 mmol) was added. The vial was then capped and the argon flow returned. Then, 
methyl 2-octynoate, 11, (100 mg, 0.595 mmol) was syringed into the flask. This was left for 
5 min to allow the oil to homogenize. The vial was then opened again and NaBH4 (11 mg, 
0.29 mmol) was added in one portion. The vial was then capped and under argon, the 
reaction was maintained for 1 h. The crude material was then extracted by Et2O and passed 
over anhydrous NaSO4 and the solvent removed under vacuum. This resulted in incomplete 
conversion of the starting material to the product. Comparison of the alkene protons to the 
methyl ester showed a 1:1.2:3 ratio of the alkene protons and the methyl ester. 
To an oven-dried microwave vial with Teflon coated stir bar, Pd(OAc)2 (1.2 mg, 0.006 
mmol) and NaBH4 (2 mg, 0.053 mmol) were added. The vessel was then capped and an 
argon balloon was attached. The solids were then stirred for 30 min until the mixture went 
black. To this was added a 2 wt % solution of TPGS-750-M in D2O. This was left for 2 h to 
stir leading to a black homogeneous-looking mixture. The cap was then removed and LiCl 
(48 mg, 1.19 mmol) was added to the solution. The vial was then capped and the argon flow 
returned. Then, methyl 2-octynoate (100 mg, 0.595 mmol) was syringed into the flask. This 
was left for 5 min to allow the oil to homogenize. Then the vial was opened again and 
NaBH4 (11 mg, 0.29 mmol) was added as one portion. The vial was then capped and under 
argon the reaction was maintained for 1 h. The crude material was then extracted with Et2O 
and passed over anhydrous NaSO4 and the solvent removed under vacuum. This resulted in 
incomplete conversion of the starting material to the product. Comparison of the alkene 
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protons to the acyl methyl showed a 1:1:3 ratio of the alkene protons and the acyl methyl 
protons. 
2.6 Compound Data 
Characterization of Alkynes 
 
 
Undec-4-yn-3-ol (4). Rf 0.29 (1:3 Et2O/hexanes); colorless oil, 2.61 g (78%). 1H NMR 
(500 MHz, CDCl3) δ 4.25 (m, 1H), 2.37 (s,1H), 2.16 (td, 2H), 1.64 (m, 2H), 1.46 (quin, 2H), 
1.37-1.30 (m, 2H), 1.30-1.21 (m, 4H), 0.95 (t, 3H), 0.85 (t, 3H); 13C NMR (125 MHz, 
CDCl3) δ 85.28, 81.04, 63.72, 31.20, 31.06, 28.56, 28.39, 22.41, 18.53, 13.87, 9.32. IR 
(neat):  3342 (m, br), 2959 (m), 2930 (m), 2873 (m), 2859 (m), 2244 (w) cm-1. 
 
 
Undec-4-yn-3-yl acetate (5). Rf 0.20 (1:19 Et2O/hexanes); colorless oil, 0.77 g (75%).  
1H NMR (500 MHz, CDCl3) δ 5.31 (td, 1H), 2.21 (td, 2H), 2.08 (s, 3H), 1.75 (m, 2H), 1.50 
(m, 2H), 1.41-1.23 (m, 6H), 1.00 (t, 3H), 0.89 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 
169.97, 86.19, 77.33, 65.63, 31.20, 28.40, 28.38, 28.29, 22.44, 21.00, 18.60, 13.91, 9.27; IR 
(neat):  2931 (m), 2859 (m), 2251 (m), 1740 (s) cm-1. HRMS (ESI, [C13H22O2 + Na]+) calcd 
233.1517, found m/z 233.1523.  
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Hex-3-yn-2-yl 2,3,4,5,6-pentafluorobenzoate (6). Rf 0.29 (1:19 diethyl ether/hexanes); 
colorless oil, 1.02 g (78%). 1H NMR (500 MHz, CDCl3) δ 5.71 (qt, 1H, J = 6.49, 2.08 Hz), 
2.24 (qd, 2H, J = 7.53, 2.08 Hz), 1.60 (d, 3H), 1.15 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 
158.07, 146.36, 144.30, 142.13, 138.67, 136.64, 88.29, 76.64, 63.78, 21.64, 13.45, 12.34. IR 
(neat):  2985 (m), 2941 (m), 2853 (m) 2249 (m), 1739 (s) cm-1. HRMS (EI, [C13H9F5O2]) 
calcd 292.0523, found m/z 292.0531. 
 
 
5-(1-((Tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-yn-1-ol (7). Rf 0.20 (1:3 
EtOAc/hexanes); colorless oil, 2.0 g (62%). 1H NMR (500 MHz, CDCl3) δ 5.04 (m, 1H), 
3.93 (m, 1H), 3.75 (t, 2H, J = 12.20, 5.97) 3.51 (m, 1H) 2.34 (m, 2H), 2.00-1.64 (m, 13H), 
1.52 (m, 3H); 13C NMR (125 MHz, CDCl3) δ. 96.21, 84.07, 82.59, 80.85, 63.25, 61.79, 
41.24, 40.37, 32.01, 31.29, 25.44, 23.29, 22.86, 20.22 IR (neat):  3445 (b), 3065 (w) 2928 (s) 
2856 (s) 1471 (s) cm-1. HRMS (ESI, [C15O3H24 + Na]+) calcd 275.1620, found m/z 
275.1623. 
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1-(Benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-yn-2-ol (8). Rf 0.10 (1:9 
EtOAc/hexanes); colorless oil, 1.05 g (63%). 1H NMR (500 MHz, CDCl3) δ 7.34 (m, 5H), 
4.57 (s, 2H), 3.92 (m, 1H), 3.681 (t, 2H), 3.60 (dd, 1H, J = 13.43, 9.52, 3.91 Hz), 3.490 (dd, 
1H, J = 16.12, 9.52, 6.59), 2.42 (m, 2H), 2.37 (m, 2H), 0.90 (s, 9H), 0.07 (s, 6H); IR (neat):  
3460 (br), 3032 (w), 2958 (s), 2927 (s), 2856 (s), 1471 (m), 1255 (s) cm-1. HRMS (ESI, 
[C20H32O2Si + Na]+) calcd 371.2018, found m/z 371.2023. 
 
 
(((6,6-Diethoxyhex-4-yn-1-yl)oxy)methyl)benzene. Rf 0.40 (1:3 Et2O/hexanes); 
colorless oil, 1.18 g (83%). 1H NMR (500 MHz, CDCl3) δ 7.37-7.32 (m, 4H), 7.30-7.26 (m, 
1H), 5.25 (t, 1H, J =1.56 Hz), 4.51 (s, 2H), 3.77-3.70 (m, 2H), 3.60-3.54 (m, 4H), 2.39 (td, 
2H, J =7.27, 1.56 Hz), 1.85 (m, 2H), 1.23 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 138.32, 
128.24, 127.46, 127.43, 91.34, 85.62, 75.93, 72.84, 68.65, 60.48, 28.44, 15.42, 15.00. IR 
(neat):  3030 (m), 2975 (m), 2928 (m), 2880 (m), 2238 (m), 17.12 (m), 1148 (s), 1102 (s), 
1077 (s), 1049 (s), 1004 (s) cm-1. HRMS (ESI, [C17H24O3 + Na]+) calcd 299.3658, found m/z 
299.1626. 
 
 
2-(5-(Benzyloxy)pent-1-yn-1-yl)aniline (10). Rf 0.49 (1:3 EtOAc/hexanes); red oil, 
487.4 mg (78%). 1H NMR (500 MHz, DMSO-d6) δ 7.37-7.31 (m, 4H), 7.30-7.26 (m, 1H), 
7.06 (dd, 1H), 7.00 (m, 1H), 6.66 (dd, 1H), 6.47 (dt, 1H), 5.19 (s, 2H), 4.49 (s, 2H), 3.56 (t, 
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2H), 2.53 (t, 2H), 1.83 (quin, 2H); 13C NMR (125 MHz, DMSO-d6) δ 149.26, 138.56, 
131.42, 128.77, 128.21, 127.38, 127.32, 115.65, 113.54, 106.70, 94.49, 77.63, 71.84, 68.37, 
28.61, 15.99. IR (neat):  3468 (m), 3372 (m), 3062 (m), 3029 (m), 2926 (m), 2857 (m) cm-1. 
HRMS (EI, [C18H19NO]+) calcd 265.1467, found m/z 265.1466. 
 
 
Ethyl 3-phenylpropiolate (12). Rf 0.31 (1:9 Et2O/hexanes); colorless oil, 732.3 mg 
(95%). 1H NMR (500 MHz, CDCl3) δ 7.60-7.57 (m, 2H), 7.46-7.42 (m, 1H), 7.39-7.35 (m, 
2H), 4.30 (q, 2H), 1.36 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 154.03, 132.94, 130.58, 
128.54, 119.64, 86.01, 80.71, 62.06, 14.07. IR (neat):  3060 (w), 2983 (m), 2938 (w), 2906 
(w), 2235 (m), 2209 (m), 1703 (s) cm-1. 
 
 
4-Acetylphenyl non-2-ynoate (13). Rf 0.19 (1:3 Et2O/hexanes); colorless oil, 0.54 g 
(81%). 1H NMR (500 MHz, CDCl3) δ 8.00 (m, 2H), 7.24 (m, 2H), 2.59 (s, 3H), 2.40 (t, 2H), 
1.62 (quin, 2H), 1.47-1.39 (m, 2H), 1.36-1.27 (m, 4H), 0.9 (t, 3H); 13C NMR (125 MHz, 
CDCl3) δ 196.64, 153.64, 151.19, 135.00, 129.94, 121.59, 93.10, 72.39, 31.12, 28.47, 27.31, 
26.53, 22.39, 18.78, 13.95. IR (neat):  2954 (m), 2929 (m), 2859 (m), 1730 (s), 1686 (s) cm-
1. HRMS (ESI, [C17H20O3 + Na]+) calcd 295.1310, found m/z 295.1308. 
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Oxiran-2-ylmethyl non-2-ynoate (14). Rf 0.16 (1:9 EtOAc/hexanes); colorless oil, 0.34 
g (60%). 1H NMR (500 MHz, CDCl3) δ 4.44 (dd, 1H, 12.20, 3.37 Hz), 4.04 (dd, 1H, 12.20, 
6.23 Hz), 3.25 (m, 1H), 2.87 (dd, 1H), 2.67 (dd, 1H, J = 4.93, 2.60 Hz), 2.35 (t, 2H), 1.62-
1.56 (m, 2H), 1.44-1.38 (m, 2H), 1.36-1.25 (m, 4H), 0.90 (t, 3H); 13C NMR (125 MHz, 
CDCl3) δ 153.42, 90.90, 72.57, 66.05, 48.93, 44.74, 31.18, 28.50, 27.43, 22.44, 18.71, 
13.99. IR (neat):  ν = 2958 (m), 2930 (m), 2860 (m), 2235 (m), 1712 (s), 1244 (s) cm-1. 
HRMS (ESI, [C12H18O3 + Na]+) calcd 233.1154, found m/z 233.1165. 
 
 
Pent-4-yn-1-yl 2-phenylacrylate (15). Rf 0.16 (1:9 Et2O/hexanes); colorless oil, 671.0 
mg (63%). 1H NMR (500 MHz, CDCl3) δ 7.46-7.43 (m, 2H), 7.40-7.33 (m, 3H), 6.38 (d, 
1H, J = 1.30 Hz), 5.92 (d, 1H, J = 1.30 Hz), 4.36 (t, 2H), 2.32 (dt, 2H), 2.01 (t, 1H), 1.94 
(quin, 2H); 13C NMR (125 MHz, CDCl3) δ 166.42, 141.20, 136.51, 128.10, 127.99, 127.91, 
126.57, 82.75, 69.04, 63.41, 27.32, 15.11. IR (neat): 3290 (m), 3061 (w), 2960 (m), 2118 
(w), 1731 (s), 1690 (m) cm-1. HRMS (ESI, [C14H14O2]+) calcd 214.0994, found m/z 
214.0988. 
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1-Benzyl 2-(pent-4-yn-1-yl) (S)-pyrrolidine-1,2-dicarboxylate (16). Rf 0.26 (1:3 
EtOAc/hexanes); colorless oil, 1.20 g (76%). 1H NMR (500 MHz, CDCl3) δ 7.40-7.27 (m, 
5H), 5.23-5.01 (m, 2H), 4.37 (ddd, 1H), 4.25 (m, 1H), 4.11 (m, 1H), 3.67-3.58 (m, 1H), 
3.57-3.46 (m, 1H), 2.31-2.19 (m, 2H), 2.17 (dt, 1H), 2.05-1.94 (m, 2H), 1.94-1.84 (m, 2H), 
1.72 (m, 1H); 13C NMR (125 MHz, CDCl3) δ 172.70,172.52, 154.81, 154.24, 136.70, 
136.55, 128.42, 128.38, 127.93, 127.86, 127.85, 82.95, 82.71, 69.11, 68.99, 66.97, 63.54, 
63.46, 59.25, 58.88, 46.91, 46.39, 30.94, 29.92, 27.48, 27.30, 24.29, 23.50, 15.07, 14.98. IR 
(neat):  3289 (m), 3033 (w), 2956 (m), 2882 (m), 2118 (w), 1773 (s), 1700 (s) cm-1. HRMS 
(ESI, [C18H21NO4 + Na]+) calcd 338.1368, found m/z 338.1380. 
 
 
Pent-4-yn-1-yl ((benzyloxy)carbonyl)-D-alaninate (17). Rf 0.06 (1: 9 EtOAc/hexanes); 
colorless oil, 0.85 g (69%). 1H NMR (500 MHz, DMSO-d6) δ 7.76 (d, 1H), 7.44-7.27 (m, 
5H), 5.03 (s, 2H), 4.14-4.03 (m, 3H), 2.82 (m, 1H), 2.20 (dt, 2H), 1.74 (quin, 2H), 1.27 (d, 
3H); 13C NMR (125 MHz, CDCl3) δ 172.72, 155.45, 136.09, 128.22, 127.84, 127.82, 82.55, 
69.08, 66.55, 63.62, 49.41, 27.10, 18.17, 14.81. IR (neat):  3295 (m, br), 3033 (m) 2938 (m), 
2118 (m), 1709 (s) cm-1. HRMS (ESI, [C16H21NO4 + Na]+) calcd 312.1212, found m/z 
312.1205. 
 
 
Trimethyl(oct-1-yn-1-yl)silane (19). Rf 0.51 (hexanes); yellow oil, 1.64 g (83%). 1H 
NMR (500 MHz, CDCl3) δ 2.22 (t, 2H), 1.52 (quin, 2H), 1.42-1.35 (m, 2H), 1.35-1.25 (m, 
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4H), 0.9 (t, 3H), 0.15 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 107.78, 84.21, 31.27, 28.59, 
28.45, 22.50, 19.85, 14.01, 0.17. IR (neat):  2958 (m), 2931 (m), 2860 (m), 2175 (m) cm-1.  
 
 
Pent-4-yn-1-yl ((benzyloxy)carbonyl)-DL-alaninate (17-rac). Rf 0.06 (1: 9 
EtOAc/hexanes); colorless oil, 1.06 g (73%). 1H NMR (500 MHz, CDCl3) δ 7.38-7.30 (m, 
5H), 5.39 (s, 1H) 5.11 (s, 2H), 4.39 (quin, 1H), 4.25 (t, 2H), 2.29 (m, 2H), 1.98 (t, 1H), 1.87 
(quin, 2H), 1.42 (d, 2H); 13C NMR (125 MHz, CDCl3) δ 172.86, 155.53, 136.23, 128.46, 
128.10, 128.04, 82.67, 69.17, 66.83, 63.88, 49.60, 27.29, 18.62, 15.04. IR (neat):  3296 (m, 
br), 3034 (w) 2941 (m), 2118 (w), 1714 (s) cm-1. 
Characterization of Alkenes 
 
 
(Z)-Undec-4-en-3-ol (4a). Rf 0.22 (1:3 diethyl ether/hexanes); colorless oil, 86.9 mg 
(90%). 1H NMR (500 MHz, CDCl3) δ 5.50 (dtd, 1H, J = 10.90, 0.78 Hz), 5.35 (ddt, J = 
10.90, 8.82 Hz), 4.35 (dtd, 1H, J = 8.82, 0.78 Hz), 2.08 (m, 2H), 1.62 (m, 1H), 1.46 (m, 1H), 
1.39-1.23 (m, 9H), 0.92-0.87 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 132.54, 132.22, 
69.03, 31.66, 30.33, 29.66, 28.92, 27.70, 22.57, 14.03, 9.66. IR (neat):  3344 (m, br), 3006 
(w), 2958 (m), 2924 (m), 2873 (m), 2855 (m), 1656 (w) cm-1.  
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(Z)-Undec-4-en-3-yl acetate (5a). Rf 0.11 (1:19 Et2O/hexanes); colorless oil, 105.3 mg 
(99%). 1H NMR (500 MHz, CDCl3) δ 55.5 (dtd, 1H, J = 10.90, 0.78 Hz), 5.47 (dtd, 1H, J = 
9.08, 0.78 Hz), 5.28 (ddt, 1H, J = 10.90, 9.08 Hz), 2.20-2.06 (m, 2H), 2.02 (s, 3H), 1.67 (m, 
1H), 1.53 (m, 1H), 1.39-1.23 (m, 8H), 0.88 (t, 6H); 13C NMR (125 MHz, CDCl3) δ 170.33, 
134.33, 127.71, 71.63, 31.67, 29.48, 28.92, 27.89, 27.76, 22.58, 21.27, 14.02, 9.40. IR 
(neat):  3013 (m), 2959 (m), 2926 (m), 2925 (m), 2873.2 (m), 1737 (s), 1652 (w) cm-1. 
HRMS (EI, [C13H24O2]) calcd 212.1776, found m/z 212.1785. 
 
 
(Z)-Hex-3-en-2-yl 2,3,4,5,6-pentafluorobenzoate (6a). Rf 0.53 (1:19 Et2O/hexanes); 
colorless oil, 112.3 mg (97%).  1H NMR (500 MHz, CDCl3) δ 5.94 (dqd, 1H, J=9.08, 6.49, 
0.78 Hz), 5.60 (dtd, 1H, J = 10.90, 7.40, 0.78 Hz), 5.42 (ddt, J = 10.90, 9.08, 1.56), 2.30-
2.13 (m, 2H), 1.43 (d, 3H), 1.02 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 158.25, 146.16, 
144.08, 141.91, 136.57, 136.17, 127.38, 70.21, 21.17, 20.75, 13.99. IR (neat):  2971 (m), 
2936 (m), 2879 (m) 1736 (s), 1652 (w) cm-1. HRMS (EI, [C13H11F5O2]) calcd 294.0679, 
found m/z 294.0686. 
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(Z)-5-(1-((Tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)pent-4-en-1-ol (7a). Rf 0.20 
(1:3 EtOAc/hexanes); colorless oil, 98.0 mg (98%). 1H NMR (500 MHz, CDCl3) δ 5.74 (t, 
1H, J = 11.68, 3.37, 1.82 Hz), 5.46 (dq, 1H, J = 11.42, 8.04, 6.23 Hz), 4.68 (m, 1H), 3.930 
(m, 1H), 3.65 (t, 2H), 3.45 (m, 1H), 2.45-1.49 (m, 21H); 13C NMR (125 MHz, CDCl3) δ 
133.76, 133.45, 95.92, 86.99, 63.72, 62.12, 39.76, 39.02, 32.55, 32.55, 34.39, 25.40, 25.18, 
23.22, 22.94, 20.71. IR (neat):  3476 (br), 3016 (w), 2940 (s), 2867 (s), 1726 (w), 1440 (m), 
1352 (m) cm-1. HRMS (ESI, [C15O3H26 + Na]+) calcd 277.1779, found m/z 277.1772. 
 
 
(Z)-1-(Benzyloxy)-7-((t-butyldimethylsilyl)oxy)hept-4-en-2-ol (8a). Rf 0.12 (1:9 
EtOAc/hexanes); colorless oil, 92.0 mg (91%). 1H NMR (500 MHz, CDCl3) δ 7.34 (m, 1H), 
5.22 (m, 2H), 3.85 (m, 1H), 3.62 (t, 2H, J = 14.88, 7.44 Hz), 3.51 (dd, 1H, J = 12.98, 9.34, 
3.63 Hz), 3.67 (dd, 1H, 15.62, 10.04, 6.69 Hz), 2.45 (d, 1H), 2.29  (m, 5H), 0.89 (s, 9H), 
0.05 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 138.03, 129.11, 128.43, 127.74, 126.51, 73.93, 
73.39, 70.18, 62.74, 31.51, 31.08, 25.97, 18.41. IR (neat):  3460 (br), 3032 (w), 2958 (s), 
2927 (s), 2856 (s), 1471 (m), 1255 (s) cm-1. HRMS (ESI, [C20H34O2Si + Na]+) calcd 
373.2157, found m/z 373.2175. 
 
 
(Z)-(((6,6-Diethoxyhex-4-en-1-yl)oxy)methyl)benzene. Rf 0.33 (1:3 Et2O/hexanes); 
colorless oil, 145.0 mg (99%). 1H NMR (500 MHz, CDCl3) δ 7.37-7.33 (m, 4H), 7.31-7.27 
  66 
(m, 1H), 5.64 (dtd, 1H, J = 11.16, 7.53, 1.04 Hz), 5.51 (ddt, 1H, J = 11.16, 6.75, 1.04), 5.22 
(dd, 1H, J = 6.75, 1.04 Hz), 4.51 (s, 2H), 3.65 (m, 2H), 3.51 (m, 4H), 2.27 (qd, 2H, J = 7.53, 
1.30 Hz), 1.73 (quin, 2H), 1.22 (t, 6H); 13C NMR (125 MHz, CDCl3) δ 138.51, 133.85, 
128.29, 127.86, 127.52, 127.45, 97.58, 72.84, 69.54, 60.48, 29.40, 24.64, 15.27. IR (neat):  ν 
= 3029 (m), 2974 (m), 2928 (m), 2865 (m), 1682 (w), 1100 (s), 1051 (s) cm-1. HRMS (ESI, 
[C17H26O3 + Na]+) calcd 301.1780, found m/z 301.1772. 
 
 
(Z)-2-(5-(Benzyloxy)pent-1-en-1-yl)aniline (10a). Rf 0.47 (1:3 EtOAc/hexanes); red oil, 
104.0 mg (93%), 1H NMR (500 MHz, DMSO-d6) δ 7.35-7.24 (m, 5H), 6.96-6.92 (m, 2H), 
6.65-6.62 (m, 1H), 6.49 (td, 1H), 6.29 (dt, 1H), 5.64 (dt, 1H, J = 11.42 Hz); 13C NMR (125 
MHz, DMSO-d6) δ 145.99, 138.61, 131.61, 129.04, 128.14, 127.62, 127.37, 127.24, 125.80, 
121.02, 115.49, 114.51, 111.03, 71.77, 69.07, 29.39, 24.96. IR (neat):  3465 (m), 3370 (m), 
3061 (w), 3028 (m), 3002 (m), 2925 (m), 2854 (m), 1689 (m) cm-1. HRMS (EI, [C18H21NO]) 
calcd 267.1623, found m/z 267.1616. 
 
 
Methyl (Z)-non-2-enoate (11a). Rf 0.15 (3:97 EtOAc/hexanes); colorless oil, 91.0 mg 
(90%). 1H NMR (500 MHz, CDCl3) δ 6.22 (dt, 1H, J = 14.90, 11.48, 7.57 Hz), 5.76 (dt, 1H, 
J = 11.48, 3.42, 1.71 Hz), 3.70 (s, 3H), 2.64 (dq, 2H), 1.43 (m, 2H), 1.29 (m, 7H), 0.87 (t, 
3H). 
  67 
 
 
Ethyl (Z)-3-phenylacrylate (12a). Rf 0.33 (1:9 Et2O/hexanes); colorless oil, 75.7 mg 
(82%), 1H NMR (500 MHz, CDCl3) δ 7.62-7.57 (m, 2H), 7.39-7.19 (m, 3H), 6.96 (d, 1H, J = 
12.46 Hz), 5.96 (dd, 1H, J = 12.46, 0.78), 4.19 (qd, 2H), 1.26 (t, 3H); 13C NMR (125 MHz, 
CDCl3) δ 166.20, 142.94,134.87, 129.65, 128.94, 127.96, 119.88, 60.27, 14.07. IR (neat):  
2977 (m), 2927 (m), 2855 (m), 1712 (s), 1631 (m) cm-1. 
 
 
4-Acetylphenyl (Z)-non-2-enoate (13a). Rf 0.17 (1:3 Et2O/hexanes); colorless oil, 117.3 
mg (95%). 1H NMR (500 MHz, CDCl3) δ 8.03-8.00 (m, 2H), 7.25-7.22 (m, 2H), 6.49 (dt, 
1H, J = 11.42, 7.53 Hz), 6.01 (dt, 1H, J =11.42, 1.69 Hz), 2.72 (qd, 2H), 2.61 (s, 1H), 1.49 
(quin, 2H), 1.39-1.26 (m, 6H), 0.89 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 196.89, 163.88, 
154.61, 154.34, 134.56, 129.88, 121.87, 118.23, 31.58, 29.34, 28.98, 28.83, 26.60, 22.56, 
14.05. IR (neat):  2958 (m), 2924 (m), 2853 (m), 1743 (m), 1687 (m), 1599 (m) cm-1. HRMS 
(ESI, [C17H22O3 + Na]+) calcd 297.1467, found m/z 297.1472. 
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Oxiran-2-ylmethyl (Z)-non-2-enoate (14a). Rf 0.41 (1:3 Et2O/hexanes); colorless oil, 
yield 101.6 mg (95%).  1H NMR (500 MHz, CDCl3):  δ 6.28 (dt, 1H, J = 11.68, 7.53 Hz), 
5.80 (dt, 1H, J = 11.68, 1.82 Hz), 4.43 (dd, 1H, J = 12.46, 3.11 Hz), 3.98 (dd, 1H, J = 12.46, 
6.23 Hz), 3.25-3.22 (m, 1H), 2.85 (dd, 1H, J = 4.67, 4.15 Hz), 2.68-2.63 (m, 3H), 1.47-1.41 
(m, 2H), 1.37-1.25 (m, 6H), 0.88 (t, 3H); 13C NMR (125 MHz, CDCl3) δ 165.89, 151.99, 
118.73, 64.31, 49.42, 44.71, 31.59, 29.09, 28.93, 28.90, 22.53, 14.0. IR (neat):  2956 (m), 
2926 (m), 2856 (m), 1721 (s), 1642 (m), 1242 (s) cm-1. HRMS (ESI, [C12H20O3 + Na]+) 
calcd 235.1310, found m/z 235.1319. 
 
 
Pent-4-en-1-yl 2-phenylacrylate (15a). Rf 0.38 (1:9 Et2O/hexanes); colorless oil, 97.3 
mg (82%). 1H NMR (500 MHz, CDCl3) δ 7.45-7.42 (m, 2H), 7.39-7.32 (m, 3H), 6.37 (d, 
1H, J = 1.30 Hz), 5.90 (d, 1H, J = 1.30 Hz), 5.83 (tq, 1H, J  = 17.13, 10.38, 6.75 Hz), 5.06 
(dq, J = 17.13 Hz), 5.01 (m, 1H, J = 10.38 Hz), 4.26 (t, 2H), 2.17 (m, 2H), 1.82 (quin, 2H); 
13C NMR (125 MHz, CDCl3) δ 166.76, 141.52, 137.39, 136.74, 128.27, 128.10, 128.04, 
126.53, 115.33, 64.48, 30.10, 27.78. IR (neat):  3079 (m), 3026 (m), 2935 (m), 2851 (m), 
1717 (s), 1641 (m), 1614 (m) cm-1. HRMS (ESI, [C14H16O2 + Na]+) calcd 239.1048, found 
m/z 239.1042.  
 
 
1-Benzyl 2-(pent-4-en-1-yl) (S)-pyrrolidine-1,2-dicarboxylate (16a). Rf 0.35 (1:3 
EtOAc/hexanes); colorless oil, 155.3 mg (98%). 1H NMR (500 MHz, CDCl3) δ 7.38-7.26 
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(m, 5H), 5.76 (m, 1H), 5.20-5.06 (m, 2H), 5.06-4.95 (m, 2H), 4.36 (ddd, 1H), 4.15 (m, 1H), 
4.00 (m, 1H), 3.66-3.58 (m, 1H), 3.56-3.45 (m, 1H), 2.28-2.16 (m, 1H), 2.12 (q, 1H), 2.05-
1.84 (m, 5H), 1.74 (quin, 1H), 1.61 (quin, 1H); 13C NMR (125 MHz, CDCl3) δ 172.67, 
172.49, 154.70, 154.17, 137.27, 137.11, 136.64, 136.48, 128.31, 128.25, 127.80, 127.78, 
127.72, 127.67, 115.24, 115.23, 66.83, 66.82, 59.20, 58.84, 30.84, 29.83, 29.81, 29.74, 
27.65, 27.53, 24.17, 23.38. IR (neat):  3066 (w), 3033 (w), 2954 (m), 2933 (m), 2890 (m), 
2851 (m), 1743 (s), 1703 (s), 1641 (m) cm-1. HRMS (ESI, [C18H23NO4 + Na]+) calcd 
340.1525, found m/z 340.1525. 
 
 
Pent-4-en-1-yl ((benzyloxy)carbonyl)-D-alaninate (17a). Rf 0.10 (1: 9 
EtOAc/hexanes); colorless oil, 145.5 mg (96%). 1H NMR (500 MHz, CDCl3) δ 7.39-7.31 
(m, 5H), 5.80 (m, 1H), 5.33 (d, 1H), 5.12 (s, 2H), 5.08-4.99 (m, 2H), 4.39 (quin, 1H), 4.16 
(t, 2H), 2.13 (q, 2H), 1.76 (quin, 2H), 1.43 (d, 3H); 13C NMR (125 MHz, CDCl3) δ 172.96, 
155.54, 137.15, 136.25, 128.48, 128.12, 128.06, 115.46, 66.85, 64.80, 49.64, 29.86, 27.62, 
18.74. IR (neat):  3342 (m, br), 3066 (m), 3034 (m) 2939 (m), 1721 (s), 1641 (w) cm-1. 
HRMS (ESI, [C16H21NO4 + Na]+) calcd 314.1368, found m/z 314.1373. 
 
 
Oct-1-en-3-ol (18a). Rf 0.20 (5:95 Et2O/hexanes); colorless oil, 91.0 mg (90%). 1H 
NMR (500 MHz, CDCl3) δ 5.857 (m, 1H), 5.21 (d, J = 16.00 1H), 5.09 (d, 2H, J = 10.43), 
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1.43 (quin, 1H J = 23.30, 17.04, 11.48, 5.91), 1.59-1.25 (m, 10H), 0.88 (t, J = 13.91,6.96 
3H). 
 
 
Pent-4-en-1-yl ((benzyloxy)carbonyl)-L-alaninate (17a-L). Rf 0.10 (1: 9 
EtOAc/hexanes); colorless oil, 0.78 g (71%). 1H NMR (500 MHz, CDCl3) δ 7.38-7.29 (m, 
5H), 5.79 (m, 1H), 5.44 (s, 1H), 5.11 (s, 2H), 5.07-4.99 (m, 2H), 4.39 (quin, 1H), 4.16 (t, 
2H), 2.12 (q, 2H), 1.75 (quin, 2H), 1.42 (d, 3H); 13C NMR (125 MHz, CDCl3) δ 172.92, 
155.52, 137.10, 136.22, 128.41, 128.04, 127.99, 115.39, 66.76, 64.71, 49.58, 29.80, 27.56, 
18.60. IR (neat):  3341 (br m), 3066 (m), 3034 (m) 2923 (m), 1713 (s), 1641 (w) cm-1.   
HRMS (ESI, [C16H21NO4 + Na]+) calcd 314.1368, found m/z 314.1371. 
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2.7 NMR Spectra 
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 hex-3-yn-2-yl 2,3,4,5,6-pentafluorobenzoate_H1.esp
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 2-(5-(benzyloxy)pent-1-yn-1-yl)aniline_H1.esp
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 ethyl 3-phenylpropiolate_H1.esp
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 4-acetylphenyl non-2-ynoate_H1.esp
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 oxiran-2-ylmethyl non-2-ynoate_H1.esp
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 pent-4-yn-1-yl 2-phenylacrylate_H1.esp
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 1-benzyl 2-(pent-4-yn-1-yl) (S)-pyrrolidine-1,2-dicarboxylate_H1.esp
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 pent-4-yn-1-yl ((benzyloxy)carbonyl)-D-alaninate_H1.esp
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 (Z)-undec-4-en-3-ol_H1.esp
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.008.681.171.812.060.880.870.87
7
.2
7
 
 (Z)-undec-4-en-3-ol_C13.esp
200 180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
7
7
.0
0
 
  87 
 (Z)-undec-4-en-3-yl acetate_H1.esp
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 (Z)-hex-3-en-2-yl 2,3,4,5,6-pentafluorobenzoate_H1.esp
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 (Z)-(((6,6-diethoxyhex-4-en-1-yl)oxy)methyl)benzene_H1.esp
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 4-acetylphenyl (Z)-non-2-enoate_H1.esp
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 oxiran-2-ylmethyl (Z)-non-2-enoate_H1.esp
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 pent-4-en-1-yl 2-phenylacrylate_H1.esp
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 1-benzyl 2-(pent-4-en-1-yl) (S)-pyrrolidine-1,2-dicarboxylate_H1.esp
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 pent-4-en-1-yl ((benzyloxy)carbonyl)-D-alaninate_H1.esp
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2.8 HPLC Chromatograms 
Chiral Purity Analysis of Product 17a 
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Chiral Purity Analysis of Alkyne 17 
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Racemic Standard for Product 17a 
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Racemic Standard for Alkyne 17a 
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III. Amide and Peptide Bond Formation in Water at Room 
Temperature 
3.1 Introduction 
The amide bond is a functionality found extensively throughout many classes of 
molecules. This important linkage is the key feature for the construction and stability of 
proteins within living systems, many of which have led to the widespread development of 
peptide-based drugs.1 Furthermore, it is because of the stability and low toxicological 
liability that the amide/peptide linkage is so ubiquitously found across many industries, 
being highly prevalent throughout many of the top selling drugs including isentris, incivek, 
zoladex, and diovan. Amides are also found among many important agrochemicals such as 
boscolid, cylclaniliprole, and oxathiapiprolin. Excellent examples of how the stability of this 
bond can be used as functional materials are products such as Kevlar and nylon. In addition, 
compounds containing amides are found extensively in organocatalysis,2 are prevalent in 
ligand scaffolds for transition metal catalysis,3 and is often the linkage of choice for directing 
groups in C-H activation.4 
Amides are generally well tolerated over a wide range of reaction types due to the high 
activation energy required for hydrolysis5 as the result of delocalization of electrons across 
the functional group as well as their relatively high pKa of about 17-266 (depending on 
substituents) generally making this disconnection one which can be made early or late within 
a synthetic route. As a synthetic handle, however dehydration of an amide to the 
corresponding iminium salt can be achieved with a variety of reagents to arrive at the 
corresponding nitrile7 (from 1° amides) or an electrophilic synthon for the construction of 
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ketones, imine derivatives,8 and enamines,9 or cyclcic imines via the Bischler-Napieralski 
Reaction.10 Furthermore, Weinreb amides and amido-morpholines have been used 
extensively as stable precursors to ketones which are constructed under metalation 
conditions.11 Amides can be reduced to the corresponding amine with LiAlH412 while 
Weinerb amides can be reduced with LiAlH4 or DiBAlH to arrive at the corresponding 
aldehyde.13 Transition metal-catalyzed reduction of amides is also an intense field of study 
with recent advances being made with systems using Fe,14a,b Ru,14c Zn,14d Cu,14e Pt,14f Mo,14g 
Rh,14h and Ni.14i Amides may also be reduced catalytically via transition metal catalysis. In 
the presence of Br2 and a strong base, the Hofmann Rearrangement, can be performed on 
primary amides to deliver primary amines,15a,b carbamates,15c and ureas15d with the loss of 
the carbonyl carbon. 
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Figure 1. Representative examples of industrially important compounds containing amides. 
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3.2 Background 
Many routes to amides exist to date and a complete overview of all synthetic procedures 
is not appropriate here. This section will focus on the construction of amides from 
carboxylic and amine starting materials as this is by far the most widely utilized 
disconnection for the synthesis of peptides and industrial relevant amides. Used directly, the 
direct condensation of a carboxylic acid with an amine is possible, however in combination, 
the two coupling partners form a salt and consequently require high reaction temperatures of 
160-180°C which is energy intensive and generally incompatible with advanced 
intermediates due to the lability of sensitive functional groups and protected amino acids 
derivatives.5,16 As an alternate strategy, the acid may be activated by the displacement/direct 
conversion of the hydroxyl group of the carboxylic acid to a good leaving group (activation), 
allowing for displacement by the amine (aminolysis).17  
 
 
Scheme 1. Activation/aminolysis pathway for amide bond formation. 
 
Amidation by acid activation is done using one of three approaches, where a) the reactive 
activated acylating species is generated prior to the amidation reaction in a separate step; b) 
the activated species is generated, isolated, and purified prior to amidation; or c) activation 
of the acylating partner is generated in situ as a one-pot procedure, reacting the active 
species upon its formation in the presence of an amine.17 Classically, this approach has been 
demonstrated in many ways, including activation as acyl halides,18 acyl azides,19 
acylimidazoles,20 mixed anhydrides,21 as well as electron deficient “activated esters”. Each 
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activated species has its own merits, where acyl chlorides are conveniently prepared from a 
variety of reagents inexpensive reagents such as thionyl chloride22 and oxalyl chloride23 
which furnish the active intermediates cleanly within short reaction times as the reaction is 
driven by the generation of gaseous by-products, SO2 and CO/CO2 respectively. Other 
reagents for the generation of acyl chlorides include phosphorous trichloride,24a phosphorous 
oxychloride,24b phosphorous pentachloride,24c,d and cyanuric chloride.24e Acyl chlorides can 
be stored is some cases, but hydrolysis can be problematic. While the use of acyl chlorides is 
a convenient procedure for amide bond formation, this approach is not necessarily 
appropriate for the synthesis of peptides. In addition to the liberation of quantitative HCl as a 
by-product which is not amenable to Boc-protected peptides,0 the formation of oxazolone 
intermediates may be encountered leading to racemization of the α-stereocenter under mildly 
basic conditions (Scheme 2A).17 Chiral integrity of peptides may also be compromised using 
acid chlorides under basic conditions as the result of ketene formation by deprotonation of 
the chiral α-carbon (Scheme 2B).26 Other by-products that may arise from the use of acyl 
chlorides as well including N-carboxy anhydride formation (Scheme 2C).27 The issue of 
racemization via base-promoted oxozolone formation is one that extends to several other 
activated acyl derivatives across a broad range of highly electrophilic activated 
intermediates.17  
Acyl azides have been used extensively for peptide coupling showing minimal 
racemization in comparison to acyl chlorides, however the synthesis of such compounds 
requires the use of hazardous reagents such as hydrazine28a and DPPA,28b both of which are 
highly toxic and explosive.29 Amidation by this method is limited by the competing Curtius 
rearrangement which leads to side products in the form of isocyanates which can be 
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hydrolyzed to the corresponding amine, and thus compete with the desired amine 
nucleophile (Scheme 2D).30 
 
 
Scheme 2. A. oxazolone formation from acyl chlorides; B. Ketene formation from acyl 
chloride activation; C. N-carboxy anhydride formation from acyl chloride containing amino 
acid derivatives; D. Curtis rearrangement of acyl azides; E. Direct enolization of amino acid 
derivatives. 
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Acyl imidazoles deliver amides in good yields with minimal racemization, however their 
method of preparation is reliant on the use of carbonyl diimidazole (CDI) which decomposes 
in the presence of water.31 Similar to the previous cases presented, the formation of acyl 
imidazoles occurs in the reaction prior to addition of the amine to the reaction mixture, and 
isolation of the activated amide is generally not possible due to its rapid decomposition.17 
Mixed anhydrides remain as an important route to amide bonds, however their 
construction predominately utilizes coupling with a bulky acyl chloride,32a expensive 
reagents such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihyroquinoline (EDDQ) 32b again having 
the limitations of requiring anhydrous conditions and often low temperatures to arrive at 
active intermediates. Aside from the use of pivalic or carbonic anhydrides, selectivity can be 
an issue leading to lower overall yields and difficulties in removing by-products. 
Symmetrical anhydrides are simple to prepare and offer a cleaner reaction profile than their 
mixed counterparts, however the obvious drawback of this intermediate to the generation of 
one equivalent of waste from the carboxylic acid starting material. 32c  
As it stands, the major issue facing peptide coupling comes in the form of racemization 
which may go through two major pathways, namely: oxazolone formation (Scheme 2A) or 
direct enolization (Scheme 2E). The factors which influence oxazolone formation include a.) 
the electrophilicity of the activated species, b.) the nature of the α-amine (oxalonone 
formation is less favorable for amines protected as carbamates), and substitution of the α-
carbon (Figure 2).33 
 
 
Figure 2. α-proton acidity trend for various amino acids. 
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Development of reagents and conditions for activating the carbonyl center with control 
of racemization has thus been an intense area of research for nearly a half a century. Most 
commonly, carbodiimide reagents are employed such as EDC,34a DCC,34b and DIC34c to 
serve this purpose. The use of such reagents in combination with activators such as those 
derived from benzotriazoles (HOBt, HOAt, 6-Cl-HOBt) have been found as excellent 
additives to increase reaction rates, and suppress racemization beyond the selectivities of 
earlier developed activators such as DMAP, HOSu, and HONB (Figure 3).17 As a result of 
the dual nature of the carbodiimide/benzotriazole activation conditions, several advanced 
reagents have been developed that incorporate both compounds onto one scaffold as an 
uronium salt, such as TBTU, TATU, and TCTU or as a guinidinium salt such as HATU.17 
Alternate dual activation reagents for peptide coupling are phosphonium salts that work via a 
similar mechanism. These advanced coupling reagents have had a profound effect on peptide 
coupling today both in the solution and solid phase, and have been incorporated in the 
synthesis of many drugs including velcade35 and incivek,36 and victrelis.36  
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Figure 3. Common coupling reagents and activators for peptide coupling. 
 
In an attempt to further increase the safety of these reagents, a new class of oxime-
derived activators has since emerged with the goal of replacing the benzotriazole scaffold 
which is known to undergo autocatalytic decomposition.37 That is, benzotriazoles are 
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explosive. Oximes were explored due to the similar pKa to benzotriazoles, and from the 
screening of various electron deficient oximes, an old reagent with a new application arrived 
as Oxyma (1, Figure 4).38 Oxyma was found to offer excellent retention of stereochemistry 
with lower racemization than its benzotriazole counterparts, and can couple highly sterically 
hindered amino acids/peptides in high yields in short reaction times. The emerging success 
of this activator led to the development of a new coupling reagent, COMU (2), as a safer 
alternative to the existing state-of-the-art reagents.39 
 
 
Figure 4. Structures of Oxyma and COMU. 
 
Recently, much effort has been made towards forming amide bonds by boronic acid 
catalysis (BAC).40 While this transformation shows considerable promise in the field of 
peptide coupling, major limitations such as the requirement of a large excess of molecular 
sieves, expensive catalysts, narrow substrate scope, and irreproducibility suggests that the 
technology has yet to mature to the point where these conditions can complete with the 
current technology. Similarly, impressive progress has been made in the Ni-catalyzed 
catalytic amide bond formation from phenyl ethers,41 however high reaction temperatures, 
air-sensitive reaction conditions, high loading of the expensive catalyst, and narrow substrate 
scope renders this method inappropriate for peptide coupling as well. Another important 
contribution to the field is the Ru-catalyzed amide synthesis from amines and carboxylic 
acids activated in situ with acetylenes.42 This method requires high reaction temperatures as 
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well and uses another egregious solvent: 1,4-dioxane to afford highly variable yields for 
peptide and amide products (18-99%). The evolution of this transformation has a long 
history with remarkable advancements, yet one parameter in particular seemingly overlooked 
is solvent usage. Standard reaction conditions for peptide coupling rely heavily on the use of 
DCM and DMF,17 two of the most egregious solvents in synthesis. It is quite puzzling that 
less effort has been made to overcome the use of these solvents especially considering thier 
general avoidance for other transformations on scale and the correlation between 
racemization and the use of DMF.43 While it is well understood that the use of these polar 
aprotic solvents effectively solvate a broad spectrum of substrates, it is quite evident that a 
direct replacement exists to solubilize charged species: water. Interestingly, a 
communication was released for the suggestion of various alternative solvents including 2-
Me-THF, EtOAc, and IPA, yet water was excluded as a viable solvent for amide bond 
formation.0 It would seem that the call for a safer protocol has been answered by replacing 
benzotriazole activators; however, a method can hardly be considered “green” when 
reactions require genotoxic DMF as the reaction solvent.  
The absence of a general peptide coupling in water without the use of benzotriazole 
activators spurred interest in our group and inspired us to develop a protocol which would 
utilize a safer reagent such as COMU under aqueous reaction conditions and offer a method 
that not only replaces DMF and DCM, but also allows for recycling of the reaction 
medium.45 
3.3 Early Work 
Prior to our investigations on developing a sustainable method for peptide coupling, very 
few examples existed in the literature utilizing water as the reaction solvent. The use of 
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water dispersible nanoparticles for solid phase synthesis is one such example, utilizing 
Maryfield-type coupling under ball milling conditions.46 This method was used to synthesize 
the pentapeptide natural product Leu-enkaphaline and is a great development in peptide 
synthesis as water is generally disregarded as a solvent for solid phase peptide synthesis due 
to its less than optimal ability to swell peptide support resins.47 In these reports, material 
solubility is overcome mechanically with zirconium beads at high shear rates and thus may 
not be feasible in a conventional laboratory. In addition, the limitations of this method are 
clear, in that many non-peptide amide bond disconnections may not contain a handle for 
solid phase synthesis.  
PEG has been proven as an effective support for solid phase synthesis of peptides as 
well, where De Marco and co-workers described a method under aqueous conditions.48 Their 
procedure benefits from Leuch’s anhydrides,27 thus alleviating the necessity for amino acid 
protecting groups. In addition to the limitation of being amenable solely to the synthesis of 
peptides, the use of neat triphosgene under microwave irradiation (for synthesis of Leuch’s 
anhydrides) poses concerns in terms of safety,49 and the use of basic reaction conditions (pH 
= 10.4) may lead to racemized products. 
In the solution phase, Kurosu and co-workers developed a method in water utilizing 
EDC and an Oxyma derivative containing a ketal functionality for access to several short 
peptides under mild conditions.50 The ketal functionality was designed to improve water 
solubility of the oxime and enhanced reaction rate and de when used in the presence of 
NaHCO3. This method in particular is one that stands out among literature reports in terms 
of addressing safety, ease, and environmental responsibility. Limitations of this method are 
the lack of generality for amino acid coupling partners, in that more lipophilic amino acids 
require the use of a phase transfer catalyst (OTAB) or the use of DMF as a cosolvent.  
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On the contrary, use of DMT-Cl has been shown to work quite well under aqueous 
conditions for amidation of fatty acids.51 The unusual rate enhancement was attributed to 
incorporation of fatty acid salts in the micellar structure allowing reactions to take place at 
the micelle/H2O interface. The presented substrate scope is limited to only fatty acids and 
aliphatic amines. 
Seminal work on amidation in our studies began from a single example presented within 
a communication for the reduction of nitroarenes with Zn/NH4Cl under micellar catalysis 
conditions.52 The work describes the use of EDC and HOBt with Et3N as suitable conditions 
for the synthesis of a Procainamide precursor (Scheme 3). Based on these results, we set out 
to expand the scope and limitations of these conditions. The envisioned method would be 
general for amide bond formation in solution phase and would be amendable for both simple 
amide bonds as well as peptides under micellar catalysis conditions offering opportunity for 
solvent recycling. 
 
 
Scheme 3. Initial report of amide bond formation using TPGS-750-M/H2O. 
3.4 Results and Discussion 
Looking towards developing a sustainable method for amide and peptide bond formation 
in water method development began by assessing the use of EDC-based activators utilizing 
micellar conditions as a starting point (Table 1). Rather than optimizing from a simple 
primary amine, the screening was carried out with Leu-OEt HCl with hopes that the 
optimized conditions would readily be translated to a peptide bond forming event. p-Toluic 
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acid was chosen such that the products would be easily identified (by TLC and NMR) and 
purified by column chromatography. From this screening, it was found that modifying the 
equivalents of base showed a pronounced effect, where 2.0 equivalents of Et3N gave 
quantitative conversion to amide 4, either increasing to 3.0 equivalents or dropping to 1.0 
equivalent resulted in a lower isolated yield (entries 4 and 2, respectively). An explanation 
for this is that lower base loading leads to conditions that do not favor the nucleophilic 
attack of the amine onto the activated ester 5, rationalized by the buildup of activated 
intermediate in the isolated product, and under base-free conditions (entry 1). Excessively 
basic conditions favors nucleophilic attack of the amine onto the carboxydiimide center, 
irreversibly forming the corresponding guanidine species evident by the complete 
consumption of the amine and low overall yield (Scheme 4). Although excellent conversion 
was achieved for EDC/HOBt system, a major focus of this work was to use a non-
benzotriazole activator, such as Oxyma. In combination with EDC, only mediocre yields 
resulted while interestingly only 5% yield was achieved from the use of COMU (entry 8). 
 
 
Table 1. Initial screening of coupling reagents and activators. 
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Scheme 4. Guanidine by-product formation with EDC. 
 
These findings suggest that amide coupling in water is highly sensitive to base and 
prompted the screening of several other amine bases (Table 2). An interesting correlation 
was found where increasing the pKb led to higher overall yield of 4 where the weakest base 
in the series, N-methyl morpholine (NMM) yielded 93%, while the strongest base, 2,2,4,4-
tetramethylpiperidine (TMP), yielded only 4% product. This observation is in line with the 
prior observation of how increased base loading diminishes product yield, increased basicity 
favors direct attack of the amine on COMU to generate the guanidine by-product (Scheme 
5B). 
 
 
Table 2. Initial base screening with COMU in aqueous micellar catalysis conditions. 
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Scheme 5. A. Mechanism for COMU-mediated amide bond formation. B. Guanidine by-
product pathway from amine attack on COMU. 
 
Further investigation of the reaction medium was undertaken, investigating the surfactant 
and its concentration, as well as the global concentration of reagents (Table 3). It is well 
understood for chemistry developed under micellar conditions, that certain functional groups 
respond with greater difficulty to emulsion formation with aqueous surfactants, including 
amides and nitroarenes, which may require tuning for optimal stirring. The neutral nature of 
the initial reaction mixture solvates reaction components well, however as the reaction 
proceeds, precipitation of the highly crystalline product 4 may halt stirring and effect a lower 
yield. It was found for the model reaction that when the TPGS-750-M concentration was 
increased to 4 wt %, a higher isolated yield of 97% was realized in comparison to the 93% 
yield obtained with 2 wt % simply on the basis of stirring. TPGS-750-M was also found to 
outperform the 3rd generation designer surfactant SPGS-550-M53 as well as the system in the 
absence of surfactant. 
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Table 3. Surfactant screening for COMU-mediated amide bond formation. 
 
At this point, it was understood that side reactions involving our coupling reagent, 
COMU could lead to lower conversion to the desired product. It was determined that 1.1 
equivalents worked best for the synthesis of 4 showing the highest isolated yields, in 
comparison to 1.3 equivalents as recommended by the seminal report on COMU as a 
coupling reagent (Table 4). In fact, the optimized conditions established by our screening 
efforts afforded the product in higher yield than the system run under literature conditions in 
DMF (entries 2 & 5).39 
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Table 4. COMU equivalence optimization and literature comparison. 
 
At this stage, it was perceived that the optimal conditions had been found for amide bond 
formation under aqueous micellar conditions, and the conditions were attempted for peptide 
bond formation. Unfortunately, the coupling of Z-Phe-OH with Leu-OEt·HCl afforded only 
a 53% isolated yield for 5 at 18 h (Scheme 6). This led to additional screening of several 
additional bases including many in the pyridyl series (Table 5). These bases were chosen due 
to their relatively high pKb’s, allowing for neutral reaction conditions (pH = 6-7). From this 
screening, it was found that 2,6-lutidine not only afforded product 4 in quanitative yield, but 
also increased reaction rate significantly, reaching completion in only 15 minutes. 
 
 
Scheme 6. Initial attempt at peptide bond formation under optimized conditions. 
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Table 5. Weak base screening for peptide optimization. 
 
The success of changing the base to 2,6-lutidine from NMM for the model system was 
then applied once again to the formation of peptide bonds, which translated quite well, 
requiring only 2 wt % TPGS-750-M while maintaining a global concentration of 0.5 M to 
deliver excellent yields in short reaction times (Figure 5). Without modification to the 
general method, a variety of aliphatic amino acids were coupled including sterically hindered 
Z-Aib-OH (products 6-10), Boc-Phg-OH and Z-Phg-OH (15 & 16), and Fmoc-Val-OH (20) 
coupling nicely to hindered and secondary amines such as Phg-OMe (9 & 15) and prolines 
(10, 14, 21, & 23). These conditions show no limitations for common amino acid protecting 
groups including Cbz, Boc, and Fmoc N-terminus protected amino acids as well as C-
terminus alkyl, allyl, tert-butyl, and benzyl esters. The retention of Fmoc is an interesting 
feature of this chemistry as deprotection of this protecting group typically employs basic 
conditions.0  
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Figure 5. Representative example of COMU peptide coupling with 2,6-lutidine and 2 wt % 
TPGS-750-M/H2O. 
 
In addition to the versatility of this method for the construction of dipeptides, several 
important oligopeptides were also prepared including Chlamydocin precursor 21,54 and 
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Streptocidin C precursor 23 (Figure 6).55 The literature describing other syntheses of 
Chlamydocin precursor 24 highlights the utility of the newly optimized protocol in water, 
where yields in organic solvent were much lower (79% for both reports compared to 93%), 
and required low temperatures with longer reaction times (Figure 7).56 
 
 
Figure 6. Structures of natural products Chlamydocing and Streptocidin C. 
 
 
 
Figure 7. Literature comparison for initial coupling step in route to Chlamydocin. 
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Use of 2,6-lutidine was originally pursued for its known ability as an effective base for 
amide couplings, while reducing the extent of epimerization/racemization due to steric bulk 
surrounding its basic site.57 Under our standard conditions leading to products Z-Aib-Phg-
OMe (9) and Z-Aib-Phe-OMe (24), no epimerization was observed (Table 5). Chiral 
integrity of these materials was maintained for the synthesis of 24 even when pyridine was 
used in place of 2,6-lutidine. The mildly acidic to neutral conditions (pH = 6−7) involved 
explains the low occurrence of epimerization which is insufficient for deprotonation of the 
α-proton of phenylglycine (Figure 8).6 Not only do the neutral conditions protect from 
epimerization but, in fact, effect overall conversion as well. As stated earlier, strongly basic 
conditions such as reactions with DBU or DABCO, resulted in a more alkaline reaction 
mixture (pH = 9), and no detectable coupling product was observed due to the formation of 
the guanidine species from the reaction of the free amine with the uronium carbon center of 
COMU (Scheme 5B).  
 
 
Figure 8. Epimerization study with 2,-6-lutidine and pyridine. 
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Consistent with the base effects from the initial screening in Table 1, pH of the reaction 
is directly related to product yield. It was found that either increasing or decreasing the pH of 
a reaction outside of the 6-7 window leads to lower overall yields even when 2,6-lutidine as 
the base (Figure 9). It is believed that in addition to diminishing the occurrence of guanidine 
by-products, correlation between pH and reaction yield may be due to amino acid solubility. 
Most coupling partners will dissolve readily into the aqueous surfactant solution containing 
2,6-lutidine, which may solubilize each component as its corresponding carboxylate or 
ammonium salt. The increased solubility allows reactions to take place within short reaction 
times while slightly retarding the nucleophlicity of the amine component. Upon formation of 
the water insoluble amide, the surfactant plays its major role by sequestering the product 
within the micellar core.  
 
 
Figure 9. Peptide coupling with COMU/2,6-lutidine under standard neutral, acidic, and 
basic conditions. 
 
Support for this hypothesis is that fact that these reactions do occur to varying extents in 
the absence of surfactant (i.e., on water), however yields may vary depending on the nature 
of the coupling partners and products (Figure 10). For example, significantly lower yield is 
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obtain for the synthesis of 20 on water (53%) compared to the reaction in aqueous TPGS-
750-M (96%). In some cases, it was found that dissolution of amino acids was troublesome 
even with TPGS-750-M, resulting in notably reduced yields. This issue was addressed by the 
use of the new surfactant LB-1000-M that offered increased solubility due to the presence of 
a sulfone group within the aliphatic region of the surfactant, designed to mimic the solvation 
properties of DMSO. The results of changing surfactant were substantial, offering on 
average a 40% increase in yield (Figure 11). 
 
 
Figure 10. Representative examples for the comparison of optimized conditions to on water 
conditions. 
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Figure 11. Comparison of optimized conditions with 2 wt % TPGS-750-M to sulfone 
surfactant LB-1000. 
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The generality of the method optimized in TPGS-750-M was further explored for 
products resulting from amide bond formation as illustrated in Figure 12. Without 
modification to the existing procedure several products were generated including simple 
alkanoic acid-alkylamine-derived amides (products 31−33) and secondary amines such as 
piperazine in 34. A variety of conjugated carboxylic acids produce amides as well under 
standard conditions including propargyl amide (35), as well as substituted benzamides 
(36−39). Reaction of p-chlorobenzoic acid with L-Trp-OMe·HCl afforded Benzotript58 
methyl ester 37 in high yield (92%) after only 2 h, while the unprotected indole nitrogen of 
tryptophan showed no influence on the coupling. Racemic 38 was unexpectedly challenging, 
affording the product in only 36% after 16 h, with the Oxyma-activated ester of 4-n-
butoxybenzoic acid was isolated in 57% yield. Heating the reaction to 45°C circumvented 
the reduced electrophilicity of this activated ester to afford a 90% yield with only trace 
amounts of the activated intermediate remaining within only 2 h. In addition, adduct 39 was 
isolated in 85% yield after only 1 h from the condensation of m-bromobenzoic acid and the 
N,O-dimethylhydroxylamine hydrochloride, this being the first reported synthesis of a 
Weinreb amide11 in the absence of organic solvent. 
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Figure 12. Representative examples of amide bond formation in water at room temperature. 
 
Isolation of the amide or peptide is simplified based on the nature of the starting 
materials and by-products of COMU in water. Extraction directly from the reaction mixture 
with minimal amounts of organic solvent such as MTBE or iPrOAc is effective to remove 
the coupling product from the reaction mixture (Figure 13), offering an exceptionally low E 
Factor0 of 2.8 (E Factor = 7.8 when water is included in the calculation). Enrichment of the 
organic extracts from unreacted amine and carboxylic starting materials as well as Oxyma 
and the urea by-product of COMU are easily removed by washes with saturated Na2CO3 
followed by 1 M HCl. Once enriched, the organic extracts are passed through a plug of silica 
which is sufficient for the isolation of pure product. In some cases column chromatography 
is necessary, such as the presence of unreacted activated esters, for example. It should be 
noted that less polar extraction solvents such as MTBE or iPrOAc lower the partition of 
Oxyma during extractions requiring less Na2CO3 washes during work up. Alternately, a 
mixture of EtOAc and hexanes suffices to afford a similar effect. Furthermore, the remaining 
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aqueous reaction mixture can be recycled at least four additional times without decreasing 
yields (Figure 14). In fact, yields were shown to increase most likely due to the increased 
loading of Oxyma with every subsequent reaction. 
 
 
Figure 13. Extraction with MTBE directly from reaction mixture. 
 
 
 
Figure 14. Recycle capabilities of COMU-mediated peptide bond formation in water. 
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In order to explore the versatility of the developed conditions, many of the most 
commonly utilized coupling reagents were explored under our conditions (Figure 15). While 
this list was not intended to be exhaustive, the goal was to prove the applicability of these 
coupling reagents in water at room temperature. As previously described, base loading has a 
tremendous effect on the success of amide bond formation under micellar catalysis 
conditions, and it is our belief that any of the reagents described in Figure 15 could be 
optimized for success under aqueous conditions. 
 
 
Figure 15. Survey of coupling reagents under optimized conditions. 
 
Over the course of this study, one limitation of this methodology was recognize in that 
amide bond formation from anilines halted the reaction at the activated ester due to their 
poor nucleophlicity. This was observed upon attempting the coupling of Boc-Pro-OH with 
3,5-xylidine for the synthesis of 40, an important intermediate for the synthesis of ACT-
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462206, Actelion’s potent  dual orexin receptor antagonist candidate for the treatment of 
insomnia (Scheme 7).60 Several modifications were made to the existing protocol including: 
increased COMU loading, portion-wise COMU loading, increased global concentration to 
(1M), heating (to 40 °C), screening other bases (NMM and DMAP), and extended reaction 
times. In all cases, only the activated oxime ester of Boc-Pro-OH (41) was isolated. At the 
time of this study it was accepted as a limitation that anilines were inappropriate 
nucleophiles for this method and the communication was submitted absent of this product 
type. This limitation was one that was particularly important to overcome, as many 
important compounds contain this scaffold.  
 
 
Scheme 7. Attempt at amide bond formation from an aniline nucleophile en route to     
ACT-462206. 
 
A recent report by Parmentier and co-workers at Novartis showed that amide bonds from 
anilines could be effected in aqueous TPGS-750-M, utilizing EDC, HOBt, and NMM with 
the use of PEG-200 as co-solvent.61 This communication certainly proved that this 
disconnection could be possible with the use of HOBt surrogates such as COMU or Oxyma. 
Looking back at initial screening data from our method, it was considered that the risk of 
forming guanidine by-products may be less favorable even under highly basic conditions due 
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to the decreased nucleophilicity of anilines in comparison to aliphatic amines. Revisiting this 
method for the coupling of phenylacetic acid and o-toluidine, it was found that the amide 
product 42 could be effectively produced within 4 h to achieve 89% conversion (Figure 16, 
entry 1). Further optimization is now underway to improve conversion and expand the scope 
for N-aryl amides. 
 
 
Figure 16. COMU-mediated amide bond formation from o-toluidine with DABCO. 
3.5 Summary and Conclusions 
In summary, a mild, efficient, and general method has been developed for the synthesis 
of peptide and amide bonds in water at room temperature. The use of commercially available 
COMU alleviates the need for hazardous benzotriazole activators which poss issues in terms 
of safety. Furthermore, reactions take place under neutral conditions protecting valuable 
peptide products from racemization.  These reactions take place in the absence of organic 
solvent, having major safety and environmental improvements over current state-of-the-art 
technology which generally requires egregious solvents such as DCM and DMF. Isolation 
and purification of the peptide/amide products is routinely simple, taking advantage of the 
aqueous nature of by-products to arrive at pure material after acid/base washes and filtration 
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through a short plug of silica. The sustainability of this method can be quantified by the low 
E Factor of 2.8 and the ability to recycle the aqueous reaction solvent without effecting 
reaction rates or yields. Further investigation into scope expansion to include aniline 
nucleophiles is now underway. 
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3.6 List of Acronyms and Abbreviations 
2-Me-THF 2-methyltetrahydrofuran 
6-Cl-HOBt 6-chloro-1-hydroxybenzotriazole 
Aib  amino isobutyric acid 
Ala  L-alanine 
BAC   boronic acid catalysis 
Boc  tert-butoxy carbamate 
Cbz, Z  benzyloxycarbonyl 
CDI   carbonyl diimidazole 
COMU 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino   
  morpholinomethylene)] methanaminium hexafluorophosphate 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DBU  1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC  N,N'-dicyclohexylcarbodiimide 
DCM  dichloromethane 
DiBAlH  diisobutylaluminium hydride 
DIC  N, N′-Diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine 
DMAP  4-Dimethylaminopyridine  
DMF  N,N-dimethylformamide 
DMSO  Dimethyl sulfoxide 
DMT-Cl 4,4′-Dimethoxytrityl chloride 
DPPA  Diphenylphosphoryl azide 
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EDC  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDDQ  2-ethoxy-1-ethoxycarbonyl-1,2-dihyroquinoline 
Et3N  triethylamine 
EtOAc  ethyl acetate 
Fmoc  9-fluorenylmethyloxcarbonyl 
GC/MS gas chromatography–mass spectrometry 
HATU  N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N- 
  methylmethanaminium hexafluorophosphate N-oxide 
HOAt  1-hydroxy-7-azabenzotriazole 
HOBt  hydroxybenzotriazole 
HONB  N-hydroxy-5-norbornene-2,3-dicarboxylimide 
HOSu  N-hydroxysuccinimide 
HPLC  high performance liquid chromatography 
IPA  isopropyl alcohol 
iPrOAc isopropyl acetate  
Leu  L-leucine 
MMTM 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium   
  tetrafluoroborate 
MTBE  methyl tert-butyl ether 
NMM   N-methyl morpholine 
NMR  nuclear magnetic ressonance 
OTAB  octyltrimethylammonium bromide 
PEG  polyethylene glycol 
Phe  L-phenylalanine 
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Phg  L-phenylglycine 
Pro  L-proline 
PyAOP [(7-azabenzotriazol-1-yl)oxy]tris(pyrrolidino) phosphonium   
  hexafluorophosphate 
PyBOP benzotriazol-1-yloxytri(pyrrolidino) phosphonium hexafluorophosphate 
SM  starting material 
SPGS-550-M β-sitosterol methoxypolyethyleneglycol succinate 
TATU  O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
TBTU  N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate 
TCTU  O-(6-Chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium   
  tetrafluoroborate 
TLC  thin layer chromatography 
TMP   2,2,4,4-tetramethylpiperidine 
TPGS-750-M DL-α-Tocopherol methoxypolyethylene glycol succinate 
Trp  L-tryptophan 
Val  L-Valine 
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3.7 Experimental Procedures 
General Information 
A solution of 2 wt % TPGS-750-M/H2O solution was prepared by dissolving TPGS-750-
M in degassed HPLC grade water and was stored under argon. TPGS-750-M was made as 
previously described62 and is available from Sigma-Aldrich (catalog #733857). All 
commercially available reagents were used without further purification.  Thin layer 
chromatography (TLC) was done using Silica Gel 60 F254 plates (Merck, 0.25 mm thick). 
Flash chromatography was done in glass columns using Silica Gel 60 (EMD, 40-63 μm). 1H 
and 13C NMR were recorded at 22 °C on a Varian UNITY INOVA at 500 MHz. Chemical 
shifts in 1H NMR spectra are reported in parts per million (ppm) on the δ scale from an 
internal standard of residual CDCl3 (7.27 ppm) or the central peak of DMSO-d6 (2.50 ppm). 
Data are reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, quin = quintet), and integration. Chemical shifts in 13C chemical spectra are 
reported in ppm on the δ scale from the central peak of residual CDCl3 (77.00 ppm) or the 
central peak of DMSO-d6 (39.51 ppm). IR data were collected on a Perkin Elmer Spectrum 
Two UATR FT-IR Spectrometer and peaks were described according to relative intensity 
and resolution as follows:  s = strong, m = medium, w = weak, br = broad. Chiral HPLC data 
were collected using a Shimadzu LC-20AT Prominence liquid chromatograph coupled with 
Shimadzu SPD-M20A Prominence diode array detector. HPLC method ran at 1 mL/min 
using 10% v/v isopropanol/hexanes through a CHIRALCEL® OD-H column. 
General Procedure for Amide Bond Formation in Water 
To a clean microwave vial with Teflon coated stir bar, carboxylic acid is transferred (1.1 
equiv) followed by 2 wt % TPGS-750-M/H2O (0.5 M) and 2,6-lutidine (3.1 equiv). After 
stirring ~5 min, the amine is transferred (1.0 equiv) followed by COMU (1.1 equiv). Within 
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1 min a successful reaction will become yellow in color which indicates the free-base form 
of the oxime activating agent. The reaction is monitored by TLC utilizing bromocresol green 
and ninhydrin or KMnO4 to indicate disappearance of carboxylic acid and amine starting 
materials, respectively. 
Work-up Procedure 
The aqueous reaction mixture is extracted with 3 x 2 mL MTBE, EtOAc, i-PrOAc, or 3:1 
EtOAc:hexanes. The organic extracts are then washed with 2 x 6 mL 1 M HCl and 3 x 6 mL 
Na2CO3 saturated solution in water. The organic phase is then passed through a plug of silica 
and evaporated to dryness. 
Note:  Less polar extraction solvents such as MTBE (methyl t-butyl ether) or i-PrOAc 
(isopropyl acetate) are generally used in order to minimize the partition of the oxime into the 
organic phase during basic extractions. Additional basic extractions may be required if 
EtOAc is used as extraction solvent. Most peptide coupling products can be isolated without 
additional purification; however, column chromatography can be utilized in order to purify 
any of the products in this work.  
Coupling Reagent Screening Procedure 
To a microwave vial with stir bar was transferred carboxylic acid (0.55 mmol), 2 wt % 
TPGS-750-M/H2O (1.0 mL), 2,6-lutidine, amine (0.5 mmol), and coupling reagent (+ 
additive). Reaction was stirred in an open vial for 30 min before extracting with 3 x 2 mL 
MTBE. Organic fractions were combined and washed with 2 x 6 mL 1 M HCl, 3 x 6 mL 
saturated Na2CO3 solution in water, and then filtered through a plug of silica and condensed 
under reduced pressure. 
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Aqueous Surfactant Recycling Procedures 
To a clean microwave vial with Teflon coated stirbar, Z-Aib-OH (1.1 mmol) was 
transferred followed by 2 wt % TPGS-750-M/H2O (2.0 mL) and 2,6-lutidine (0.36 mL). 
After stirring ca. 5 min, Phe-OEt.HCl (1.0 mmol) was transferred followed by COMU (1.1 
mmol). After ca. 30 min, 3 x 1 mL extractions with MTBE were done followed by 2 x 1 mL 
1 M HCl, and 4 x 1 mL saturated aqueous Na2CO3 washes and filtration through silica plug 
with subsequent rinse with 2 mL MTBE to obtain pure Z-Aib-Phe-OEt. To the surfactant 
solution remaining in the reaction flask appropriate amounts of each reagent were then 
added:  Z-Aib-OH (1.1 mmol), 2,6-lutidine (0.36 mL), Phe-OEt.HCl (1.0 mmol), and 
COMU (1.1 mmol). The reaction was again allowed to stir for 30 min before work-up. This 
procedure was continued until the surfactant solution had been recycled five times. 
E Factor Determination Procedure 
To a clean microwave vial with Teflon coated stirbar, Z-Aib-OH (261.0 mg, 1.1 mmol) 
was transferred followed by 2 wt % TPGS-750-M/H2O (2.0 mL) and 2,6-lutidine (0.36 mL, 
3.1 mmol). After stirring ca. 5 min, Phe-OEt.HCl (230.2 mg, 1.0 mmol) was transferred 
followed by COMU (471.1 mg, 1.1 mmol). After ca. 30 min, the product was extracted with 
1 x 0.5 mL (435.0 mg) and 1 x 0.75 mL (652.5 mg) i-PrOAc followed by 2 x 1 mL 1 M HCl, 
and 4 x 1 mL saturated aqueous Na2CO3 washes and filtration through silica plug to obtain 
pure Z-Aib-Phe-OEt (394.9 mg, 96%). 
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E Factor Calculations (without water) 
E Factor = (Mass of Organic Waste) / (Mass of Product) 
Mass of Organic Waste = (0.5 + 0.75) mL iPrOAc = 1.25 mL iPrOAc (0.870 g/mL)  
= 1087.5 mg 
Mass of Product = 394.9 mg 
E Factor = (1087.9 mg) / (394.9 mg) = 2.75 
E Factor Calculations (with water) 
E Factor = (Mass of Organic Waste + Aqueous waste) / (Mass of Product) 
Mass of Water = (2.0 mL) (1.0 g/mL) = 2000 mg 
E Factor = (1087.5 mg + 2000 mg) / (394.9 mg) = 7.8 
3.8 Compound Data 
 
 
Ethyl (4-methylbenzoyl)-L-leucinate (4). Rf 0.28 (1:3 EtOAc/hexanes); white solid, 
mp: 90-91 °C, 137.8 mg (99%). 1H NMR (500 MHz, CDCl3) δ 7.70 (dt, 2H), 7.22 (dt, 2H), 
6.58 (d, 1H), 4.84 (m, 1H), 4.22 (q, 2H), 2.39 (s, 3H), 1.79-1.71 (m, 2H), 1.71-1.61 (m, 1H), 
1.30 (t, 3H), 0.99 (d, 3H), 0.97 (d, 3H). 13C NMR (125 MHz, CDCl3) δ 173.31, 166.94, 
142.05, 131.12, 129.14, 127.00, 61.35, 51.09, 41.95, 24.95, 22.81, 22.09, 21.41, 14.13. IR 
(neat): ν = 3356 (m, br), 3076 (w), 3031 (w), 2956 (m), 2933 (m), 2872 (m), 1744 (s), 1637 
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(s), 1522 (s), 1501 (s). HRMS (ESI+, [C16H23NO3 + Na]+) calcd 300.1576, found m/z 
300.1573. 
 
 
Z-Aib-Leu-OEt (6). Rf 0.52 (1:1 EtOAc/hexanes); white solid, mp: 63-65 °C, 181.1 mg 
(96%). 1H NMR (500 MHz, DMSO-d6) δ 7.38 (d, 1H), 7.38-7.27 (m, 5H), 7.22 (s, 1H), 4.98 
(q, 2H), 4.22 (m, 1H), 4.05 (m, 2H), 1.66-1.54 (m, 2H), 1.47-1.40 (m, 1H), 1.35 (s, 6H), 1.16 
(t, 3H), 0.85 (d, 3H), 0.81 (d, 3H); 13C NMR (125 MHz, DMSO-d6) δ 174.16, 172.41, 
154.55, 137.01, 128.27, 127.68, 127.62, 65.01, 60.27, 55.84, 50.45, 39.46, 25.41, 24.54, 
24.08, 22.88, 21.11, 14.01. IR (neat): ν = 3324 (m), 3037 (w), 2982 (m), 2957 (m), 2931 
(m), 2869 (m), 1748 (s), 1738 (s), 1692 (s), 1656 (s). HRMS (ESI, [C23H28N2O5 + Na]+) 
calcd 401.2052, found m/z 401.2036. 
 
 
Z-Aib-Leu-OAllyl (7). Rf 0.30 (1:3 EtOAc/hexanes); white solid, mp: 78-80 °C, 152.7 
mg (80%). 1H NMR (500 MHz, DMSO-d6) δ 7.80 (d, 1H), 7.43-7.26 (m, 5H), 7.22 (s, 1H), 
5.88 (m, 1H), 5.30 (dd, 1H), 5.20 (dd, 1H), 4.99 (q, 2H), 4.55 (m, 2H), 4.30 (m, 1H), 1.70-
1.56 (m, 2H), 1.52-1.43 (m, 1H), 1.36 (s, 6H), 0.85 (d, 3H), 0.81 (d, 3H); 13C NMR (125 
MHz, DMSO-d6) δ 174.25, 172.14, 154.56, 137.01, 132.41, 128.25, 127.67, 127.61, 117.61, 
65.04, 64.66, 55.86, 50.50, 39.47, 25.43, 24.51, 22.87, 21.07. IR (neat): ν = 3318 (s), 3092 
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(w), 3069 (w), 3032 (w), 2960 (m), 2872 (m), 1750 (s), 1737 (s), 1670 (s), 1692 (s), 1652 
(s), 1519 (s). HRMS (ESI, [C21H30N2O5 + Na]+) calcd 413.2052, found m/z 413.2048. 
 
 
Z-Aib-Phe-OEt (8). Rf 0.49 (1:1 EtOAc/hexanes); white solid, mp: 94-95 °C, 206.5 mg 
(>99%). 1H NMR (500 MHz, DMSO-d6) δ 7.73 (d, 1H), 7.43-7.15 (m, 11H), 4.97 (s, 2H), 
4.45 (dt, 1H), 4.04 (q, 2H), 3.00 (m, 2H), 1.29 (s, 6H), 1.13 (t, 3H); 13C NMR (125 MHz, 
DMSO-d6) δ 174.02, 171.35, 154.52, 137.24, 136.93, 129.16, 128.28, 128.09, 127.72, 
127.65, 126.41, 65.09, 60.48, 55.83, 53.56, 36.51, 25.12, 24.78, 13.92. IR (neat): ν = 3318 
(m, br), 3063 (m), 3031 (m), 2983 (m), 2938 (m), 1723 (s), 1662 (s). HRMS (ESI, 
[C23H28N2O5 + Na]+) calcd 435.1896, found m/z 435.1879. 
 
 
Z-Aib-Phg-OMe (9). Rf 0.45 (1:1 EtOAc/hexanes); white solid, mp: 125-126 °C, 179.7 
mg (90%). 1H NMR (500 MHz, DMSO-d6) δ 8.13 (d, 1H), 7.40-7.28 (m, 11H), 5.40 (d, 
1H), 5.00 (m, 2H), 3.63 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H); 13C NMR (125 MHz, DMSO-d6) 
δ 174.02, 171.85, 154.79, 136.93, 136.56, 128.44, 128.27, 127.97, 127.69, 127.58, 127.49, 
65.14, 56.24, 55.98, 52.26, 25.14, 24.73. IR (neat): ν = 3323 (m, br), 3065 (m), 2925 (m), 
2854 (m), 1744 (s), 1688 (s), 1674 (s), 1660 (s). HRMS (EI+, [C21H24N2O5]+) calcd 
384.1685, found m/z 384.1671. 
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Z-Aib-Pro-OBn (10). Rf 0.14 (1:2 EtOAc/hexanes); sticky white solid, mp: 92 °C, 151.1 
mg (74%, 2.5 h), 174.5 mg (84%, 22 h). 1H NMR (500 MHz, DMSO-d6) δ 7.75 (s, 1H), 
7.40-7.26 (m, 10H), 5.13-5.13 (m, 4H), 4.30 (dd, 1H), 3.61 (m, 1H), 3.27 (m, 1H), 1.95 (m, 
1H), 1.87-1.64 (m, 3H), 1.34 (s, 3H), 1.23 (s, 3H); 13C NMR (125 MHz, DMSO-d6) δ 
171.93, 171.59, 154.24, 137.02, 136.06, 128.32, 128.27, 128.03, 127.92, 127.85, 127.72, 
65.54, 65.16, 60.24, 55.66, 47.22, 27.30, 25.54, 25.30, 24.28. IR (neat): ν = 3307 (s), 3088 
(w), 3034 (m), 2997 (m), 2970 (m), 2947 (m), 2877 (m), 1737 (s), 1718 (s), 1610 (s), 1536 
(s).  
 
 
Z-Leu-Phe-OEt (11). Rf 0.18 (1:3 EtOAc/hexanes); white solid, mp: 91-92 °C, 210.5 
mg (95%). 1H NMR (500 MHz, CDCl3) δ 7.40-7.07 (m, 10H), 6.44 (d, 1H), 5.11 (m, 3H), 
4.83 (q, 1H), 4.17 (m, 3H), 3.12 (m, 2H), 1.74-1.57 (m, 2H), 1.47 (m, 1H), 1.24 (t, 3H), 0.92 
(d, 6H). 13C NMR (125 MHz, CDCl3) δ 171.61, 171.15, 156.02, 136.16, 135.70, 129.31, 
128.50, 128.46, 128.16, 127.99, 127.05, 67.03, 61.50, 53.45, 53.16, 41.36, 37.88, 24.60, 
22.82, 21.96, 14.04. IR (neat): ν = 3315 (m), 3278 (m), 3066 (w), 3034 (w), 2956 (m), 2935 
(m), 2871 (m), 1734 (s), 1682 (s), 1665 (s). HRMS (ESI+, [C25H32N2O5 + Na]+) calcd 
463.2209, found m/z 463.2190. 
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Z-Leu-D-Phe-OMe (12). Rf 0.56 (1:1 EtOAc/hexanes); white solid, mp: 114 °C, 2199.8 
mg (95%). 1H NMR (500 MHz, DMSO-d6) δ 8.75 (d, 1H), 7.44-7.28 (m, 11H), 5.43 (d, 1H), 
5.03 (s, 2H), 4.23 (dt, 1H), 3.63 (s, 3H), 1.58 (m, 1H), 1.50-1.41 (m, 1H), 1.39-1.31 (m, 1H), 
0.84 (d, 3H), 0.83 (d, 3H); 13C NMR (125 MHz, DMSO-d6) δ 172.40, 170.87, 155.82, 
137.06, 136.37, 128.65, 128.31, 128.20, 127.74, 127.58, 127.56, 65.34, 56.02, 52.82, 52.26, 
40.85, 24.17, 22.98, 21.33. IR (neat): ν = 3298 (m), 3064 (w), 2958 (m), 2932(m), 1732 (s), 
1687 (s), 1647 (s). HRMS (ESI, [C24H30N2O5 + Na]+) calcd 449.2052, found m/z 449.2032. 
 
 
Z-Phe-Leu-OEt (6). Rf 0.66 (1:1 EtOAc/hexanes); white solid, mp: 118 °C, 189.3 mg 
(90%). 1H NMR (500 MHz, DMSO-d6) δ 8.37 (d, 1H), 7.48 (d, 1H), 7.37-7.15 (m, 10H), 
4.93 (s, 2H), 4.29 (m, 2H), 4.08 (m, 2H), 3.00 (dd, 1H), 2.73 (dd, 1H), 1.71-1.46 (m, 3H), 
1.17 (t, 3H), 0.91 (d, 3H), 0.86 (d, 3H). 13C NMR (125 MHz, DMSO-d6) δ 172.31, 171.83, 
155.78, 138.06, 137.01, 129.17, 128.24, 127.99, 127.64, 127.40, 37.35, 24.19, 22.74, 21.33, 
14.02. IR (neat): ν = 3309 (m), 3065 (m), 3034 (m), 2952 (m), 2928 (m), 2866 (m), 1727 (s), 
1691 (s), 1651 (s), 1525 (s). HRMS (ES+, [C25H32N2O5 + Na]+) calcd 463.2209, found m/z 
463.2196. 
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Boc-Phe-Met-OMe (13). Rf 0.44 (1:1 EtOAc/hexanes); white solid, mp: 75-77 °C, 202.4 
mg (99%). 1H NMR (500 MHz, CDCl3) δ 7.28-7.23 (m, 2H), 7.22-7.15 (m, 3H), 6.73 (d, 
1H), 5.14 (d, 1H), 4.62 (q, 1H), 4.37 (m, 1H), 3.68 (s, 3H), 3.04 (d, 2H), 2.39 (m, 2H), 2.09 
(m, 1H), 2.03 (s, 3H), 1.91 (m, 1H), 1.38 (s, 9H). 13C NMR (125 MHz, CDCl3) δ 171.67, 
171.09, 155.26, 136.39, 129.18, 128.45, 126.76, 80.02, 55.56, 52.29, 51.39, 37.94, 31.41, 
29.58, 28.11, 15.19. IR (neat): ν = 3308 (m), 3063 (w), 2974 (m), 2919 (m), 1743 (s), 1682 
(s), 1651 (s), 1520 (s). 1H & 13C NMR was in agreement with previously reported data on 
this compound.63 
 
 
Z-Phe-Pro-OBn (14). Rf 0.23 (1:2 EtOAc/hexanes); colorless oil, 211.7 mg (90%). 1H 
NMR (500 MHz, 80.0 °C, DMSO-d6) δ 7.41-7.16 (m, 17H), 5.14 (m, 2H), 4.96 (m, 2H), 
4.47 (m, 2H), 3.44 (m, 1H), 2.92 (dd, 1H), 2.80 (dd, 1H), 2,22-1,70 (m, 4H). 13C NMR (125 
MHz, 80.0 °C, DMSO-d6) δ 171.05, 169.72, 153.95, 137.21, 136.61, 135.68, 128.78, 
127.93, 127.80, 127.65, 127.51, 127.27, 127.23, 127.02, 125.87, 65.46, 65.10, 58.46, 53.80, 
46.06, 39.51, 36.49, 28.10, 24.15. IR (neat): ν = 3302 (m), 3035 (w), 2955 (m), 1734 (s), 
1689 (s), 1660 (s). HRMS (ESI+, [C29H30N2O5 + Na]+) calcd 509.2052, found m/z 509.2029. 
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Boc-Phg-Phg-OMe (15). Rf 0.36 (1:2 EtOAc/hexanes); white solid, mp: 64 °C, 84.5 mg 
(88%). 1H NMR (500 MHz, DMSO-d6) δ 9.02 (d, 1H), 7.44-7.20 (m, 11H), 5.40 (m, 2H), 
3.63 (s, 3H), 1.38 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ. 170.79, 170.10, 159.18, 
135.82, 135.12, 128.61, 128.28, 128.17, 127.53, 127.50, 127.08, 79.91, 57.23, 56.15, 52.32, 
28.13. 1H & 13C NMR was in agreement with previously reported data on this compound.64 
 
 
Z-Phg-Phe-OtBu (16). Rf 0.36 (3:7 EtOAc/hexanes); white solid, mp: 124-125 °C, 
2188.0 mg (82%). 1H NMR (500 MHz, CDCl3) δ 7.41-7.23 (m, 13H), 7.15 (d, 2H), 6.55 (d, 
1H), 6.24 (d, 1H), 5.33 (d, 1H), 5.10 (m, 2H), 4.72 (q, 1H), 3.10 (m, 2H), 1.33 (s, 9H). 13C 
NMR (125 MHz, CDCl3) δ 169.63, 169.14, 155.55, 137.57, 136.12, 135.81, 129.37, 128.83, 
128.32, 128.25, 127.94, 127.89, 127.05, 126.85, 82.25, 66.88, 58.67, 53.90, 37.77, 27.69. IR 
(neat): ν = 3331 (m), 3062 (m), 3031 (m), 2978 (m), 1731 (s), 1694 (s), 1652 (s). 1H & 13C 
NMR was in agreement with previously reported data on this compound.50 
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Boc-Pro-Leu-OEt (17). Rf 0.47 (1:1 EtOAc/hexanes); white solid, mp: 90-92 °C, 337.4 
mg (95%). 1H NMR (500 MHz, DMSO-d6) δ 8.21-8.10 (2xd, 1H), 4.24 (m, 1H), 4.12 (m, 
1H), 4.07 (m, 2H), 3.36 (m, 1H), 3.25 (m, 1H), 2.17-1.98 (m, 1H), 1.85-1.71 (m, 3H), 1.71-
1.62 (m, 1H), 1.62-1.53 (m, 1H), 1.51-1.43 (m, 1H), 1.42-1.28 (2xs, 9H), 1.17 (t, 3H), 0.89 
(d, 3H), 0.85 (d, 3H). 13C NMR (125 MHz, DMSO-d6) δ 172.62, 172.39, 153.25, 78.24, 
60.33, 59.13, 50.15, 46.42, 30.85, 28.07, 27.88, 24.07, 22.85, 20.98, 13.99. IR (neat): ν = 
3279 (m), 3083 (w), 2959 (m), 2873 (m), 1733 (s), 1690 (s), 1661 (s), 1547 (s). HRMS (ES+, 
[C18H32N2O5 + Na]+) calcd 379.2209, found m/z 379.2194. 
 
 
Boc-Pro-D-Phe-OMe (18). Rf 0.37 (1:1 EtOAc/hexanes); white solid, mp: 103-104 °C, 
886.7 mg (94%). 1H NMR (500 MHz, 80.0 °C, DMSO-d6) δ 7.92 (d, 1H), 7.29-7.24 (m, 
2H), 7.23-7.17 (m, 3H), 4.62 (m, 1H), 4.11 (m, 1H), 3.62 (s, 3H), 3.28 (m, 2H), 3.08 (m, 
1H), 2.95 (m, 1H), 1.96 (m, 1H), 1.67 (m, 2H), 1.57 (s, 1H), 1.35 (s, 9H). 13C NMR (125 
MHz, 80.0 °C, DMSO-d6) δ 171.67, 171.25, 153.15, 136.77, 128.59, 127.66, 125.97, 78.12, 
59.16, 52.57, 51.18, 46.06, 36.73, 27.65, 22.66. IR (neat): ν = 3299 (m), 3064 (w), 3026 (w), 
2974 (m), 1745 (s), 1684 (s), 1669 (s), 1545 (s). HRMS (ESI, [C20H28N2O5 + Na]+) calcd 
399.1896, found m/z 399.1876. 
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Boc-Pro-Phe-OEt (19). Rf 0.22 (1:2 EtOAc/hexanes); yellow oil, 183.1 mg (93%). 1H 
NMR (500 MHz, 80.0 °C, DMSO-d6) δ 7.84 (d, 1H), 7.30-7.25 (m, 2H), 7.24-7.18 (m, 3H), 
4.53 (m, 1H), 4.12 (m, 1H), 4.07 (m, 1H), 3.31 (m, 2H), 3.06 (dd, 1H), 2.98 (dd, 1H), 2.04 
(m, 1H), 1.79-1.67 (m, 3H), 1.32 (s, 9H), 1.14 (t, 3H). 13C NMR (125 MHz, 80.0 °C, 
DMSO-d6) δ 171.83, 170.80, 153.23, 136.82, 128.56, 127.70, 125.98, 78.19, 60.01, 59.16, 
53.03, 46.13, 36.51, 27.64, 22.78, 13.43. IR (neat): ν = 3314 (m), 3063 (w), 3030 (w), 2977 
(m), 2932 (m), 2878 (m), 1739 (s), 1673 (s), 1520 (s). 1H & 13C NMR was in agreement with 
previously reported data on this compound.65 
 
 
Fmoc-Val-Leu-OEt (20). Rf 0.25 (1:3 EtOAc/hexanes); white solid, mp: 161-162 °C, 
236.3 mg (96%). 1H NMR (500 MHz, DMSO-d6) δ 8.23 (d, 1H), 7.88 (d, 2H), 7.74 (t,2H), 
7.41 (t, 2H), 7.38 (d, 1H), 7.31 (t, 2H), 4.32-4.18 (m, 4H), 4.06 (m, 2H), 3.92 (t, 1H), 1.99 
(m, 1H), 1.70-1.44 (m, 3H), 1.15 (t, 3H), 0.90 (d, 3H), 0.88 (d, 6H), 0.82 (d, 3H); 13C NMR 
(125 MHz, DMSO-d6) δ 172.25, 171.37, 156.03, 143.89, 143.74, 140.69, 127.60, 127.01, 
125.35, 125.33, 120.05, 65.67, 60.35, 59.87, 50.32, 46.68, 39.63, 30.44, 24.15, 22.69, 21.27, 
19.12, 18.25, 13.98. IR (neat): ν = 3294 (m, br), 3065 (m), 3958 (m), 2871 (m), 1728 (s), 
1692 (s), 1646 (s). HRMS (ESI+, [C28H36N2O5 + Na]+) calcd 503.2522, found m/z 503.2501. 
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Z-Aib-Phe-D-Pro-OMe (21). Rf 0.23 (1:1 EtOAc/hexanes); white solid, mp: 96-98 °C, 
226.1 mg (91%). 1H NMR (500 MHz, 80.0 °C, DMSO-d6) δ 7.44-7.01 (m, 12H), 5.07-4.91 
(m, 2H), 4.89-4.77 (m, 1H), 4.25 (m, 1H), 3.58 (s, 3H), 3.25-3.08 (m, 2H), 2.91 (m, 2H), 
2.21-1.67 (m, 4H), 1.40-1.27 (m, 6H). 13C NMR (125 MHz, 80.0 °C, DMSO-d6) δ 173.16, 
171.52, 168.83, 154.33, 136.75, 136.68, 128.91, 127.84, 127.64, 127.22, 125.96, 125.55, 
64.99, 58.31, 58.25, 55.82, 51.45, 51.38, 51.10, 45.98, 45.74, 39.51, 37.42, 28.14, 24.83, 
24.47, 23.82. IR (neat): ν = 3313 (m, br), 3062 (w), 3030 (w), 2881 (m), 2952 (m), 2881 (w), 
1721 (s), 1633 (s), 1497 (s). 1H & 13C NMR was in agreement with previously reported data 
on this compound.66 
 
 
Z-Aib-Phe-Met-OMe (22). Rf 0.32 (1:1 EtOAc/hexanes); white solid, 218.9 mg (90%). 
1H NMR (500 MHz, DMSO-d6) δ 7.99 (d, 1H), 7.80 (d, 1H), 7.56 (s, 1H), 7.40-7.13 (m, 
10H), 5.00 (dd, 2H), 4.53 (m, 2H), 3.64 (s, 3H), 3.18 (dd, 1H), 2.94 (dd, 1H), 2.62-2.45 (m, 
2H), 2.03 (s, 3H), 2.02-1.90 (m, 2H), 1.20 (s, 3H), 1.15 (s, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 173.67, 171.92, 171.19, 155.35, 138.15, 136.66, 129.14, 128.32, 127.90, 
127.81, 127.71, 126.08, 65.44, 56.01, 53.72, 51.90, 51.06, 36.17, 30.53, 29.45, 25.25, 24.81, 
14.51. IR (neat): ν = 3564 (m), 3458 (m), 3300 (m), 3061 (w), 3031 (w), 2951 (m), 2920 
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(m), 2854 (w), 1743 (m), 1695 (s), 1657 (s), 1532 (s). HRMS (ESI+, [C27H35N3O6S + Na]+) 
calcd 552.2144, found m/z 552.2135. 
 
 
Z-Leu-D-Phe-Pro-Leu-OEt (23). Rf 0.17 (1:1 EtOAc/hexanes); light yellow solid, mp: 
42-43 °C, 218.9 mg (87%). 1H NMR (500 MHz, CDCl3) δ 7.38-7.13 (m, 11H), 6.97 (d, 1H), 
5.88 (d, 1H), 5.10 (q, 2H), 4.75 (q, 1H), 4.55 (m, 1H), 4.44 (m, 1H), 4.26 (q, 1H), 4.06 (m, 
2H), 3.62 (m, 1H), 3.05 (m, 1H), 2.95 (dd, 1H), 2.68 (q, 1H), 2.08 (m, 1H), 1.73 (m, 2H), 
1.68-1.53 (m, 6H), 1.45 (m, 1H), 1.16 (t, 3H), 0.90 (2xd, 12H). 13C NMR (125 MHz, 
CDCl3) δ 173.30, 172.63, 170.80, 170.48, 156.56, 136.24, 135.95, 129.31, 128.46, 128.43, 
128.39, 127.99, 127.81, 127.06, 66.90, 61.21, 60.47, 53.02, 51.05, 50.43, 46.71, 41.25, 
40.94, 40.85, 37.79, 28.74, 24.90, 24.56, 24.03, 22.93, 22.76, 22.11, 22.00, 21.80, 13.93. IR 
(neat): ν = 3300 (m, br), 3062 (w), 3034 (w), 2956 (m), 2932 (m), 2871 (m), 1723 (s), 1634 
(s), 1525 (s). HRMS (EI+, [C36H50N4O7]+) calcd 650.3679, found m/z 650.3667. 
 
 
Z-Aib-Phe-OMe (24). Rf 0.45 (1:1 EtOAc/hexanes); white solid, mp: 84-85 °C, 185.1 
mg (93%). 1H NMR (500 MHz, DMSO-d6) δ 7.75 (d, 1H), 7.42-7.14 (m, 11H), 4.97 (s, 2H), 
4.48 (dt, 1H), 3.60 (s, 3H), 3.00 (m, 2H), 1.28 (s, 6H); 13C NMR (125 MHz, DMSO-d6) δ 
174.04, 171.88, 154.52, 137.24, 136.93, 129.13, 128.28, 128.10, 127.70, 127.66, 126.42, 
65.10, 55.83, 53.51, 51.80, 36.46, 25.06, 24.79. IR (neat): ν = 3315 (m, br), 3065 (w), 3030 
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(m), 2981 (m), 2948 (m), 2927(m), 2859 (w), 1748 (s), 1688 (s), 1658 (s).  1H & 13C NMR 
was in agreement with previously reported data on this compound.67 
 
 
N-(3,4-dimethoxyphenethyl)dodecanamide (31). Rf 0.28 (1:1 EtOAc/hexanes); white 
solid, mp: 85-86 °C, 176.3 mg (89%). 1H NMR (500 MHz, CDCl3) δ 6.82 (d, 1H), 6.73 (m, 
2H), 5.45 (s, 1H), 3.87 (2xs, 6H), 3.50 (q, 2H), 2.76 (t, 2H), 2.12 (t, 2H), 1.59 (m, 2H), 1.34-
1.21 (m, 16H), 0.88 (t, 3H). 13C NMR (125 MHz, CDCl3) δ 173.08, 149.05, 147.69, 131.43, 
120.61, 111.35, 103.72, 55.91, 55.85, 40.57, 36.87, 35.30, 31.88, 29.59, 29.58, 29.46, 29.34, 
29.30, 29.28, 25.76, 22.65, 14.08. IR (neat): ν = 3310 (m), 2999 (w), 2954 (m), 2919 (s), 
2871 (m), 2850 (m), 1637 (s), 1518 (s). 1H & 13C NMR was in agreement with previously 
reported data on this compound.68 
 
 
N-hexyl-2-phenylacetamide (32). Rf 0.38 (1:1 EtOAc/hexanes); white solid, mp: 54-55 
°C, 118.3 mg (97%). 1H NMR (500 MHz, CDCl3) δ 7.39-7.24 (m, 5H), 5.34 (s, 1H), 3.58 (s, 
2H), 3.20 (m, 2H), 1.57 (m, 2H), 1.41 (m, 2H), 1.31-1.18 (6H, m), 0.86 (m, 3H). 13C NMR 
(125 MHz, CDCl3) δ 170.79, 135.07, 129.45, 129.00, 127.31, 43.93, 39.66, 31.36, 29.38, 
26.40, 22.48, 13.93. IR (neat): ν = 3252 (m), 3065 (m), 3032 (w), 2957 (m), 2935 (m), 2915 
(m), 2873 (m), 2860 (m), 1655 (m), 1626 (s), 1551 (s). 1H & 13C NMR was in agreement 
with previously reported data on this compound. 
  160 
 
 
N-(3,4-dimethoxyphenethyl)-2-phenylacetamide (33). Rf 0.50 (EtOAc); white solid, 
mp: 108-109 °C, 136.7 mg (93%). 1H NMR (500 MHz, CDCl3) δ 7.34-7.14 (m, 5H), 6.73 
(m, 1H), 6.61 (m, 1H), 6.56 (m, 1H), 5.36 (s, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.54 (s, 2H), 
3.45 (m, 2H), 2.68 (t, 3H). 13C NMR (125 MHz, CDCl3) δ 170.82, 149.01, 147.63, 134.78, 
131.11, 129.39, 128.95, 127.27, 120.55, 111.77, 111.32, 55.92, 55.81, 43.89, 40.73, 35.02. 
IR (neat): ν = 3286 (m), 3063 (w), 3029 (w), 3001 (w), 2934 (m), 2834 (w), 1644 (s), 1514 
(s). 1H & 13C NMR was in agreement with previously reported data on this compound.70 
 
 
2-phenyl-1-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethan-1-one (34). Rf 0.32 
(1:2 EtOAc/hexanes); light yellow oil, 173.8 mg (>99%). 1H NMR (500 MHz, CDCl3) δ 
7.39-7.32 (m, 3H), 7.30-7.24 (m, 3H), 7.12 (1H, dt), 7.07 (t, 1H), 7.03 (dd, 1H), 3.83 (t, 2H), 
3.80 (s, 2H), 3.62 (t, 2H), 3.20 (t, 2H), 3.03 (t, 2H). 13C NMR (125 MHz, CDCl3) δ 169.51, 
150.87, 145.37, 134.79, 131.67, 131.42, 129.67, 128.83, 128.50, 126.94, 119.24, 116.67, 
112.71, 112.68, 48.95, 48.75, 45.74, 41.44, 41.08. IR (neat): ν = 3465 (w), 3063 (w), 3029 
(w), 2916 (m), 2829 (m), 1731 (s), 1640 (s), 1448 (m). 1H & 13C NMR was in agreement 
with previously reported data on this compound.69 
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N-hexyl-3-phenylpropiolamide (35). Rf 0.26 (1:2 EtOAc/hexanes); colorless oil, 100.0 
mg (86%). 1H NMR (500 MHz, CDCl3) δ 7.58-7.51 (m, 2H), 7.45-7.33 (m, 3H), 5.97 (s, 
1H), 3.35 (m, 2H), 1.63-1.52 (m, 2H), 1.41-1.27 (m, 6H), 0.90 (t, 3H). 13C NMR (125 MHz, 
CDCl3) δ 153.36, 132.44, 129.94, 128.47, 120.30, 84.36, 83.16, 40.00, 31.41, 29.32, 26.53, 
22.52, 13.98. IR (neat): ν = 3260 (m, br), 3060 (m), 2955 (m), 2928 (m), 2857 (m), 2216 
(m), 1724 (w), 1626 (s), 1538 (s). HRMS (ESI+, [C15H19NO + Na]+) calcd 252.1364, found 
m/z 252.1369. 
 
 
ethyl (4-methylbenzoyl)-L-phenylalaninate (36). Rf 0.35 (1:3 EtOAc/hexanes); white 
solid, mp: 133 °C, 153.2 mg (>99%). 1H NMR (500 MHz, CDCl3) δ 7.64 (dt, 2H), 7.31-7.21 
(m, 5H), 7.16 (m, 2H), 6.59 (d, 1H), 5.07 (dt, 1H), 4.22 (q, 2H), 3.26 (m, 2H), 2.40 (s, 3H), 
1.28 (t, 3H). 13C NMR (125 MHz, CDCl3) δ 171.64, 166.66, 142.15, 135.95, 131.11, 129.39, 
129.21, 128.48, 127.06, 126.97, 61.55, 53.47, 37.97, 21.42, 14.11. IR (neat): ν = 3360 (m, 
br), 3031 (w), 3004 (w), 2983 (m), 2963 (m), 1750 (s), 1637 (s), 1526 (s), 1504 (s). HRMS 
(ESI+, [C16H23NO3 + Na]+) calcd 334.1419, found m/z 334.1417. 
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methyl (4-chlorobenzoyl)-L-tryptophanate (37). Rf 0.44 (1:1 EtOAc/hexanes); white 
solid, 163.5 mg (92%). 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 7.59 (dt, 2H), 7.54 (d, 
1H), 7.34 (d, 1H), 7.32 (dt, 2H), 7.19 (t, 1H), 7.09 (t, 1H), 6.97 (d, 1H), 6.70 (d, 1H), 5.14 
(dt, 1H), 3.73 (s, 3H), 3.45 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 172.25, 165.91, 137.91, 
136.11, 132.09, 128.70, 128.46, 127.58, 122.81, 122.26, 119.68, 118.45, 111.36, 109.74, 
53.58, 52.44, 27.49. IR (neat): ν = 3404 (m, br), 3312 (m, br), 3058 (m), 2952 (m), 2925 (m), 
2853 (w), 1734 (s), 1643 (s). 1H & 13C NMR was in agreement with previously reported data 
on this compound.58 
 
 
4-butoxy-N-(2-oxotetrahydrofuran-3-yl)benzamide (37). Rf 0.37 (3:1 
EtOAc/hexanes); white solid, mp: 108-109 °C, 126.9 mg (90%). 1H NMR (500 MHz, 
CDCl3) δ 7.75 (dt, 2H), 6.93 (d, 1H), 6.87 (dt, 2H), 4.76 (ddd, 1H), 4.50 (dt, 1H), 4.32 (ddd, 
1H), 3.98 (t, 2H), 2.87 (m, 1H), 2.28 (m, 1H), 1.77 (m, 2H), 1.50 (m, 2H), 0.92 (t, 3H). 13C 
NMR (125 MHz, CDCl3) δ 175.98, 167.27, 162.23, 128.99, 124.90, 114.24, 67.86, 66.22, 
49.56, 31.11, 30.32, 19.15, 13.77. IR (neat): ν = 3707 (m), 3681 (m), 3287 (m), 2956 (m), 
2935 (m), 2872 (m), 2845 (m), 1771 (s), 1641 (s), 1607 (s). HRMS (ESI+, [C15H19NO4 + 
Na]+) calcd 300.1212, found m/z 300.1209. 
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3-bromo-N-methoxy-N-methylbenzamide (39). Rf 0.23 (1:3 EtOAc/hexanes); colorless 
oil, 102.5 mg (84%). 1H NMR (500 MHz, DMSO-d6) δ 7.81 (t, 1H), 7.59 (dt, 1H), 7.56 
(ddd, 1H), 7.26 (t, 1H), 3.53 (s, 3H), 3.33 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 168.11, 
135.89, 133.48, 131.15, 129.54, 126.72, 121.93, 61.12, 33.47. IR (neat): ν = 3065 (w), 2967 
(m), 2934 (m), 2818 (w), 1640 (s), 1561 (m). 
 
 
Z-Aib-D-Phe-OMe (43). Rf 0.45 (1:1 EtOAc/hexanes); white solid, mp: 84-85 °C, 182.2 
mg (91%). 1H NMR (500 MHz, DMSO-d6) δ 7.75 (d, 1H), 7.40-7.15 (m, 11H), 4.97 (s, 2H), 
4.47 (dt, 1H), 3.60 (s, 3H), 3.00 (m, 2H), 1.27 (s, 6H); 13C NMR (125 MHz, DMSO-d6) δ 
174.05, 171.85, 154.52, 137.22, 136.93, 129.11, 128.26, 128.09, 127.69, 127.62, 126.41, 
65.10, 55.83, 53.49, 51.77, 36.48, 25.05, 24.77. IR (neat): ν = 3315 (m, br), 3066 (w), 3030 
(m), 2982 (m), 2948 (m), 2927(m), 2855 (w), 1748 (s), 1688 (s), 1658 (s). HRMS (EI+, 
[C22H26N2O5]+) calcd 398.1842, found m/z 398.1837. 
 
 
Z-Aib-D-Phg-OMe (44). Rf 0.45 (1:1 EtOAc/hexanes); white solid, mp: 125-126 °C, 
173.2 mg (84%). 1H NMR (500 MHz, DMSO-d6) δ 8.13 (d, 1H), 7.40-7.28 (m, 11H), 5.40 
  164 
(d, 1H), 5.00 (m, 2H), 3.63 (s, 3H), 1.38 (s, 3H), 1.36 (s, 3H); 13C NMR (125 MHz, DMSO-
d6) δ 174.03, 170.85, 154.79, 136.93, 136.56, 128.44, 128.27, 127.97, 127.69, 127.57, 
127.49, 65.14, 56.24, 55.98, 52.26, 25.16, 24.75. IR (neat): ν = 3323 (m, br), 3063 (m), 2974 
(m), 2948 (m), 1744 (s), 1687 (s), 1674 (s), 1660 (s). HRMS (EI+, [C21H24N2O5]+) calcd 
384.1685, found m/z 384.1673. 
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3.9 NMR Spectra 
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 Z-Aib-Phg-OMe_H1.esp
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.373.072.031.0011.310.96
2
.5
0
 
 Z-Aib-Phg-OMe_C13.esp
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3
9
.5
1
 
  170 
 Z-Aib-Pro-OBn_H1.esp
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3.002.932.970.840.780.920.763.689.450.74
2
.5
0
 
 Z-Aib-Pro-OBn_C13.esp
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
3
9
.5
1
 
  171 
 Z-Leu-Phe-OEt_H1_.esp
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
6.363.000.842.421.952.820.942.760.741.957.98
7
.2
7
 
 Z-Leu-Phe-OEt_C13.esp
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
7
7
.0
0
 
  172 
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3.10 HPLC Chromatograms 
Z-Aib-Phe-OMe Racemic Standard 
 
 
 
 
Z-Aib-L-Phe-OMe with 2,6-lutidine as base 
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Z-Aib-L-Phe-OMe with pyridine as base 
 
 
 
 
 
Z-Aib -Phg-OMe Racemic Standard 
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Z-Aib-L-Phe-OMe with 2,6-lutidine as base 
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IV. Effects of Co-solvents on Reactions Run Under Micellar Catalysis 
Conditions 
4.1 Introduction 
 The expanding list of applications of designer surfactants such as TPGS-750-M and 
their in situ derived nanomicelles as an alternative reaction medium to organic solvents in 
which numerous synthetic transformations can be carried out is now quite extensive.1 While 
several types of transition metal-catalyzed processes are especially well-suited to these 
conditions (e.g., Pd- and Ni-catalyzed cross-couplings,1b,2b Au-catalyzed processes,3 etc.), 
many other reaction types not only are amenable but also offer unique opportunities to 
benefit from the presence of the surrounding water. 
Salt additives, for example have shown a pronounced effect on reaction rates and yields 
for a variety of transformations. An extensive study was conducted by our group in 2011 
which highlighted the effects of salt additives on Heck couplings, cross-metathesis, as well 
as ring closing metathesis.4 In this report, it was presented that Heck cross coupling products 
could be produced in high yields in the presence of NaCl under micellar catalysis condtions 
which would otherwise require heating to afford similar results (Figure 1). This same 
modification translated to a moderate increase in metathesis yields as well, however the 
presence of minimal KHSO4 was found to greatly accelerate these reactions by effecting the 
pH of the system (Figure 2). Another example of the salt effect is presented in a 
communication from our group for the Pd-catalyzed reductions of aryl bromides in water 
where the extent of conversion was directly associated with NaCl concentration (Figure 3).5 
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Figure 1. Effect of NaCl on the Heck Reaction in PTS/H2O. 
 
 
 
Figure 2. Salt Effect on Olefin Cross-Metathesis in PTS/H2O.  
 
 
 
Figure 3. Effect of NaCl on aryl bromide reductions in PTS/H2O. 
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The initial report described these effects examined the effects of various salts on average 
micelle size as determined by dynamic light scattering (DLS). A general trend was observed 
where a “salting out effect” led to particle growth with NaCl and several other salts tested 
which was attributed to the success of this procedure (Figure 4). Interestingly, weakly 
hydrated salts such as iodides and thiocyanates led to a “salting in” effect causing particle 
contraction and these systems were found to lead to lower product yields for the Heck 
coupling described in Figure 1.  
 
Figure 4. Effect of different salt concentrations on the diameter of PTS micelles. 
 
In addition to effecting particle size and reaction rate, salt additives have been found to 
greatly influence selectivity for Pd-catalyzed semi-reductions in aqueous TPGS-750-M 
(Chapter II).6 Here, it was discovered that LiCl could be used to yield Z-alkenes with 
excellent selectivity from functionalized alkynes such as propargyl alcohols which otherwise 
showed poor selectivity (Figure 5).  Nitro group reductions catalyzed by Fe/ppm-Pd 
nanoparticles are affected by the salt effect as well (Chapter V), where the rate enhancement 
observed by the use of KBH4 can be mimicked by the use of NaBH4 in with KCl (Figure 6).7 
  209 
 
 
Figure 5. Salt effect on selectivity of alkyne semi-reductions. 
 
 
 
Figure 6. Effect of KCl on Fe/ppm-Pd catalyzed nitro group reductions. 
 
Another parameter that can be effected under aqueous conditions is pH. A profound 
correlation between reaction yield and pH was observed for amide bond formation (Chapter 
II), where treating the system with aqueous NaOH or HCl affording lower conversions than 
for the optimized conditions at pH = 6-7 (Figure 7).8 
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Figure 7. Effect of pH on amide bond formation. 
 
In addition to reaction tuning by leveraging the presence of water, aqueous micellar 
catalysis has been proven as a viable alternative to egregious dipolar aprotic and water-
miscible organic solvents. The broad generality of this reaction medium allows for tandem 
processes to be developed, where sequences of reactions that no longer require differing 
reaction solvents can be run in a single pot, maximizing efficiency and minimizing 
waste.4,12-16  
While the notion of “getting organic solvents out of organic reactions” remains our goal, 
we have developed an appreciation for the vagaries associated with the solubility properties 
of starting materials, most notably highly crystalline solids that can be quite slow to gain 
entry into the hydrophobic micellar core, making use of this technology potentially 
impractical. Flocculent solids can be tough to fully consume, and in some cases, educts 
viewed as “brick dust” that are only soluble in highly polar media may be outside the scope 
of this green chemistry. 
 Initial solubility, however, is but one of the potential problems that may arise, 
especially with reactions run at scale.17 Starting materials, and/or the desired product(s), may 
present unpredictable practical issues during or post-reaction at the workup stage. For 
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example, materials at any stage may adhere to the stirrer and form an intractable gum, 
preventing continued stirring and/or full conversion. Extraction of the product from such 
intractable solids can be time-consuming and may require extensive handling, including 
solubilization in copious amounts of undesirable organic solvents. 
4.2 Early Work 
A straightforward modification to existing, otherwise optimized conditions that serves to 
further generalize this aqueous technology and overcome these limitations has been found; 
that is, the role that selected organic co-solvents can play in facilitating many types of 
reactions run in water, and under very mild conditions, can be influential. 
This work was based on a few preliminary findings for the effect that co-solvents may 
have under micellar catalysis conditions. The first report of the use of co-solvents from our 
group was for the asymmetric Au-catalyzed lactonizations in water, where the concept of 
“lattice softening” was presented.3a Many of the compounds used in the study were highly 
crystalline offering challenges for the formation of a microemulsion in aqueous surfactant 
which was overcome by the use of DMSO, benzene, or toluene, found to increase both 
product yields and enatioselectivity of the system. In another report, our group disclosed a 
new ligand, Handaphos, which was found to catalyze Suzuki-Miyaura cross couplings at 
exceptionally low catalyst loadings (500-1200 ppm).11 The use of nearly negligible mass of 
the catalyst brought forth the use of toluene for catalyst complexation and as a vehicle for 
catalyst transfer leading to the use of <10% toluene as cosolvent in this reaction. The 
seminal publication for nitro group reductions catalyzed by Fe/ppm-Pd nanoparticles 
represents another case involving the use of THF as co-solvent.13 This modification was 
considered on the basis of the highly crystalline and poorly soluble nature of nitroarenes. The 
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effect of THF under these conditions is described later in this chapter. In 2015, Parmentier 
and co-workers at Novartis described a method for amide bond formation in water on 
scale.18 As the physical properties of the mixture is an important parameter for a 
pharmaceutical process both in terms of stirring and product isolation, the use of THF, 
acetone, and PEG-200 as co-solvent with TPGS-750-M in water were found as the solvents 
of choice by eliminating “oiling out” in the reaction mixture. 
4.3 Results and Discussion 
Suzuki-Miyaura (SM) Cross-Couplings.1a Figure 8 shows the results of an SM 
reaction involving solids 1 and 2, in 2 wt % TPGS-750-M/H2O. For this case, it was found 
that while the use of a co-solvent had essentially no effect on the physical appearance of the 
reaction mixture run at 45 °C, the presence of 10% acetone (by volume) increased the 
isolated yield from 68% to 85%. Further increases in the acetone content (e.g., to 50%) led 
to a dramatic decrease in isolated product (25%).  
 
 
Figure 8. Effects of THF and acetone on SM cross coupling. 
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As mentioned previously, our group released a communication introducing HandaPhos, a 
highly active ligand for SM couplings enabled by only ppm levels of its 1:1 complex with 
palladium.11 Examination of THF, acetone, and toluene as co-solvents at the 10% level 
identified both THF and acetone as effective additives, thereby enhancing the rate of the 
coupling between solid 4 and liquid 5, shown in Figure 9. In comparison to the control 
system, higher isolated yields were produced using 10% co-solvent. And while the highest 
yield of 6 was achieved by utilizing THF (81%), 10% toluene showed a more uniform and 
stable suspension without precipitation.  
 
 
Figure 9. Impact of co-solvent on SM cross-coupling. 
 
Miyaura Borylation.19 C-BPin bond-forming reactions may also benefit by the addition 
of a co-solvent, due mainly to the flocculent/crystalline nature of B2Pin2. This reagent has 
the tendency to float upon the surface of the aqueous reaction mixture, which may lead to 
increased reaction times and undesirable behavior at scale. Use of either 10% THF or 
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acetone, where the B2Pin2 could be added as a predissolved solution to solid educt 7, 
completely eliminated this phenomenon affording product 8 (Figure 10).  
 
 
Figure 10. Miyaura borylation with co-solvents. 
 
SNAr Reactions.10 When performing these substitution reactions involving equimolar 
amounts of solid benzimidazole 9 and liquid 2,4,5-trichloropyrimidine, 10, use of co-solvent 
led to a distinct difference in reaction appearance compared with that seen in water alone 
(Figure 11). Under standard SNAr conditions, aggregation of the product was observed, and 
while only a modest improvement in reaction yield was achieved by the use of 15% THF, 
the mixture was transformed into a stable suspension, an important consideration when run 
at scale. 
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Figure 11. Representative SNAr reaction. 
 
Amide Bond Formation.8 As a representative case, coupling of solid diphenylacetic 
acid, 12, with solid L-tryptophan methyl ester, 13, under standard (co-solvent-free) 
conditions led to conversion to amide 14. However, precipitation of the accumulated product 
onto the stir bar halted stirring of the reaction mixture after only 30 min (Figure 12). This 
type of precipitation can grossly effect the extent of conversion, rendering these conditions 
unsuitable for scale-up. On the other hand, use of 10% THF leads to a stable suspension, 
thus allowing the reaction to stir freely and proceed to a higher degree of conversion.  
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Figure 12. COMU-mediated amide bond formation. 
 
C-H Activation.20 Palladium-catalyzed C-H activation of aryl urea solid 15, followed by 
coupling with solid 4-iodoanisole, 16, afforded a higher yield in the absence of a co-solvent 
(Figure 13). Nonetheless, utilizing 10% THF or acetone led to freely flowing material in the 
reaction mixture, which also produced heavy precipitation of the product and silver salt.  
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Figure 13. Pd-catalyzed C-H activation. 
 
Reductions of Nitroaromatics.13 Aromatic/heteroaromatic nitro compounds are often 
challenging substrates in general due to their limited solubility in aqueous nanomicelles, a 
result of their highly crystalline nature and relatively high melting points. Recently, we have 
disclosed a new method for efficient Fe/ppm Pd-catalyzed/NaBH4 nitro group reductions in 
water that utilizes a co-solvent to assist with highly crystalline, sparingly soluble 
substrates.13 For this system, the co-solvent not only enhances solubilization of the starting 
material and intermediates within the micellar core but also shows a pronounced effect on 
the amount of foaming resulting from the evolution of H2. An excellent example of this is 
the reduction of (solid) nitroaromatic 18 to amine 19, where the absence of co-solvent 
increases nucleation sites for gas evolution leading to foaming, which can grow to occupy 
the entire volume of the flask (Figure 14A). When carried out with 20% THF, foaming is 
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negligible due to the decrease in surface tension of the solvent, leading to rapid reduction of 
any foam, along with greatly improved stirring (Figure 14B). Furthermore, solid 
precipitation is not observed throughout the course of the reaction, which in the composite 
affords a significant increase in yield from 84% to 95%. 
 
 
Figure 14. Fe/ppm-Pd NP-catalyzed nitro group reduction. 
 
Cyclizations of Allenic Alcohols. As part of a more general study on HandaPhos 
technology applied to ppm level Au-catalyzed reactions run under these micellar catalysis 
conditions, cyclization of liquid allenic alcohol 20 was effected using (HandaPhos)Au (1000 
ppm, or 0.10 mol %) to produce cyclic ether 21 in good yield (Figure 15). In the same 
manner as ppm Pd-catalyzed SM couplings with HandaPhos, a low catalyst loading results 
from precomplexation in organic solvent, which is then used as a means of transferring the 
catalyst to the aqueous reaction mixture. For this transformation, a distinct relationship 
between co-solvent selection and yield was revealed. That is, the addition of 10% toluene 
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(but not acetone or THF) was found to increase the yield from 33% to 91%, further 
exemplifying the potential impact of co-solvent screening in these systems. 
 
  
Figure 15. ppm (HandaPhos)Au(I)-catalyzed ether formation. 
 
Notwithstanding the observed benefits associated with co-solvent usage, the question 
remains as to whether nanomicelles still exist in the presence of organic solvent. Insight was 
obtained using dynamic light scattering data acquired for samples containing TPGS-750-M 
in the presence of 5%, 10%, and 15% THF (Table 1). As the data illustrate, particles of 
initially 57 nm increase in size to ca. 100 nm, with populations becoming more diverse when 
compared to the control sample measured in water only. The expansion of micelles in the 
presence of organic solvent is expected, as solvent molecules can organize themselves 
within the micellar framework, causing particle growth until saturation, at which point no 
additional swelling is observed.21 These observations are in agreement with the DLS data 
collected (Figure 16). Likewise, particles of this surfactant also increased in size upon 
introduction of 15% acetone (Table 1, entry 5). 
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Table 1. Average particle size of micelles + co-solvent. 
 
 
 
Figure 16. DLS data (particle size): TPGS-750-M/H2O + THF. 
 
As previously reported, the use of TPGS-750-M for micellar catalysis lends itself for the 
opportunity to recycle the reaction medium by simply removing organic components from 
the reaction via extraction with minimal EtOAc. As Scheme 1A highlights, the aqueous 
medium used for the SNAr reaction to produce 11 can be recycled two additional times for 
the same reaction without effecting yield. Upon neutralization of the remaining aqueous 
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medium, a nearly quantitative yield of 14 from 12 and 13 under COMU-mediated peptide 
coupling conditions was obtained. And although this modification requires the addition of 
organic solvent to the reaction mixture, the amount of organic waste generated is still quite 
low when calculating Sheldon’s E Factor.22 By means of a simple filtration, 11 was isolated 
in 80% yield resulting in an exceptionally low E Factor of 1.25. The low E Factor of 6.8 was 
achieved by extraction with minimal MTBE to afford 3. 
 
 
Scheme 1. Recycle and E Factor Studies. 
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4.4 Summary and Conclusions 
In summary, use of a co-solvent as an additive to aqueous solutions containing 
nanomicelles derived from TPGS-750-M adds yet another dimension to micellar catalysis as 
an attractive alternative approach to traditional organic solvents alone as reaction media. The 
preferred co-solvents are THF, acetone, and PEG-200, although toluene is occasionally 
advantageous. These observations can help address those occasions where substrate and/or 
catalyst solubility may be an issue, and when various practical aspects, especially at 
scale,7,17,18,23 can otherwise be problematic. Such aqueous solutions are amenable to 
recycling, while DLS measurements have shown that added co-solvent enlarges the size of 
the nanoreactors in which the chemistry is taking place. Since the communication of the 
findings described above,24 scale-up protocols for nitro group reductions7 and SNAr 
reactions23 have been published incorporating the use of co-solvent in combination with 
aqueous TPGS-750-M. 
4.5 Experimental and Compound Data 
General Information 
A solution of 2 wt % TPGS-750-M/H2O solution was prepared by dissolving TPGS-750-
M in degassed HPLC grade water and was stored under argon. TPGS-750-M was made as 
previously described1a and is available from Sigma-Aldrich (catalog #733857). All 
commercially available reagents were used without further purification.  Thin layer 
chromatography (TLC) was done using Silica Gel 60 F254 plates (Merck, 0.25 mm thick). 
Flash chromatography was done in glass columns using Silica Gel 60 (EMD, 40-63 μm) or 
with pre-packed 25 gram KP-Sil Biotage® SNAP Cartridges on the Biotage® Isolera Prime 
autocolumn. 1H and 13C NMR were recorded at 22 °C on a Varian UNITY INOVA at 
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600MHz and 500 MHz. Chemical shifts in 1H NMR spectra are reported in parts per million 
(ppm) on the δ scale from an internal standard of residual CDCl3 (7.27 ppm). Data are 
reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintet), and integration. Chemical shifts in 13C chemical spectra are reported 
in ppm on the δ scale from the central peak of residual CDCl3 (77.00 ppm). IR data were 
collected on a Perkin Elmer Spectrum Two UATR FT-IR Spectrometer and peaks were 
described according to relative intensity and resolution as follows:  s = strong, m = medium, 
w = weak, br = broad. Dynamic Light Scattering (DLS) data were collected using a Malvern 
Zetasizer ZS equipped with 173° backscatter detection and a He-Ne, 4 mW, 633 nm red 
laser. 
Suzuki-Miyaura Cross Coupling Procedures 
A 1-dram vial with a Teflon coated magnetic stir bar under argon atmosphere was 
charged with PdCl2(dtbpf) (6.5 mg, 0.01 mmol), 98% 2-bromo-5-chloro-3-methylpyridine, 
2, (105.3 mg, 0.5 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 
1, (169.4 mg, 0.75 mmol), and acetone (0.1 mL) and stirred for 5 min at rt. TPGS-750-
M/H2O (2 wt %, 0.9 mL) and Et3N (0.21 mL, 1.5 mmol) were then charged into the reaction 
and allowed to stir at 45 °C for ca. 31 h. The reaction mixture was extracted with 3 x 2 mL 
EtOAc, dried over anhydrous Na2SO4, filtered, condensed via rotary evaporation, and 
purified by column chromatography eluting with hexanes/EtOAc to afford 5-chloro-2',3-
dimethyl-2,4'-bipyridine, 3, as a white solid (186 mg, 85% yield).  
A 1-dram vial with a Teflon coated magnetic stir bar under argon atmosphere was 
charged with Pd(OAc)2 (2.1 mg, 0.0094 mmol), HandaPhos (5.6 mg, 0.0103 mmol), and 
toluene (0.94 mL). The solution was allowed to stir for 15 min at 23 °C. An aliquot (0.25 
mL) of this mixture was transferred to a 1-dram vial, stripped of toluene under reduced 
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pressure, and then dissolved in the corresponding co-solvent (0.25 mL) when appropriate. 
For the control (no co-solvent), the reaction components were added directly to the vial 
containing 2000 ppm (0.20 mol %) concentrated Pd/HandaPhos complex in the order 
described below. A 1-dram vial with a Teflon coated magnetic stir bar under argon 
atmosphere was charged with 2-bromothiophene, 5, (81.5 mg, 0.5 mmol), (4-
(methoxycarbonyl)phenyl)boronic acid, 4, (99.0 mg, 1.1 mmol), bis(pinacolato)diboron 
(380.9 mg, 1.5 mmol), and 2 wt % TPGS-750-M/H2O (0.9 mL). The mixture was stirred for 
10 min before introducing Et3N (0.14 mL, 1.0 mmol). After stirring for an additional 5 min, 
Pd/HandaPhos solution in co-solvent (0.1 mL, 0.001 mmol) was added and the reaction 
stirred for 24 h at 23 °C. The reaction mixture was then extracted with 3 x 2 mL EtOAc, 
dried over anhydrous Na2SO4, filtered, condensed via rotary evaporation, and purified by 
column chromatography eluting with hexanes/Et2O to afford methyl 4-(thiophen-2-
yl)benzoate, 6, as a white solid (177 mg, 81% yield). 
Miyaura Borylation Procedure 
A 1-dram vial with a Teflon coated magnetic stir bar under argon atmosphere was 
charged with Pd(P-t-Bu3)2 (7.7 mg, 0.015 mmol), KOAc (122.7 mg, 1.25 mmol), 
bis(pinacolato)diboron (380.9 mg, 1.5 mmol),  and co-solvent (0.3 mL). After stirring for 2 
min, 2 wt % TPGS-750-M/H2O (1.7 mL) was charged into the mixture and allowed to stir 
for 10 min before adding 1-bromo-2-methoxynaphthalene, 7, (118.6 mg, 0.5 mmol) in 3 
portions over 1 h (~40 mg every 30 min). The reaction was then stirred for ca. 2 h after the 
final portion of 7 had been added. The reaction mixture was extracted with 3 x 2 mL EtOAc, 
dried over anhydrous Na2SO4, filtered, condensed via rotary evaporation, and purified by 
column chromatography eluting with hexanes/Et2O to afford 2-(2-methoxynaphthalen-1-yl)-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 8, as a white solid (133 mg, 93% yield). 
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SNAr Procedure 
A 1-dram vial with a Teflon coated magnetic stir bar was charged with K3PO4 (254 mg, 
1.2 mmol) and 98% benzimidazole, 9, (120.4 mg, 1 mmol). The vial was flushed with argon 
and charged with 2 wt % TPGS-750-M/H2O [1.7 mL (with co-solvent); 2.0 mL (without co-
solvent)], 97% 2,4,5-trichloropyrimidine, 10, (118.2 μL, 1.0 mmol), and THF (0.3 mL). The 
reaction stirred for ca. 5 h after which the reaction mixture was extracted with 3 x 2 mL 
EtOAc. The organic extracts were combined, dried over anhydrous Na2SO4, filtered, 
condensed via rotary evaporation, and purified by flash chromatography eluting with 
hexanes/EtOAc to afford 1-(2,5-dichloropyrimidin-4-yl)-1H-benzo[d]imidazole, 11, as a 
white solid (212 mg, 80% yield). 
Amide Bond Formation Procedure 
A 1-dram vial with a Teflon coated magnetic stir bar was charged with diphenylacetic 
acid, 12, (116.7 mg, 0.55 mmol), 2 wt % TPGS-750-M/H2O (2.7 mL), 2,6-lutidine (0.18 mL, 
1.55 mmol), and THF (0.3 mL). After stirring for 5 min, a solution was achieved and L-
tryptophan methyl ester hydrochloride, 13, (127.4 mg, 0.5 mmol) was added followed by the 
quick addition of COMU (321.2 mg, 0.75 mmol). The reaction was then stirred for ca. 40 
min and then extracted with 3 x 2 mL EtOAc. The organic extracts were combined, washed 
with 2 M HCl (6 mL), saturated Na2CO3 solution (3 x 6 mL), dried over anhydrous Na2SO4, 
filtered, condensed via rotary evaporation, and purified by flash chromatography eluting with 
hexanes/EtOAc to afford methyl (2,2-diphenylacetyl)-L-tryptophanate, 14, as a white solid 
(172 mg, 83% yield). 
C-H Activation Procedure 
A 1-dram vial with a Teflon coated magnetic stir bar was charged with 3-(3-
methoxyphenyl)-1,1-dimethylurea, 15, (97.1 mg, 0.5 mmol), 1-iodo-4-methoxybenzene, 16, 
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(234.0 mg, 1.0 mmol), Pd(OAc)2 (11.2, 0.05 mmol) and co-solvent (0.2 mL). After stirring 
for 2 min, 2 wt % TPGS-750-M/H2O (1.8 mL)  was charged into the mixture and 48 wt % 
HBF4 solution (1.25 mmol, 0.16 mL) was added by syringe and vigorously stirred for ca. 20 
h. After completion, the contents of the flask were quenched with NaHCO3 and extracted 
with EtOAc (3 x 2 mL). The solution obtained was filtered through a plug of silica gel and 
anhydrous MgSO4, and concentrated by rotary evaporation. The residue was purified by 
flash chromatography eluting with hexanes/EtOAc to afford 3-(4,4'-dimethoxy-[1,1'-
biphenyl]-2-yl)-1,1-dimethylurea, 17, the product as an off-white solid (108 mg, 72% yield). 
Nitro Group Reduction Procedure 
A 10 mL round bottom flask with a Teflon coated magnetic stir bar was charged with 
Fe/ppm Pd nanoparticles (FeNPs; 10 mg, 0.071 μmol) and morpholino(4-
nitrophenyl)methanone, 18, (118 mg, 0.5 mmol). The flask was flushed with argon and 
charged with THF (0.2 mL), stirred, and then 2 wt % TPGS-750-M/H2O (0.8 mL, with co-
solvent trial) was added; or 1.0 mL 2 wt % TPGS-750-M/H2O (without co-solvent trial). 
After briefly stirring, the flask was charged with NaBH4 (113 mg, 3 mmol). The reaction was 
stirred for 2 h, then the reaction mixture was extracted with 3 x 1 mL EtOAc (in the co-
solvent trials, compressed air was briefly blown across the surface of the reaction to remove 
some co-solvent prior to extraction). The organic extracts were combined, dried over 
anhydrous Na2SO4, filtered, concentrated by rotary evaporation, and purified by flash 
chromatography eluting with 100% EtOAc to afford (4-
aminophenyl)(morpholino)methanone, 19, as an off-white solid (99 mg, 96% yield). 
Allenic Alcohol Cyclization 
To a 1-dram vial equipped with Teflon-coated magnetic stir bar, 100 µL of gold pre-
catalyst in DCM (1000 ppm or 0.1 mol %) was added and the DCM was removed under 
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reduced pressure. Hydroxyallene 20 (28 mg, 0.1 mmol) was added to the vial followed by 
toluene (200 µL), 3 wt % Nok / H2O (0.2 mL), and trifluoroacetic acid (23 mg, 0.2 mmol). 
The resulting mixture was stirred at rt for ca. 24 h. After completion, the product was 
exacted with EtOAc (3 x 0.1 mL), and concentrated by rotary evaporation. The residue was 
purified by flash chromatography eluting with hexanes/EtOAc to afford methyl 2-phenyl-1-
oxaspiro[5.5]undec-4-ene-2-carboxylate, 21, as a colorless liquid (26 mg, 91% yield). 
Aqueous Surfactant Recycling Procedures 
Reaction A (SNAr). A microwave vial with a Teflon coated magnetic stir bar was 
charged with K3PO4 (254 mg, 1.2 mmol) and 98% benzimidazole, 9, (120.4 mg, 1 mmol). 
The vial was flushed with argon and charged with 2 wt % TPGS-750-M/H2O (1.7 mL), 97% 
2,4,5-trichloropyrimidine, 10, (118.2 μL, 1.0 mmol), and THF (0.3 mL). The reaction stirred 
for ca. 5 h and the reaction mixture was then extracted with 3 x 2 mL EtOAc. The organic 
extracts were combined, dried over anhydrous Na2SO4, filtered, condensed via rotary 
evaporation, and purified by flash chromatography eluting with hexanes/EtOAc to afford 1-
(2,5-dichloropyrimidin-4-yl)-1H-benzo[d]imidazole, 11, as a white solid (212.1 mg, 80% 
yield). 
Reaction B (1st Recycle, SNAr). The microwave vial was briefly opened and charged 
with K3PO4 (254 mg, 1.2 mmol) and 98% benzimidazole, 9, (120.4 mg, 1 mmol). The vial 
was flushed with argon and charged with 2 wt % TPGS-750-M/H2O (1.7 mL), 97% 2,4,5-
trichloropyrimidine, 10, (118.2 μL, 1.0 mmol), and THF (0.3 mL). The reaction stirred for 
ca. 8 h and the reaction mixture was extracted with 3 x 2 mL EtOAc. The organic extracts 
were combined, dried over anhydrous Na2SO4, filtered, condensed via rotary evaporation, 
and purified by flash chromatography eluting with hexanes/EtOAc to afford 1-(2,5-
dichloropyrimidin-4-yl)-1H-benzo[d]imidazole, 11, as a white solid (217.4 mg, 82% yield). 
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Reaction C (2nd Recycle, SNAr). The microwave vial was briefly opened and charged 
with K3PO4 (254 mg, 1.2 mmol) and 98% benzimidazole, 9, (120.4 mg, 1 mmol). The vial 
was flushed with argon and charged with 2 wt % TPGS-750-M/H2O (1.7 mL), 97% 2,4,5-
trichloropyrimidine, 10, (118.2 μL, 1.0 mmol), and THF (0.3 mL). The reaction stirred for 
ca. 8 h and the reaction mixture was extracted with 3 x 2 mL EtOAc. The organic extracts 
were combined, dried over anhydrous Na2SO4, filtered, condensed via rotary evaporation, 
and purified by flash chromatography eluting with hexanes/EtOAc to afford 1-(2,5-
dichloropyrimidin-4-yl)-1H-benzo[d]imidazole, 12, as a white solid (216.7 mg, 82% yield). 
Reaction D (3rd Recycle, amide bond formation). The microwave vial was briefly 
opened and charged with 0.16 mL 2 M HCl (final pH = 6-7), followed by diphenylacetic 
acid, 13, (70.0 mg, 0.33 mmol), 2,6-lutidine (0.11 mL, 0.93 mmol), and THF (0.18 mL). 
After stirring for 5 min, a solution was achieved and L-tryptophan methyl ester 
hydrochloride (76.4 mg, 0.3 mmol) was added followed by the quick addition of COMU 
(192.7 mg, 0.45 mmol). The reaction stirred for ca. 1 h and the reaction mixture was 
extracted with 3 x 2 mL EtOAc. The organic extracts were combined, washed with 2 M HCl 
(6 mL), saturated Na2CO3 solution (3 x 6 mL), dried over anhydrous Na2SO4, filtered, 
condensed via rotary evaporation, and purified by flash chromatography eluting with 
hexanes/EtOAc to afford methyl (2,2-diphenylacetyl)-L-tryptophanate, 15, as a white solid 
(123.7 mg, 99% yield). 
E Factor Procedures and Calculations 
A 1-dram vial with a Teflon coated magnetic stir bar under argon atmosphere was 
charged with PdCl2(dtbpf) (6.5 mg, 0.01 mmol), 98% 2-bromo-5-chloro-3-methylpyridine, 
2, (105.3 mg, 0.5 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine, 
1, (169.4 mg, 0.75 mmol), and acetone (0.1 mL) and then stirred for 5 min at rt. TPGS-750-
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M/H2O (2 wt %; 0.9 mL) and Et3N (0.21 mL, 1.5 mmol) were then charged into the reaction 
and the mixture allowed to stir at 45 °C for ca. 48 h. The reaction was then stirred for ca. 30 
min under a stream of Ar at 45 °C to remove acetone, followed by extraction with 2 x 0.4 
mL MTBE. The organic extracts were dried over anhydrous Na2SO4, filtered, condensed via 
rotary evaporation, and purified by column chromatography eluting with hexanes/EtOAc to 
afford 5-chloro-2',3-dimethyl-2,4'-bipyridine, 3, as a white solid (98.2 mg, 90%). 
 
E Factor Calculations (without water): 
E Factor = (Mass of Organic Waste) / (Mass of Product) 
Mass of Organic Waste = (0.8 mL MTBE)(0.740 g/mL) + (0.1 mL acetone)(0.791 g/mL) = 
671 mg 
Mass of Product = 98.2 mg 
E Factor = (671 mg) / (98.2 mg) = 6.8 
E Factor Calculations (with water): 
E Factor = (Mass of Organic Waste + Aqueous Waste) / (Mass of Product) 
Mass of Water = (0.9 mL) (1.0 g/mL) = 900 mg 
E Factor = (671 mg + 900 mg) / (98.2 mg) = 16.0 
 
A microwave vial with Teflon coated magnetic stir bar was charged with K3PO4 (254 
mg, 1.2 mmol) and 98% benzimidazole, 9, (120.4 mg, 1 mmol). The vial was flushed with 
argon and charged with 2 wt % TPGS-750-M/H2O (1.7 mL), 97% 2,4,5-trichloropyrimidine, 
10, (118.2 μL, 1.0 mmol), and THF (0.3 mL). The reaction was stirred for ca. 5 h and then 
extracted with 3 x 2 mL EtOAc. The organic extracts were combined, dried over anhydrous 
Na2SO4, filtered, condensed via rotary evaporation, and purified by flash chromatography 
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eluting with hexanes/EtOAc to afford 1-(2,5-dichloropyrimidin-4-yl)-1H-benzo[d]imidazole, 
11, the product as a white solid (213.3 mg, 80% yield). 
 
E Factor Calculations (without water): 
E Factor = (Mass of Organic Waste) / (Mass of Product) 
Mass of Organic Waste = (0.30) mL THF (0.889 g/mL) = 266.7 mg 
Mass of Product = 213.3 mg 
E Factor = (266.7 mg) / (213.3 mg) = 1.3 
E Factor Calculations (with water): 
E Factor = (Mass of Organic Waste + Aqueous Waste) / (Mass of Product) 
Mass of Water = (1.7 mL) (1.0 g/mL) = 1700 mg 
E Factor = (266.7 mg + 1700 mg) / (213.3 mg) = 9.2 
 
Characterization of Products 
 
 
5-Chloro-2',3-dimethyl-2,4'-bipyridine (3). Rf 0.27 (1:1 EtOAc/hexanes); white solid, 
mp 63-64 °C, 186 mg (85%). 1H NMR (500 MHz, CDCl3) δ 8.52 (d, 1H), 8.43 (d, 1H), 7.55 
(dd, 1H), 7.24 (s, 1H), 7.15 (d, 1H), 2.56 (s, 3H), 2.29 (s, 3H); 13C NMR (101 MHz, CDCl3) 
δ 158.54, 154.06, 148.90, 147.07, 145.84, 138.02, 132.23, 131.06, 122.91, 120.44, 24.37, 
19.51. IR (neat): ν = 3392 (br), 3042 (m), 3011 (m), 2960 (m), 2923 (m), 2870 (w), 1604 (s), 
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1575 (m), 1541 (s), 1451 (s), 1426 (s). HRMS (EI, [C12H11ClN2 - H]) calcd. 217.0538, found 
m/z 217.0529. 
 
 
Methyl 4-(thiophen-2-yl)benzoate (6). Rf 0.31 (1:9 EtOAc/hexanes); mp 132-133 °C, 
177 mg, (81%). 1H NMR (500 MHz, CDCl3) δ 8.05 (dt, 2H), 7.68 (dt, 2H), 7.43 (dd, 1H), 
7.37 (dd, 1H), 7.13 (dd, 1H), 3.94 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 166.73, 138.59, 
130.24, 128.72, 128.29, 126.27, 125.49, 124.45, 123.58, 52.13. IR (neat) ν = 3099 (m), 3076 
(m), 2991 (w), 2947 (m), 2848 (w), 1714 (s), 1605 (m), 1283 (s), 1114 (s). HRMS (EI, 
[C12H10O2S]) calcd. 218.0402, found m/z 218.0397.  
 
 
2-(2-Methoxynaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (8). Rf 0.20 
(15:85 diethyl ether/hexanes); mp 93-94 °C, 133 mg (93%). 1H NMR (500 MHz, CDCl3) δ 
7.94 (d, 1H), 7.86 (d, 1H), 7.77 (d, 1H), 7.45 (m, 1H), 7.32 (m, 1H), 7.23 (d, 1H), 3.93 (s, 
3H), 1.50 (s, 12H); 13C NMR (101 MHz, CDCl3) δ 161.41, 137.04, 131.60, 128.83, 128.09, 
126.75, 126.50, 123.25, 112.81, 83.90, 56.56, 24.88. IR (neat) ν = 3055 (w), 2976 (m), 2932 
(m), 2837 (w), 1620 (m), 1589 (m), 1576 (m), 1144 (s), 1132 (s). 1H & 13C NMR was in 
agreement with previously reported data on this compound.25 
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1-(2,5-Dichloropyrimidin-4-yl)-1H-benzo[d]imidazole (11). Rf 0.27 (4:6 
EtOAc/hexanes); white solid, mp 150-152 °C, 212 mg (80%). 1H NMR (500 MHz, CDCl3) δ 
8.178 (s, 1H), 8.76 (s, 1H), 8.01 (m, 1H), 7.87 (m, 1H), 7.44 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 161.50, 158.78, 153.65, 143.41, 140.90, 131.83, 125.27, 124.77, 120.80, 119.74, 
114.22. IR (neat) ν = 3145 (w), 3126 (w), 1528 (m), 1425 (m), 1365 (m), 1150 (s), 1133 (s), 
748 (s). HRMS (EI, [C11H6Cl2N4]) calcd 263.997, found m/z 263.996.  
 
 
Methyl (2,2-diphenylacetyl)-L-tryptophanate (14). Rf 0.38 (1:1 EtOAc/hexanes); mp 
62-64 °C, 172 mg (83%). 1H NMR (500 MHz, CDCl3) δ 8.35 (s, 1H), 7.43 (d, 1H), 7.34-
7.22 (m, 2H), 7.65 (m, 9H), 7.20 (m, 1H), 7.16-7.12 (m, 2H), 7.08 (m, 1H), 6.57 (d, 1H), 
6.23 (d, 1H), 5.02 (dt, 1H), 4.89 (s, 1H), 4.89 (s, 1H), 3.69 (s, 3H), 3.28 (d, 2H); 13C NMR 
(101 MHz, CDCl3) δ 172.12, 171.66, 138.96, 138.91, 135.98, 128.85,128.70, 128.61, 
128.56, 127.20, 127.16, 127.07, 122.79, 121.96, 119.49, 118.28, 111.24, 109.12, 58.78, 
52.78, 52.28, 27.27. IR (neat) ν = 3409 (br), 3313 (br), 3060 (w), 3028 (w), 2951 (w), 2925 
(w), 2851 (w), 1507 (s), 1656 (s). HRMS (EI, [C26H24N2O3]) calcd. 412.1787, found m/z 
412.1780. 
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3-(4,4'-Dimethoxy-[1,1'-biphenyl]-2-yl)-1,1-dimethylurea (17). Rf 0.22 (1:1 
EtOAc/hexanes); mp 131-133 °C, 108 mg (72%). 1H NMR (500 MHz, CDCl3) δ 7.94 (d, 
1H), 7.27 (dt, 2H), 7.06 (d, 1H), 6.99 (dt, 2H), 6.64-6.59 (m, 2H), 3.85 (2 x s, 6H), 2.81 (s, 
6H); 13C NMR (125 MHz, CDCl3) δ 159.45, 158.92, 155.29, 137.44, 130.58, 130.44, 
130.30, 123.01, 114.38, 109.10, 104.21, 55.30, 55.25, 36.13. IR (neat) ν = 3439 (w), 3015 
(w), 2938 (w), 2838 (w), 1666 (m). 1H & 13C NMR were in agreement with previously 
reported data on this compound.20 
 
 
(4-Aminophenyl)(morpholino)methanone (19). Rf 0.3 (EtOAc); off-white solid, mp 
129-131 °C, 99 mg (96%). 1H NMR (600 MHz, CDCl3) δ 7.23 (d, 2H), 6.61 (d, 2H), 3.90 (s, 
2H), 3.66 (s, 4H), 3.61 (s, 4H). 13C NMR (101 MHz, CDCl3) δ 170.83, 148.28, 129.33, 
124.39, 114.12, 66.90. IR (neat) ν = 3418 (m), 3330 (m), 3222 (m), 2980 (w), 2921 (m), 
2866 (m), 1592 (s), 1428 (m), 1257 (m), 1103 (m). HRMS (EI, [C11H14N2O2]) calcd. 
206.1055 found m/z 206.1050. 1H and 13C NMR were in agreement with previously reported 
data on this compound.26 
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Methyl 2-phenyl-1-oxaspiro[5.5]undec-4-ene-2-carboxylate (21). Rf 0.44 (1:9 
EtOAc/hexanes), 26 mg (91%). 1H NMR (600 MHz, CDCl3) δ 7.53 (d, 2H), 7.33 (t, 2H), 
7.26 (t, 1H), 5.89 (dq, 1H), 5.77 (dd, 1H), 3.60 (s, 3H), 3.09 (dd, 1H), 2.18 (dt, 1H), 1.90 (m, 
2H), 1.70 (m, 1H), 1.63 (m, 2H), 1.56-1.42 (m, 3H), 1.40-1.23 (m, 3H); 13C NMR (125 
MHz, CDCl3) δ 174.36, 143.36, 133.75, 128.23, 127.41, 124.56, 121.69, 78.05, 74.83, 
51.92, 39.25, 36.20, 33.09, 29.67, 25.47, 22.19, 21.54. IR (neat) ν = 3034 (w), 2931 (m), 
2856 (m), 1732 (s), 1456 (w), 1448 (m), 1435 (m), 1057 (s). HRMS (EI, [C18H22O3]) calcd. 
286.1569, found m/z 286.1571. 
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4.6 NMR Spectra 
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 Methyl 4-(thiophen-2-yl)benzoate_H1.esp
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 2-(2-Methoxynaphthalen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane_H1.esp
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 1-(2,5-Dichloropyrimidin-4-yl)-1H-benzo[d]imidazole_H1.esp
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 Methyl (2,2-diphenylacetyl)-L-tryptophanate_H1.esp
8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
1.932.990.991.021.001.001.072.041.169.411.020.95
7
.2
7
 
 
 Methyl (2,2-diphenylacetyl)-L-tryptophanate_C13.esp
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
7
7
.0
0
 
  240 
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V. Sustainable and Scalable Fe/ppm Pd Nanoparticle Nitro Group 
Reductions in Water at Room Temperature  
5.1 Introduction 
Nitro group reductions represent a transformation in the synthetic chemist’s toolbox that 
is used extensively to access a broad range of products. The ubiquity of this transformation 
comes as the consequence of the ease and predictability at which nitro groups may be 
installed.1 Typically, nitro groups are installed by nucleophilic aromatic substitution 
reactions utilizing cheap and readily available nitric and sulfuric acid. In addition, by 
utilizing nitro group reductions, the synthetic route benefits from the electronic differences 
between starting materials and products. For example, by utilizing the resonantly electron 
withdrawing characteristics of a nitro group, one can routinely perform SNAr reactions on 
activated aryl chlorides1,3 and fluorides,4,5 or utilize the electron deficient nature to 
participate in facile oxidative addition in cross coupling events with aryl halides.6-7 The nitro 
group reduction can then be performed on the substituted aryl product thereby unmasking 
the nitro group as a free amine which can act as a nucleophile for subsequent chemistry, 
including amide bond formations7-9 and heterocylic transformations. The sequence of 
exploiting the relatively inert and highly electron withdrawing nature of the nitro 
functionality followed by reduction and nucleophilic substitution is a prevalent route to a 
variety of pharmaceuticals. Scheme 1 shows one such example of this route, where 
quetiapine (Seroquel) is accessed from a sequential SNAr/nitro-group 
reduction/lactamization.3 Other important cases include the synthesis of imiquimod,1 
linezolide,4 boscalid,7 imatinib,9 and levofloxacin.11 
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Scheme 1. Preferred synthetic route to quetiapine from SNAr/nitro-group 
reduction/lactamization sequence. 
 
5.2 Background 
The reduction of nitro groups has been a transformation of intense interest for nearly a 
century and a half,12 where the Béchamp13 reduction of nitrobenzene was used as the method 
of choice for the large scale production of aniline. The development of catalytic 
hydrogenation methods redefined how chemists approach nitro group reductions and 
remains the most widely utilized method to date. Common catalysts for hydrogenation 
include Pd/C,13 Raney-Ni,14 and PtO215 which are generally employed under ambient to very 
high pressures of H2. Hydrogenation from catalytic non-platanoids is also an intense field of 
research with many impressive developments being made from systems with Fe,17 Cu,18 
Co,18c,19 Pt/Zn,20 Ti,21 Ir,21 and Rh.23 Similair to the Béchamp reduction, other methods rely 
on less expensive metals such as Fe,23 Zn,24 and Sn,25 however these conditions generally 
require stoichiometric or even super stoichiometric amounts of metals and/or harsh reaction 
conditions which may be a concern in terms of saftey, waste generation, and functional 
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group compatability. Additionally, many of the described reduction conditions may stall at 
intermediate stages, and/or go through accumulation of highly energetic species such as 
nitroso- or hydroxylamine intermediates. The ubiquity of this transformation for the 
synthesis of pharmaceuticals, dyes, explosives, agrochemicals, functional materials, and 
bioactive natural products27 certainly raises the questions: how safe/environmentally 
responsible are the state of the art technologies, and what can be done to address these 
concerns for nitro group reductions on scale?  
For a given transformation in a process, safety and cost are important considerations 
when evaluating current technologies. For instance, if a given advanced intermediate can be 
functionalized in near quantitative conversion in high purity, safety may take a back seat due 
to the influence of cost and reproducibility of the method. An excellent example of this is the 
synthesis of varenicline where the Upjohn Dihydroxylation using toxic OsO4 is preferred 
over other oxidants due improved yield, selectivity, and purity profile over other less 
harmful oxidants such as KMnO4.28 This is not unlike catalytic hydrogenation where the 
hazards and cost associated with the use of H2 under high pressures are considered 
acceptable due to the success of these methods. If hydrogenation is considered state-of-the-
art and developments focus predominately on the front of catalyst improvements,12 the major 
hazard of the highly flammable gas is still not addressed because it is perceived as an 
acceptable reagent. In fact, much effort today in the field looks towards a less expensive 
catalysts, often in the form of Fe nanoparticles,28 to address cost, and safety improvements 
focus on flow reaction development.29 While there is tremendous merit to these 
advancements, there still remains the issue of high pressure reaction systems. It is well 
understood that a method is likely to be overlooked in systems requiring an atmosphere of 
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O2,31 yet the hazards of this gas are no greater than those associated with H2. So why are we 
still using it? 
5.3 Early Work 
Recently, a new catalyst has been developed for nitro group reductions which meets 
many of the safety and environmental concerns associated with expensive platanoid 
catalyzed hydrogenation of the nitro group functionality.48 Developed from earlier finding 
from our group in the areas of Pd nanoparticle-catalyzed semi-reduction of alkynes33 
(Chapter 2) and the Fe nanoparticle supported ppm Pd-catalyzed Suzuki-Miyaura cross 
couplings,34 the developed precatalyst nanoparticles (NPs) are synthesized from the 
treatment of Pd(OAc)2-doped FeCl3 with 1.1 equivalents of MeMgCl. Nitro compounds can 
be effectively reduced to their corresponding amines by the use of NaBH4 as the source of 
hydrogen under aqueous micellar conditions alleviating the need for H2 to be charged into 
the system. Taking place at room temperature, this method delivers exceptional yields (80-
98%) with short reaction times (typically 2-4 hours) at ambient temperature.  Key features of 
these conditions are the preferred use of aqueous TPGS-750-M over organic solvent as well 
as the functional group compatibility to a broad range of reducible structural motifs 
including aryl halides, alkenes, alkynes, esters, amides, nitriles, and ketones, as well as 
benzyl protected alcohols and amines which would otherwise be cleaved under Pd-catalyzed 
hydrogenation conditions (Figure 1).35 In addition to the versatility of this method, the use of 
only trace amount of Pd for catalysis yields the purified product with residual Pd content of 
less than 1 ppm. These mild conditions were envisioned as an amenable alternative to 
standard hydrogenation conditions for nitro group reductions of active pharmaceutical 
ingredients (API’s) where late stage Pd-catalyzed transformations would generally be 
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disregarded on the basis of residual metal content. This advancement would allow for more 
flexibility in process route development to fit within the maximum allowable limits of Pd in 
a final API under the FDA Guidelines42 and other processes, especially with those reductions 
catalyzed by ≥1% Pd will generally fail to meet this criteria when performed in the final 
stages of a synthetic route. 
 
 
Figure 1. Representative examples of reduced nitroarenes catalyzed by Fe/ppm Pd 
nanoparticles with NaBH4. 
 
The standard procedure for Fe/ppm Pd-catalyzed reduction of nitro compounds calls for 
generating Fe nanoparticles (≥80 ppm Pd) in a 2 wt % TPGS-750-M solution in water by 
dissolving the precatalyst in the water and charging NaBH4 (1.5-3.0 equiv) to the mixture 
arriving at the active nanomaterial catalyst (activation). It is during this activation step that 
the gross reductant for the system is present for the subsequent reduction as well. In a 
separate vessel, the nitro group-containing starting material is dispersed in 2 wt % TPGS-
750-M/H2O prior to its addition into the reaction mixture. The reaction typically proceeds in 
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a sealed dram vial and allowed to stir at room temperature until full conversion of starting 
material and productive intermediates is determined by TLC or GC/MS. Isolation and 
purification of the product amine is carried out via extraction of the crude product with ethyl 
acetate or t-butyl methyl ether (MTBE) from the reaction mixture, followed by column 
chromatography. Alternately, direct recrystallization of the amine as the corresponding HCl 
may be effected from the extraction solvent, thus providing another indication that this 
process is well suited for scale up. 
Encouraged by the efficiency and ease of this method, in combination with reduced 
environmental impact and purity profile, development of a scale-up process was pursued at 
Novartis AG in Basel, Switzerland, as was a study of several other reaction parameters 
including calorimetry in the safety lab. 
5.4 Results and Discussion 
In order to successfully achieve this task, we broke down the method into a process flow 
diagram (Figure 2). Looking at concerns from the perspective of a process chemist, initial 
focus was on the physical aspects of the system, where quite frequently nitroarenes are 
generally highly crystalline in water leading to unstable emulsions or suspensions and in 
some cases starting material will appear like sand stirring in water. This could lead to issue 
in terms of transferring large amount of the reagent to a reactor and lead to poor 
homogeneity of the system. This was also a concern in terms of intermediates that precipitate 
and deposit above the solvent level of the reaction leading to inconsistent results. 
Furthermore, the role of NaBH4 was unclear, and as the previous method was carried out in a 
sealed vial, we wanted to investigate if the pressure build up was a requirement of the system 
as in a classical hydrogenation, or if this process could be carried out in a standard reactor. 
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Foaming observed as a result of the effervescent hydrogen evolution from the aqueous 
surfactant solution was yet another obstacle which would require additional headspace in a 
reactor and may deposit catalyst and starting material/intermediates above the solvent level. 
Finally, the process would require the system to go to full completion such that purification 
could be carried out via recrystallization from the extraction solvent without the need for 
column chromatography to obtain pure product. 
 
 
Figure 2. Process Flow Diagram of literature conditions for the reduction of 1-chloro-4-
nitrobenzene catalyzed by Fe/ppm Pd nanoparticles with NaBH4. 
 
Due to the highly crystalline nature of as well as structural and physical similarities to, 
the Novartis intermediate of interest, we investigated 4-chloronitrobenzene as the model 
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substrate. Initially, considering the physical aspects of the system, an array of co-solvents 
were screened as previous findings found that the use of co-solvent could drastically affect 
the homogeneity and success of reactions under micellar catalysis conditions.48,37-40  
Solubility and the formation of a stable emulsion were important parameters to 
investigate, as nitro-group containing compounds are typically highly crystalline solids, 
oftentimes unfavorable for reactions in which water is used as the reaction medium. While 
the use of surfactants at or above their critical micellar concentrations (CMC) can be used to 
stabilize  organic material as a microemulsion, liberating material from its energetically 
more favorable crystalline state may require “softening” of the lattice, especially at higher 
concentrations such as those used in this process (0.3-0.5 M). As a result, heterogeneous 
polyphasic mixtures with suspended solids can provide challenges on scale and was foreseen 
as a potential pitfall for this method. The results for reactions run at a 0.5 mmol scale (78 mg 
4-chloronitrobenzene) are outlined in Table 1 where the co-solvents screened included: THF, 
2-Me-THF, toluene, and PEG-200. Consistent with our previous efforts,48,40 THF was found 
to be the co-solvent of choice showing, for this specific transformation based on 
observations highlighted below, slightly better conversion than literature conditions. 
Additionally the presence of 2 vol THF (156 μL co-solvent per 78 mg 1) was sufficient to 
solubilize intermediates which would have otherwise precipitated and formed a solid ring of 
material above the solvent level in the absence of co-solvent. This explains the higher 
conversion to the product amine under co-solvent conditions: upon analysis of the precipitate 
(by NMR and UPLC/MS) for the control system (no co-solvent), the makeup of the solid 
was found to be predominately nitroso- intermediate 3, hydroxylamine intermediate 4, and 
the corresponding azoxy condensation byproduct 5.  The higher local concentration of the 
two intermediates not only entropically favors the condensation pathway but also removes 
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productive intermediates from the active catalyst mixture.  The success of PEG-200 supports 
this hypothesis, where even though this cosolvent was ineffective in forming a stable 
emulsion or solubilizing precipitated intermediates, no caking was observed above the 
solvent level. This solvent was disregarded for further development towards our process due 
to the instability of the emulsion; however, these data provide a useful modification that may 
be implemented in later work. Interestingly, the addition of a solution of 1 in THF directly to 
the reaction mixture yielded surprisingly poor results in comparison to the formation of a 
microemulsion prior to transfer (Table 1, entry 6). Water-miscible alcohols such as methanol 
and isopropanol were not considered as co-solvents due to their inability to dissolve 1 prior 
to addition of the aqueous surfactant solution. Another improvement that was effected by the 
use of THF as co-solvent was the ability to collapse foaming resulting from activation of the 
catalyst. In fact, it was observed that addition of the starting material emulsion with THF to 
the reaction could collapse the foam, while the addition of THF or 1 alone did not result in 
the same physical change. 
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Table 1. Co-solvent screening for the reduction of 1. 
 
 
 
Scheme 2. Nitro group reduction and condensation pathways. 
 
In forming an emulsion for a given starting material, it was found that dissolution in THF 
prior to addition to 2 wt % TPGS-750-M/H2O achieves the desired ‘milky’ appearance much 
faster than other addition sequences. This should be done at high stirring rates (>800 rpm) 
  255 
and can be achieved easily at the lab scale by high-speed vortexing of the mixture in a 
cylindrical vessel such as a dram vial.  
As mentioned previously, when this reaction was run at lab scale, it was routinely carried 
out in a sealed vial, allowing the build-up of pressure over the course of the reaction. Upon 
completion of the reaction, it was evident that a large amount of pressure was generated due 
to the decomposition of NaBH4 to give off H2, so we set out to investigate this system under 
hydrogenation conditions to better understand the role of NaBH4 as the reductant. 
This study was carried out to assess whether NaBH4 acts as the direct hydride source or 
as an H2 precursor. Using what was already known about this system, each reaction was 
treated in two stages: catalyst activation and substrate reduction. Upon addition of NaBH4 to 
the homogeneous catalyst solution, the iron(III) salt is quickly reduced, as it precipitates as 
fine black particles while the reaction mixture foams due to gas evolution. The hypothesis 
was that NaBH4 may directly reduce that catalyst and the subsequent reduction goes by 
means of a hydrogenation mechanism. This mechanism was eliminated when activation of 
the precatalyst with a catalytic amount of NaBH4 (0.15 equiv) followed by the addition of 
substrate, and then placing the system under H2 atmosphere even under high pressures of 11 
bar, did not deliver the desired aniline product in sufficient quantities (Table 2, entries 1, 2) 
which was in agreement with the findings in the initial communication.48 No catalyst 
activation was observed in the absence of NaBH4 suggesting that the precatalyst requires 
hydride reduction to initiate activation. When the precatalyst is treated with H2 prior to 
activation, poor conversion was observed yet again leading to the conclusion that this 
reduction does not go by means of a standard hydrogen pathway but rather by means of a 
palladium hydride.  
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Table 2. Conversion data for activation/hydrogenation investigations. 
  
At this stage, we proposed that by varying the nature of the counterion on the 
borohydride might impact the success of the reduction. This modification seemed likely as 
the Z-selective semihydrogenation of alkynes with Pd(OAc)2 and NaBH4 could be drastically 
influenced in terms of selectivity by the incorporation of LiCl.33 Not surprisingly, replacing 
NaBH4 by other metal borohydride salts, a pronounced effect is observed depending on the 
nature of the counterion (Table 3). KBH4 was found to be more effective as a reductant as 
the reaction rate increased both for starting material conversion and for the rate determining 
step of reduction from hydroxylamine 4 to aniline 2 (Scheme 2). These findings not only 
benefit the process in terms of reaction time but also reduce the accumulation of highly 
energetic and toxic intermediates 3 and 4. No catalyst activation was observed for the case 
using LiBH4, which led to poor conversion of the starting material. 
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Table 3. Screening of various metal borohydride salts for the reduction of 1. 
 
When monitoring the amount of pressure accumulated for the metal borohydride 
screening it was observed that KBH4 decomposes to form H2 to a much greater extent than 
does NaBH4 (1.0 bar for KBH4 compared to 0.7 bar for NaBH4 at 0.5 mmol scale). Quite 
interestingly, only a negligible amount of pressure was accumulated when LiBH4 was used 
as the reductant. 
 
Figure 3. Measured pressure for the evolution of H2 from the decomposition of various 
metal borohydride salts during the reduction of 1. 
 
  258 
Scheme 2 represents the two typical pathways by which nitroarenes may be reduced, 
both of which result from the concurrent reductions of the nitro and nitroso- intermediates. 
In order to understand the productive pathways of this methodology, isolated hydroxylamine 
4, azoxy 5, and diazo compound 6 where submitted under standard reduction conditions 
(Table 4). Within one hour, 0.5 mmol 4 was cleanly converted to 2 while only trace amounts 
of azoxy 5 were reduced to 6, and no conversion of 6 to 7 even after allowing the reaction to 
age for ca. 18 hours. This study confirmed that the condensation pathway as a dead end 
under our conditions. The condensation by-products 4, 5, and 6 are not only a concern in 
terms of overall conversion to product, but also in terms of safety, as this class of by-
products has been found to be genotoxic and carcinogenic.41 Therefore, conditions were 
required for avoiding this pathway so as to ultimately arrive at a safer, more efficient 
process.   
 
 
Table 4. Conversion data for intermediates/condensation by-products under standard 
reduction conditions. 
 
The studies described above provided the data necessary for the development of a robust 
process. Where increasing the reaction rate and diluting the system would lead to preference 
of the productive pathway, rate enhancement could be effected by simultaneously 
influencing catalyst loading, the nature of the reductant, and equivalents of the reductant. 
Catalyst loading was increased to 200 ppm Pd loading, while substituting NaBH4 to the 
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more reactive KBH4, an increasing reductant loading from 1.5 to 3.0 equivalents. Dilution 
was considered on the basis of the entropic factor of condensation so the substrate 
concentration was decreased from 0.5 to 0.25 M. Finally, because H2 had been shown 
previously to inhibit reactivity of the system (Table 3, entry 4), the reaction was performed 
under a balloon of Ar. 
 Within one hour, quantitative conversion of 1 was achieved and by two hours the 
reaction had gone to completion free of by-products (Scheme 3). An additional equivalent of 
of 1 was then charged to the reaction mixture, achieving full conversion of the initial 
reduction, however a build-up of hydroxylamine 4 was observed as the remaining hydride in 
the system was not sufficient to bring the reaction to completion, ultimately converging to 
the condensation pathway. Reproducing the initial step of the modified system, quantitative 
conversion of 1 to 2 was observed once again within two hours and by charging the reaction 
with 3.0 additional equivalents KBH4 prior to adding the second portion of starting material, 
quantitative conversion to product was achieved. In fact, a portion-wise addition of reagents 
in this manner can be continued up to at least ten additional times without effecting reaction 
conversion, however, precipitation of product leads to a decrease in homogeneity of the 
reaction mixture which may not be desirable for this process at a larger scale. When carried 
out on a 100 mmol scale, similar results were realized, yielding quantitative conversion to 2 
after only 3 hours for the first portion and reaction completion 11 hours after addition of 
reagents for the second portion, affording 2 in 94% isolated yield as the HCl salt. The 
reaction profile for the 100 mmol reaction is shown in Figure 4, where the major peak 
corresponds to the product 2. 
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Scheme 3. Effects of increase reductant and catalyst loading with portion-wise addition of 
reagents. 
 
Incorporation of all modifications to the existing methodology on the 100 mmol scale is 
represented by the process flow diagram in Figure 5. Modifications including: co-solvent 
usage, swapping NaBH4 for KBH4 as well as the portion-wise addition of reagents are 
outlined, with the addition of each portion of KBH4 with starting material being considered 
an individual process (i.e. Stage 1; Stage 2).  It was envisioned that the portion wise addition 
at this scale could simulate the constant slow addition of materials over the course of the 
reaction, however this procedure has yet to be explored. 
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Figure 4. Reaction profiles for the reduction of 1 on a 100 mmol scale. 
 
 
 
 
Figure 5. Process Flow Diagram for the developed process at 100 mmol scale. 
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Examining this process in terms of the physical aspects of the system, the process begins 
by adding a solution of 1 to a vessel containing the aqueous solution of 2 wt % TPGS-750-M 
under an atmosphere of Ar, (Figure 5, R1) which achieves the desired appearance of a milky 
emulsion upon stirring at ≥800 rpm for approximately 30 minutes (Figure 6). The emulsion 
requires constant stirring at high speed to maintain the ideal consistency (otherwise 
recrystallization of 1 proceeds) and is generally started before the parallel reactor (Figure 5, 
R2) is charged with material. The parallel reactor is charged with Fe nanomaterial to a 
solution of 2 wt % aqueous TPGS-750-M and THF under an Ar atmosphere which appears 
as an red/orange solution upon stirring for ca. 5 minutes (Figure 7). 
 
 
Figure 6. Emulsion of 1, in 2 wt % TPGS-750-M/H2O/THF. 
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Figure 7. Dissolved precatalyst (FeNP) in 2 wt % TPGS-750-M/H2O/THF. 
 
Charging the system by the slow addition of KBH4 spontaneously activates the catalyst 
as observed by the presence of finely dispersed black particles with the evolution of a large 
amount of foam (Figure 8). It is at this stage that the majority of gas is evolved from the 
system over the entire process. Due to the high surface tension of the surfactant solution and 
the gas generated in-situ, foaming can be expected to increase the volume of the reaction up 
to four times the original solvent level (for example, 200 mL of catalyst solution can 
generate ~600 mL of foam). It was found that the amount of foaming was approximately the 
same in the absence of THF, however low stirring speeds at 200 rpm have been effective in 
slowing this process. In addition the conical reactor was utilized to increase the surface area 
of the foam as it expands thereby slowing the evolution of foam as well. The purpose of the 
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THF in the initial solution was merely for calibration purposes for the initial calorimetry 
experiment. 
 
Figure 7. Catalyst activation with KBH4 at ca. 15 minutes. 
 
In order to charge the system with the emulsion of 1 from R1, it was determined that 
adding a uniform mixture of 1 would require stirring during the course of the addition. In 
order to achieve this, an addition funnel was affixed to the reactor which was mixed at 800 
rpm via overhead stirring in the funnel itself (Figures 8 & 9).  
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Figure 8. Starting material emulsion in an addition funnel with overhead stirring. 
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Figure 10. Addition of starting material to RC1 reactor via addition funnel with overhead 
stirring. 
 
Upon charging the system with the emulsion of 1 to the center of the foam in R2, the 
foam collapses within ca. 15 minutes, leaving negligible material suspended on the walls of 
the reactor above the solvent level (Figure 11). A few important notes about this stage 
should be mentioned in that the foam dissipation is effected by the mixture including solute 
1 and THF, not merely THF alone, and charging additional KBH4 to the system at any later 
stage will not result in the generation of significant foaming. 
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Figure 11. Reaction aspect upon complete addition of starting material emulsion. 
 
Reaction work-up proceeds via acidification under air with concentrated HCl that 
deactivates and solubilizes the catalyst, quenches the remaining KBH4 (and reactive 
decomposition products thereof), and solubilizes the product amine in water. Complete 
KBH4 decomposition can be determined by monitoring gas evolution upon reaction 
neutralization and this should be investigated prior to further work-up and purification 
procedures. However, all KBH4 is assumed to be consumed at the working pH of 2-3. Also, 
catalyst deactivation goes by means of an oxidation pathway from O2 present in the air, so an 
insoluble form of the catalyst will persist if the quench is carried out under Ar. As the 
condensation by-products are poorly basic and very nonpolar, extraction with a minimal 
amount of low polarity organic solvent such as heptanes or MTBE can be used to enrich the 
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aqueous mixture (Figure 12). As stated earlier, many of the modifications made during the 
course of developing this process focused on minimizing the occurrence of condensation by-
products, and as such, the isolation of all by-products associated with this pathway 
represented less than 0.1% of the total crude mass at the 100 mmol scale further 
exemplifying the efficiency of this process.  
 
 
 
Figure 12. Enrichment of 2, by acidification/extraction/neutralization sequence. 
 
Isolation of the product is carried out by neutralization of the enriched aqueous phase 
with aqueous NaOH solution, extraction with i-PrOAc (isopropyl acetate), and filtration of 
the combined organic extracts through a plug of filter aide such as Celite® (Figure 13). The 
volume of the filtrate is then concentrated to approximately 1/3 the original volume followed 
by recrystallization of the product by the dropwise addition of 1 M HCl solution in ethyl 
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acetate to yield the HCl salt of 2 as white crystals in >99.8% purity. Consistent with the 
initial report, ICP analysis revealed residual Pd content at < 1 ppm, demonstrating the 
applicability of this process as one that can be used at a late stage en route to an API. 
 
 
 
Figure 13. Product isolation/purification by recrystallization as the HCl salt of 2. 
 
To assure that all parameters of the system were considered on the basis of maximum 
efficiency, the limitations of the conditions were investigated, such as decreasing catalyst 
and reductant loading (Table 5, entries 2, 3 respectively). For both modifications, the 
undesired condensation by-products were observed once more as the result of the more 
sluggish reaction rate in comparison to the control system. Further examining the effect of 
counterion realized by the use of KBH4, experiments proceeded with less reactive reductants 
LiBH4 and NaBH4 in the presence of KCl. It was observed that NaBH4 (3.0 equiv) in 
combination with 1.0 equivalent of KCl mirrored the optimized conditions (entry 6) while 
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decreasing KCl loading to 0.1 equivalent showed no significant effect on NaBH4 (entry 5) 
and the LiBH4/KCl system was found to remain as an inferior reductant for this system 
(entry 4). This modification to the existing protocol not only sheds light on the components 
which effect rate enhancement, but also may allow for of KCl with NaBH4 as a replacement 
for KBH4 which would serve as a more cost effective alternative on scale.42 
 
 
Table 5. Catalyst/reductant loading and the effect of KCl. 
 
Further demonstrating the capabilities of the newly optimized conditions, additional 
nitroarene substrates bearing reducible functionalities including aryl bromide, a 
dihalocyclopropane, a protected acylhydrazine derivative, and an α,β-unsaturated ester were 
successfully reduced to the corresponding anilines in good isolated yields (Figure 14). This 
shows once more that mild conditions are compatible with a high range of substrate types 
which may be present in advanced intermediates. 
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Figure 14. Advanced substrate scope under modified process conditions. 
5.5 Calorimetry 
To assess the safety of the Fe/ppm Pd-catalyzed nitro group reduction for eventual 
transfer to the pilot plant, the process was carried out in a 0.5 L RC1 reactor for a 
calorimetry study, following the process flow diagram (PFD) outlined in Figure 5 on a 40 
mmol scale, sequentially charging KBH4 and 1 stepwise and portion-wise the results of 
which are concisely summarized in Figure 15. Addition of each portion of KBH4 and 1 was 
considered a separate process and continued upon conformation of full conversion to 2 by 
UPLC/MS analysis of an aliquot from the reaction mixture. Energy corresponding to the 
nitro group reduction and decomposition of KBH4 was measured by calorimetric analysis. It 
was found that the heat of reaction (kJ/mol) was within the same order of magnitude for a 
standard nitro group reduction via hydrogenation, finding values in the range of 
approximately -896 to -850 kJ/mol after each addition. As anticipated, the heat of reaction is 
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directly correlated to the concentration of the unreduced species in the reaction mixture, 
where a strong exotherm occurs [ca. -153 kJ/kg FRM (final reaction mass), corresponding to 
a theoretical adiabatic temperature increase of about 37 °C] in the initial portion and ca. -115 
kJ/kg FRM corresponding to theoretical adiabatic temperature increase of about 29 °C in the 
subsequent portion. Approximately 50% of the whole energy is accumulated at the end of 
the addition corresponding to a theoretical adiabatic temperature increase of about 18 °C to 
15 °C. In the event of an undetected loss of cooling for this process, the maximum 
theoretical temperature that could be reached is approximately 62 °C (IT + ΔTad = 25 + 
37°C = 62 °C), well below the boiling point of water thereby making the major concern in 
terms of safety the potential increase of H2 evolved. Within 10 minutes of charging the 
system with the second portion of 1 at 20 °C, a sample was removed for analysis via 
dynamic SEDEX thermostability test resulting in no significant exothermal decomposition 
up to 160 °C (Figure 16). From a 3:1 stoichiometry of KBH4 to 1, it is calculated that the 
expected H2 evolved would be 36.7 L / kg FRM43 from which the majority of this gas is 
evolved at the stages of catalyst activation and reaction work-up. However, it is necessary to 
evaluate the accumulation of KBH4 as this will result in higher gas release. Performing the 
reduction under continuous flow of Ar alleviates the need for additional safety measures for 
accumulated gas in the headspace of the reactor and may be required for optimal 
performance of the catalyst to obtain good conversion. In addition, without the need for 
maintaining pressurized H2 gas within the headspace this process lends itself to being safer 
than hydrogenation alleviating the need for specialized high pressure reactors.  
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Figure 15. Summary of results from calorimetry study at 40 mmol scale. 
 
 
Figure 16. Dynamic SEDEX thermogram of the reaction mixture after second portion 
addition of 1-chloro-4-nitrobenzene emulsion within 10 minutes at 20°C. 
 
5.6 Summary and Conclusions 
In conclusion, a safe, mild, and environmentally responsible scale-up process for the 
Fe/ppm Pd-catalyzed reduction of nitro compounds in water at room temperature was 
developed. This process benefits from the use of minimal amounts of palladium (80-200 
ppm) to catalyze the transformation, aqueous conditions leveraging micellar catalysis from a 
solution of TPGS-750-M, short reaction times to deliver highly pure product without 
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accumulation of highly energetic and toxic intermediates. Moreover, the developed process 
alleviates the necessity for highly pressurized hydrogenation equipment and can be run in 
any standard reactor showing no major safety concerns as determined through calorimetry 
experiments in comparison to classical hydrogenation. The work-up of this process is 
operationally simple, taking advantage of the aqueous nature of the process itself. This 
process is envisioned as offering promising conditions for late stage reductions of nitro-
group containing compounds involving mild conditions that have little-to-no-effect on 
functionalized substrates while yielding products with exceptionally low levels of residual 
Pd content. 
5.7 Experimental and Compound Data 
General Information 
Unless otherwise noted, all reactions were performed under an atmosphere of argon. A 
solution of 2 wt % TPGS-750-M/H2O solution was prepared by dissolving TPGS-750-M in 
degassed Millipore purified water. All commercially available reagents and solvents were 
used without further purification including TPGS-750-M (CAS-No. 1309573-60-1). Thin 
layer chromatography (TLC) was done using Silica Gel 60 F254 plates (Merck, 0.25 mm 
thick). The developed chromatogram was analyzed by UV lamp (254 nm). Flash 
chromatography was performed using a Biotage IsoleraTM Four using prepacked Biotage® 
SNAP Ultra cartridges. Hydrogenation experiments utilized Argonaut Technologies 
EndeavorTM Katalysator Screening system. 1H and 13C NMR were recorded at 297.8 K on a 
Bruker® 400 MHz spectrometer. The FID was processed using ACD Labs NMR analysis 
software. Chemical shifts in 1H NMR spectra are reported in parts per million (ppm) on the δ 
scale from an internal standard of residual CDCl3 (7.27 ppm) or the central peak of DMSO-
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d6 (2.50 ppm). Data are reported as follows:  chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, quin = quintet), and integration. Chemical shifts in 13C 
chemical spectra are reported in ppm on the δ scale from the central peak of residual CDCl3 
(77.0 ppm) or the central peak of DMSO-d6 (39.51 ppm). ICP-OES measurements were 
conducted by Solvias AG. Reaction profile based on analysis of UPLC/MS data using 
Acquity HSS T3 1.8 µm 2.1 x 50 mm at 60°C with the following eluent system: (A: water + 
0.05 % formic acid + 3.75 mM ammonium acetate; B: acetonitrile + 0.04% formic acid); 
gradient from 5 to 98 % B in 1.4 min; flow 1.0 mL/min. 
Preparation of Fe NP Precatalyst 
According to the procedure outlined in the literature,48 0.003 equiv of Pd(OAc)2 was 
used in relation to FeCl3. An Ar-purged, flame-dried 50 mL round bottom flask with Teflon 
coated stir bar was charged with Pd(OAc)2 (27.5 mg, 0.123 mmol) in a drybox, sealed with a 
septum, and then charged with 3.60 mL of dry THF. The mixture stirred under argon until a 
solution was achieved after ca. 15 min. A separate Ar-purged, flame-dried 150 mL round 
bottom flask with Teflon-coated stir bar was charged with anhydrous FeCl3 (1871.3 mg, 
11.54 mmol) in a drybox, sealed with a septum, and then charged with 30 mL of dry THF. 
The mixture was allowed to stir at rt for ca. 10 min before the addition of 1.13 mL Pd(OAc)2 
solution in THF (0.034 M). The mixture was allowed to stir for ca. 15 minutes before the 
dropwise addition of freshly titrated 2.7 M MeMgCl (~1 drop/sec). The dark black/brown 
endpoint was observed after a total of 4.80 mL (12.96 mmol; 1.12 equiv) MeMgCl had been 
added. The mixture continued to stir for ca. 15 min before removal of the stir bar and the 
mixture was evaporated to dryness under reduced pressure. The material was then scraped 
from the sides of the flask with a spatula and pulverized in flask before treatment with 25 
mL pentane. The solvent was stripped from the solid material and the pulverizing/stripping 
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procedure was continued twice more. The light grey, free flowing powder was transferred to 
an oven-dried 20-mL scintillation vial and set under high vac for ca. 2 days in a 
lyophilization chamber. The product catalyst was isolated as a light grey/brown free-flowing 
powder (5411.7 mg). The Pd content of the final product was calculated as follows: 
Total Pd in batch: 
0.0385 mmol Pd(OAc)2 = 0.0385 mmol Pd 
0.0385 mmol Pd x 106.4 mg/mmol Pd = 4.1 mg Pd 
From the total batch yield: 
5411.7 mg NP 
Pd content by mass (ppm): 
(4.1 mg Pd / 5411.7 mg NP) x 106 = 757 ppm Pd by mass 
“Molecular Weight” of Pd NP: 
0.0385 mmol Pd / 5411.7 mg NP = 7.11 x 10-6 mmol/mg 
Preparation of 4-chloroaniline hydrochloride (2)  
In a three-neck RC1 reactor with overhead stirring at 200 rpm, 1.117 g Fe nanomaterial 
(11.4 μmol Pd) was dissolved in 200.0 mL 2 wt % TPGS-750-M/H2O and 23.6 mL THF. 
KBH4 (8.091 g, 150 mmol) was slowly charged to the catalyst solution resulting in catalyst 
precipitation as black solids, foaming, and gas evolution. In a separate 500 mL reactor with 
overhead stirring, 1-chloro-4-nitrobenzene 1 (15.76 g, 100 mmol), was dissolved in 40 mL 
THF followed by the slow addition of 110.0 mL 2 wt % TPGS-750-M/H2O while stirring at 
1000 rpm. A milky emulsion was achieved after stirring ca. 30 min. Chloro-4-nitrobenzene 
emulsion (78.7 mL) was then transferred dropwise (1 drop/sec) via addition funnel with 
overhead stirring to the center of the reaction mixture. Upon reaction completion (as 
determined by TLC and UPLC/MS), the reaction was charged with an additional KBH4 
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(8.091 g, 150 mmol) followed by the remaining 70 mL of the chloro-4-nitrobenzene 
emulsion as described above. Upon completion after ca. 11 h, the reaction was exposed to 
air and quenched with 37% HCl to pH = 3 and stirred for ca. 1 h. The quenched reaction 
mixture was then extracted with 50 mL n-heptane to remove condensation by-products. The 
aqueous phase was then separated, charged back into the reaction flask and neutralized with 
11 M NaOH, precipitating 4-chloroaniline (2). The mixture was then extracted with 3 x 50 
mL isopropyl acetate, the organic layers were combined, filtered through Celite into a 500 
mL round bottom flask, concentrated under reduced pressure to ~75 mL and 75 mL n-
heptane was charged into the flask. The flask was then charged with a Teflon coated stir bar 
and 1 M HCl solution in EtOAc (110 mL, 110 mmol) was transferred via addition funnel at a 
rate of 1 drop/sec while stirring at 200 rpm leading to the precipitation of 4-chloroaniline 
hydrochloride as white crystals. Stirring continued for an additional 1 h after complete 
addition of HCl solution, the solid was collected via vacuum filtration and dried at 45 °C and 
0 torr for 18 h to afford 15.49 g (94%).  
General Nitro Group Reduction Procedure  
A 50 mL round bottom flask with Teflon-coated stir bar was charged with 16 mg Fe 
nanomaterial (0.11 μmol Pd) and was dissolved in 1.5 mL 2 wt % TPGS-750-M/H2O. KBH4 
(162 mg, 3.0 mmol) was slowly charged to the catalyst solution resulting in catalyst 
precipitation as black solids, foaming, and gas evolution. A separate 8 mL dram vial with a 
Teflon coated stir bar was charged with nitroarene (1.0 mmol), 0.4 mL THF, followed by the 
slow addition of 1.5 mL 2 wt % TPGS-750-M/H2O. The mixture was mixed via vortex and 
stirred at high speed (>1000 rpm) and approximately half of the mixture was transferred to 
the catalyst reaction. After complete conversion was observed via analysis by TLC and 
GC/MS (usually about ca. 4 h), the reaction was charged with KBH4 (162 mg, 3.0 mmol) 
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and the remaining portion of the starting material mixture. After ca. 16 h (reaction time not 
optimized), the crude product was extracted with 3 x 3 mL EtOAc, dried over anhydrous 
Na2SO4, and purified via flash chromatography.  
Characterization of Products 
 
 
Preparation of 4-chloroaniline hydrochloride (2).  1H NMR (500 MHz, DMSO-d6) δ 
10.12 (brs, 3H), 7.53 (dt, 2H), 7.39 (dt, 2H). 13C NMR (125 MHz, DMSO-d6) δ 132.02, 
131.66, 129.58, 124.68. 
 
 
5-Bromopyridin-2-amine (8).  
 157.6 mg, 91%. 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, 1H, J = 2.60, 0.52 Hz), 7.21 
(dd, 1H, J = 8.56, 0.52 Hz), 6.88 (dd, 1H J = 8.56, 3.11 Hz). 13C NMR (125 MHz, CDCl3) δ 
142.06, 137.01, 129.48, 127.75, 124.68. 1H & 13C NMR was in agreement with previously 
reported data on this compound.44 
 
 
(2,2-Dibromo-3,3-dimethylcyclopropyl)methyl 4-amino-benzoate (9).  
400.5 mg, 88%. 1H NMR (500 MHz, CDCl3) δ 7.88 (dt, 2H), 6.66 (m, 2H), 4.38 (m, 
2H), 4.12 (s, 2H), 1.78 (t, 1.78), 1.45 (s, 3H), 1.33 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
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166.37, 151.02, 131.69, 119.24, 113.74, 103.67, 99.03, 63.20, 43.73, 37.25, 28.96, 27.12, 
19.67. 
 
 
t-Butyl 2-(3-aminobenzoyl)hydrazine-1-carboxylate (10).  
233.0 mg, 93%. 1H NMR (500 MHz, DMSO-d6) δ 9.91 (d, 1H, J = 1.30 Hz), 8.78 (s, 
1H), 7.08 (t, 1H, J = 7.79 Hz), 7.03 (s, 1H), 6.95 (d, 1H, J = 7.53), 6.71 (ddd, 1H, J = 7.79, 
2.34, 0.78 Hz), 5.29 (s, 2H), 1.42 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ 166.73, 155.45, 
148.49, 133.49, 128.72, 116.97, 114.46, 113.05, 79.01, 28.11. 
 
 
Ethyl (E)-3-(4-aminophenyl)acrylate (11).  
181.9 mg, 93%.1H NMR (500 MHz, CDCl3) δ 7.60 (d, 1H, J = 16.09 Hz), 7.36 (m, 2H), 
6.65 (m, 2H), 6.24 (d, 1H, J = 15.8 Hz), 4.25 (q, 2H), 1.33 (t, 3H). 13C NMR (125 MHz, 
CDCl3) δ 167.65, 148.60, 144.79, 129.82, 124.76, 114.80, 113.75, 60.13, 14.37. 1H & 13C 
NMR was in agreement with previously reported data on this compound.45 
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5.8 NMR Spectra 
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 5-bromopyridin-2-amine_H1.esp
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 (2,2-dibromo-3,3-dimethylcyclopropyl)methyl 4-aminobenzoate_H1.esp
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 tert-butyl 2-(3-aminobenzoyl)hydrazine-1-carboxylate_H1.esp
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 ethyl (E)-3-(4-aminophenyl)acrylate_H1.esp
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5.9 Calorimetry Plots 
 
 
Figure 17. Reaction calorimetry of the initial KBH4 addition (3.2 g) within 10 min at 20°C. 
 
 
Figure 17. Reaction calorimetry of the initial 1-chloro-4-nitrobenzene emulsion addition 
within 10 minutes at 20 °C. 
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Figure 18. Reaction calorimetry of the second portion addition of 1-chloro-4-nitrobenzene 
emulsion addition within 10 minutes at 20 °C and 5 hours aging. 
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VI. Pd-Catalyzed Hydrazone Cross Coupling with Aryl Halides for 
One-Pot Access to Functionalized N-Heteroaromatic Scaffolds in Water 
6.1 Introduction 
One of the most significant structural components of pharmaceuticals is nitrogen 
containing heterocycles. In fact, in a 2014 survey of U.S. FDA approved drugs (1035 total) 
conducted by Njardarson and coworkers, they concluded that 59% of unique small molecule 
drugs contain a nitrogen heterocycle.1 Of these heterocycles, the ninth most prevalent was 
found to be indole which accounts for seventeen approved drugs. In addition to the 
frequency of indoles in approved drugs, this scaffold is found in an incredible number of 
natural products2 and is present in the essential amino acid tryptophan (Figure 1).  
 
 
Figure 1. Drugs and natural products containing indoles. 
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Discovered over a hundred years ago by Hermann Emil Fischer,3 indoles are classically 
prepared by condensation of an aryl hydrazine onto an enolizable ketone, catalyzed by a  
Lewis or Brønsted acid.4 This process is known as the Fisher indole synthesis, and goes by 
means of first, condensation of hydrazine with a ketone, followed by isomerization to the 
corresponding ene-hydrazine. A [3,3]-sigmatropic rearrangement affords the corresponding 
diamine intermediate that tautamerizes to restore aromaticity followed by condensation and 
extrusion of ammonia to afford the indole product (Scheme 1).5 
 
 
Scheme 1. Mechanism of the Fisher indole synthesis. 
 
This classical method is still employed today in many pharmaceutical processes due its 
predictability, simplicity, atom economy, and inexpensive components.6 Using this process, 
one can arrive at indoles with an array of substitution patterns depending on the nature of the 
aryl hydrazine and the enolizable ketone. What plagues this transformation, however is the 
limited structural diversity of available aryl hydrazines due to the methods by which they are 
generally prepared. Traditionally, aryl hydrazines are prepared using two classical methods, 
namely diazotization/reduction7 and nucleophilic aromatic substitution (SNAr) (Scheme 2).8 
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Scheme 2. Classical methods for the preparation of aryl-hydrazines. 
 
Due to the low cost and simplicity of diazotization, as well as the extent to which the 
transformation has been studied (this reaction first appeared in the literature over 130 years 
ago), this method remains as one of the most utilized procedure for the preparation of 
diazols and diazol derivatives such as hydrazines. While this inexpensive transformation can 
be pursued as an orthogonal approach to SNAr or Pd-catalyzed cross-coupling in obtaining 
hydrazines, considering that aryl halides are stable under these conditions, the cost still 
outweighs the benefits, especially in terms of safety. The use of concentrated HCl not only 
requires special handling, reaction vessels, and waste disposal, but also limits appropriate 
substrates in terms of stability and solubility properties. The stability requirement of the 
starting material is also complicated by the subsequent reduction step of the thermally labile 
diazonium salt. Each stage of this transformation possesses its own safety concerns 
including: a) the toxic nature of anilines,9 b) the use of highly caustic concentrated HCl, c) 
the thermal instability of diazonium salts, d) the use of highly toxic stannous chloride,10 and 
e) the production of highly toxic aryl hydrazines (as opposed to hydrazine surrogates).11 
Needless to say, this method is far from being regarded as environmentally responsible.  
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In comparison, SNAr reactions are widely utilized, not only for the synthesis of aryl 
hydrazines, but also for the synthesis of phenyl ethers, anilines, benzonitriles, and thioethers 
from activated aryl chlorides and fluorides.8 The ability of the substrate to undergo this 
substitution reaction relies heavily upon the presence of an electron withdrawing group, most 
commonly a nitro group, which allows for resonance stabilized Meisenheimer complex.12 
While SNAr has been proven as a highly effective and often environmentally responsible 
method for aromatic substitution, this method is limited by the structural characteristics of 
the aryl halide which must be activated toward the position being substituted (i.e. ortho/para 
nitro substitution). Based on these criteria, the resulting electron-deficient aryl hydrazine will 
require forcing conditions to effect the [3,3]-sigmatropic rearrangement in the Fisher indole 
synthesis mechanism. 
The drawbacks of the described methods for preparing aryl hydrazines can be summed 
up simply by saying, these methods lack generality. Therefore it can be concluded that more 
ideal conditions are necessary for the synthesis of aryl hydrazines, where the desired 
transformation would not be constrained by the structural diversity of the aryl component 
both in terms of electronics as well as functional group compatibility. Also, the ideal system 
would not pose the same environmental concerns as the classical approach, addressing both 
safety (which is clearly present for the diazotization/reduction procedure), as well as 
sustainability.  This method would not only expand the scope of available precursors to the 
Fisher indole synthesis, but also for other important N-heteroaromatics which are 
synthesized from aryl hydrazines such as carbazoles,13 pyrazoles,14 cinnolines,15 and many 
more which are found ubiquitously in pharmaceuticals and natural products.1  
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6.2 Background 
Since the recent advances in the field of palladium-catalyzed cross-coupling reactions, 
C-N bond formation of aryl halides via the Buchwald-Hartwig amination reaction has 
become a predominant method for preparing anilines and their derivatives.16 Relevant to the 
synthesis of aryl hydrazines, N-arylated benzophenone hydrazones can be accessed from the 
corresponding aryl halide (Scheme 3a).17 The benzophenone moiety can serve as a handle 
for selective coupling, hydrazine protection, and purification/isolation. Most commonly, the 
benzophenone hydrazone is hydrolyzed in methanolic p-toluensulfonic acid followed by 
subsequent cyclization to form indoles or condensation to the corresponding pyrazole 
(Scheme 3b). 
 
 
Scheme 3. Buchwald Modification of the Fisher indole synthesis. 
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The coupling of aryl halides and benzophenone hydrazone has surfaced in the literature 
several times, and while reaction conditions are relatively general in regards to base 
selection, reaction temperature, and solvent (KOtBu and refluxing toluene), notable 
improvements to the method were achieved by swapping the ligand, BINAP,17a for dppf17b 
or MePhos18 showing a very strong relationship between ligand selection and catalyst 
loading. The current conditions in the literature which may be regarded as the “greenest” 
method for performing this transformation requires a) low catalyst loading [0.1 mol % 
Pd(OAc)2, 0.2 mol % MePhos], b) the use of inexpensive base NaOH, and c) the reaction to 
be run at ~100 °C in amyl alcohol.18 To date, the method of choice industrially utilizes either 
BINAP or dppf as ligand in refluxing toluene (Scheme 4).19 The reason for this is most 
likely the result of the generality of these methods. For example, conditions utilizing BINAP 
have proven to be suitable for heterocyclic and functionalized substrates,17a while only 
simple, non-funtionalized substrates such as 4-bromoanisole and 4-bromotoluene have been 
reported utilizing the MePhos/Pd(OAc)2 catalyst system.18 Regardless of which method is 
used, the use of organic solvents and high temperatures are not ideal in terms of 
environmental impact. In fact, solvents with relatively high boiling points such as toluene 
and tert-amyl alcohol require additional energy for their removal. Therefore, a method that 
uses an alternate solvent system while retaining low catalyst loading and conserves energy 
would be ideal.  
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Scheme 4. Hydrazone cross coupling for access to an indazole scaffold. 
  
Another approach to the synthesis of aryl hydrazines is the cross coupling of hydrazine 
directly to an aryl halide. One such example of this was accomplished by Stradiotto and co-
workers from aryl chlorides and tosylates (Scheme 5).20 This procedure employs Mor-
DalPhos as ligand which is coordinated in situ from the [Pd(cinnamyl)Cl]2. This method was 
found to effectively deliver a wide range of substrates including those bearing electron-
withdrawing and donating groups, as well as heterocycles including pyridine, quinoline, 
pyrrole, affording product yields in the range of 27-97%. While the scope of this work is 
quite impressive, some drawbacks of this procedure should be noted. Presumably, the key to 
success of this method is the use of aryl electrophiles such as aryl chlorides and tosylates 
which undergo oxidative addition much less readily than their bromide or iodide 
counterparts in dilute concentration (0.1 M) which diminishes production of the diaryl 
hydrazine in the final product. Further limitations of this method are the use of high reaction 
temperatures (65-110 °C) under highly basic conditions which is not suitable for substrates 
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bearing more sensitive functionalities. Finally, the direct synthesis of aryl hydrazines is often 
undesirable due to their highly toxic nature and the difficulty by which they are purified. 
 
 
Scheme 5. Pd-catalyzed cross coupling of aryl chlorides and tosylates with hydrazine. 
 
Another interesting report for the direct synthesis of aryl hydrazines from aryl iodides 
desribes copper-catalyzed cross coupling of aqueous hydrazine in PEG-400 (Scheme 6).21 
This procedure further highlights limitations of direct aryl hydrazine synthesis as a one-pot 
procedure for subsequent N-tosylation, required for isolation of the product the efficiency of 
which is reflected in their yields (most are within the 50-90% range). In comparison to 
Stradiotto’s report,20 this method requires the use of more labile aryl iodides for decent 
yields as other aryl halides produced the products in lower yields, even at 120 °C. Where 
both of these methods suffer is from the use of aqueous hydrazine which is explosive and 
toxic.22 This is a major concern as both methods employ high reaction temperatures. In 
addition, the removal of residual hydrazine during the work-up stage is another safety 
concern, and the waste would require special disposal.  
 
 
Scheme 6. Pd-catalyzed cross coupling of aryl bromides and iodides with hydrazine. 
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With the advances in the area of accessing aryl hydrazines and their protected analogues, 
even the best systems require the use of organic solvents at high reaction temperatures. The 
consequence of this is that not only are recycling capabilities essentially non-existent, but 
also that isolation of the product is generally required prior to the subsequent condensation 
reactions. This seems tedious, considering that condensations to the corresponding N-
heterocycle simply requires a solvent switch (usually conducted in EtOH) and pH 
adjustment. We envisioned a process where the initial coupling would be conducted in 
aqueous surfactant at lower temperatures which would allow for either outcome where a 
protected hydrazine could be isolated or proceed to the formation of an N-heteroaromatic in 
one pot. Our hypothesis seemed reasonable for a system that produced aryl hydrazones via 
Pd-catalyzed cross coupling, as hydrolysis would be favorable under aqueous conditions, 
and the heterocyclic transformation would be pushed to completion by aromatization. 
6.3 Previous Work 
The capability of Pd-catalyzed cross coupling has been well established in our group, 
where we have shown numerous examples of these transformations over the past nine years, 
including: Suzuki-Miyaura,23 Heck,24 Kumada,25 Stille,26 Nigishi,27 Sonogashira,28 
Buchwald-Hartwig amination,29 and C-H activation.30 In 2010, our group reported the 
synthesis of protected anilines via Buchwald-Hartwig cross-coupling of protected ammonia 
equivalents (carbamates, sulfonamides, ureas) with aryl and heteroaryl halides in water 
enabled by micellar catalysis (Scheme 7).29a Notable features of this work include relatively 
low reaction temperatures, room temperature to 50 °C, in comparison to standard Pd-
catalyzed amination chemistry. These mild conditions are facilitated by the use of Takasago 
ligand, cBRIDP,31 and [Pd(allyl)Cl]2 in aqueous surfactant solution of 2 wt % TPGS-750-M. 
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Scheme 7. Installation of Protected Ammonia Equivalents onto Aromatic and 
Heteroaromatic Rings in Water Enabled by Micellar Catalysis. 
 
Based on this report we believed that this system could be used for the cross coupling of 
aryl halides and benzophenone hydrazone. The initial attempts included the coupling of 1,4-
dibromobenzene (1) as well as 4-bromoanisole (4) with benzophenone hydrazone, 2, (Figure 
2). From these initial results, it was determined not only was this transformation possible in 
aqueous surfactant, but also that only minor tuning would be necessary to develop a suitable 
method that with a broad substrate scope. In addition to the goals of developing a method for 
hydrazone coupling in water and one-pot access to N-heteroaromatics, it was envisioned that 
further optimization could potentially lead to a system under more mild conditions by 
replacing KOtBu with a weaker base in order to access scaffolds bearing labile functional 
groups which has yet to be addressed in prior reports of hydrazone coupling in the 
literature.17,18 
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Figure 2. Initial reactions for Pd-catalyzed cross coupling with benzophenone hydrazone. 
6.4 Results and Discussion 
From the initial report for amination under these conditions for the installation of 
protected ammonia equivalents, heating the reaction to 50 °C resulted in the expected 
outcome of improving reaction rate and conversion. It was considered that the yield for the 
coupling product of 4 to the corresponding benzophenone hydrazone (5) could be improved 
by heating, which was found to be true, affording 92% conversion after only two hours 
(Figure 3, entry 1). In comparison, other catalyst systems were screened, showing decreased 
conversion when Pd(OAc)2 was used in place of [Pd(allyl)Cl]2. The lower conversion is 
likely due to the higher activation barrier for generating the active Pd(0) from Pd(OAc)2 in 
comparison to [Pd(allyl)Cl]2 which is reduced via a different mechanism.32 Pd(tBu3)2 led to 
91% conversion, however, the reaction profile contained >5 unidentified impurities which 
were not present in any of the other systems (entry 3). In comparison to the catalysts 
typically used for this transformation in organic solvent, BINAP, dppf, and dtbpf yielded 
little-to-no-product (entries 4-6). 
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Figure 3. Initial catalyst screening for the synthesis of 5. 
 
Once it was determined that 4 could be successfully coupled under these conditions, a 
temperature screening was carried out in order to determine the maximum heat requirement 
of the system. It was found that by increasing the global concentration to 1.0 M, essentially 
the same outcome could be achieved at 30 °C as compared to 50 °C (Figure 4, entries 1 and 
4). 
 
 
Figure 4. Temperature and concentration screening for the synthesis of 5. 
 
Base screening for this system was carried out on the coupling of 3-bromobenzonitrile 
(6) examining conditions in the presence of various bases (Figure 5). Compound 6 was 
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chosen as the optimization substrate in this case for two reasons: (1) it is electronically 
deficient that facilitates oxidative addition readily. The idea was that if conditions where not 
suitable to turn over significant product for this “loaded case,” then the chances of coupling 
more difficult (electron rich) aryl halides would be unlikely; (2) one of the major by-
products encountered en route to Merck’s HIV inhibitor (Scheme 4) was due to the 
condensation of the benzophenone hydrazone onto the nitrile present in the product. As the 
goal of this base screening was to find a milder alternative to KOtBu, screening with 6 
which bears a nitrile serves to investigate functional group compatibility from the starting 
point of development. After screening only a few bases, it was realized that Et3N 
outpreformed KOtBu (Figure 5; entries 1 and 4). This outcome was quite surprising as very 
few methods in the literature utilize an amine base for Pd-catalyzed aminations.33 In fact, it 
was investigated extensively by Norrby and co-workers at AstraZeneca for the coupling of 
bromobenzene with morpholine, for the requirements of the Buchwald-Hartwig amination in 
terms of base. In these reports, it was concluded that the oxo-palladium species arising from 
ligation of the base to the palladium center was a requirement of the mechanism as shown by 
the lack of coupling product observed under conditions employing DBU as base.34 
 
 
Figure 5. Base screening for the synthesis of 7. 
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We can explain our findings by considering the aqueous nature of the system. 
Presumably, an equilibrium will exist where Et3N will deprotonate water to form hydroxide. 
The protonated amine may then act as a phase transfer catalyst to shuttle hydroxide into the 
micellar core thus allowing this transformation to proceed via Hartwig’s proposed 
mechanism.35 This was investigated for our system by employing our conditions in 
anhydrous toluene. In support of our findings, poor conversion to the coupled product 7 was 
observed (Figure 6, entry 1). Next, a phase transfer system was used employing 
tetramethylammonium hydroxide pentahydrate (TMAOH) in anhydrous toluene which 
afforded the coupled product in 59% yield. Finally, when the phase transfer system was used 
under micellar conditions, high conversion was met yet again, achieving a yield of 77%.  
 
 
Figure 6. Hydrazone cross coupling with a phase transfer catalyst. 
 
It should be noted that the base screening did expand past what is presented in Figure 6, 
as initial optimization was carried out on more difficult electron-rich aryl bromides 4 and 8 
(Figures 7 and 8). The stark contrast in conversion achieved, as shown in these Tables led to 
a very important observation that the order of addition is especially important for this 
system. It was found that for the initial screening represented in Figures 7 and 8, that adding 
base prior to addition of the coupling partners (e. g. the aryl halide and 2) caused a change 
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from pale yellow to red. By contrast, when base was added last for the screening represented 
in Figure 6 there was no change in appearance (the reaction remained yellow). Furthermore, 
those reactions which are represented in Figures 7 and 8 seemed to stall at very early 
reaction times. This is likely explained on the basis of work done by Colacot and co-workers 
where generation of the desired Pd(0) species from the corresponding allyl chloride complex 
is in competition with the comproportionation to the dinuclear Pd(I) species (Scheme 8).36 
While Pd(I) has been shown to catalyze a number of cross coupling reactions it may be 
inactive under these conditions. To this, we found that the diminished activity of the system 
under conditions where base was allowed to stir for an extended period of time prior to the 
addition of coupling components should be avoided, making the data acquired by this 
method somewhat irrelevant. Thus the screening represented in Figures 7 and 8 should be 
taken only under modest consideration in determining the correct base for the system. It was 
from this screening in fact that Et3N was considered as a suitable base for our conditions. 
 
 
Figure 7. Base screening for the synthesis of 9. 
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Figure 8. Base screening for the synthesis of 5. 
 
 
 
Scheme 8. Comproportionation pathway proposed by Colacot and co-workers. 
 
Et3N was considered the choice base for this system as a result of both its lower basicity 
in comparison to KOtBu, which could have major implications in terms of functional group 
compatibility, as well as its ubiquity in most organic labs. Because the conditions had 
changed to incorporate Et3N as base, an additional catalyst screening was conducted (Figure 
9). The screening was based on the coupling of 5-bromoquinoline (10) with 2. It is 
commonplace in methods development for all screening to optimize the transformation 
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based on a single substrate which may not translate well for other substrates even with 
structural and electronic similarity (see Chapter 3). For this reason, screening with 10 was 
chosen in order to consider important heterocycles such as quinolines. The previously 
established optimized conditions for the installation of ammonia equivalents29a were found 
to outperform all other systems tested (entry 9) with the exception of the pre-complexed 
Pd(II) species, PdCl(allyl)(cBRIDP) which afforded the product in quantitative yield (entry 
10). This screening probed some of the structural components required by the catalyst 
system for these conditions in that bulky, electron-rich ligands delivered products in highest 
yields (entries 4, 8, and 12). For these cases, it appears that the presence of the di-tert-butyl 
phosphine is a key feature of the ligand for highest conversion, likely due to their superior 
ability to facilitate reductive elimination. This hypothesis is supported by the comparison of 
cBRIDP to its dicyclohexylphosphine analogue Cy-cBRIDP which only yielded 19% 
product (entry 11). Pd(dtbpf)Cl2 resulted in the lowest overall yield for the series, which is 
quite interesting considering its reputation for facilitating reductive elimination in many 
transformations (entry 3).37 This suggests that the active 12 electron Pd(0) species is 
responsible for the facile conversion for this system, where the 14 electron Pd(0) species 
from the bi-dentate the bisphosphine in Pd(dtbpf)Cl2 is not especially effective for this 
system. 
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Figure 9. Catalyst screening with Et3N as base. 
 
The pre-complexed form of PdCl(allyl)(cBRIDP) was then compared to the use of 
(Pd(ally)Cl]2 and cBRIDP individually (Figure 10). This screening was carried out for the 
coupling of 1-bromo-2-methoxynaphthalene (12) with 2, investigating the lower threshold 
for catalyst loading. Napthyl bromide 12 was chosen based on the electron rich nature of the 
aryl halide due to its electron rich ortho-methoxy group which makes oxidative addition 
more difficult in comparison to 10. Best results were found at 2 mol % palladium loading in 
both cases with the individual catalyst components added individually affording a 92% 
isolated yield (entry 3) in comparison to the use of 2 mol % pre-coordinated complex which 
afforded an 86% yield (entry 1).  
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Figure 10. Comparision of PdCl(allyl)(cBRIDP) to [Pd(allyl)Cl]2 + cBRIDP. 
 
The optimized conditions examined for a representative scope of aryl halides are shown 
in Figure 11. In most cases, aryl hydrazone products were achieved in high yields within 
short reaction times. As expected, nitriles survive the conditions affording products in near 
quantitative yields, with 2-bromobenzonitrile coupling in only 30 minutes to afford 14. 
Compound 15 was isolated in 94% yield, showing great improvement over Buchwald’s 
method which required refluxing toluene over 16 hours to afford the same product in 72% 
yield.17a Sterics provided by ortho-substituents showed no obvious limitations (compounds 
13, 14, 16, 17, and 20) with no substitution for chloride being observed for products 17 and 
20. The low yield obtained for 19 was simply a factor of oxidative decomposition on the 
bench following purification, and it is believed that a higher yield is certainly achievable. 
Similarly, product 20 was isolated in only 60% yield most likely due to the short reaction 
time. Limitations were observed for this system, however, in that many electron rich aryl 
halides do not undergo coupling to an appreciable extent (<10% yield). Examples are shown 
in Figure 12, and it is believed that under conditions employing a stronger base (e.g. 
KOtBu), higher yields are achievable. This will be the focus of future investigations. 
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Figure 11. Representative examples of hydrazone coupling products under optimized 
conditions. 
 
 
 
Figure 12. Aryl halides affording <10% yield under optimized conditions. 
 
As mentioned previously, one the ultimate objectives of this methodology was to allow 
for one-pot access to N-heteroaromatics. Initial focus in this area was examination of the 
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ability of phenylhydrazine (21) to undergo the Fisher indole synthesis with 2-propanone in 
aqueous TPGS-750-M (Figure 13). At the onset of these experiments, it was found that the 
cyclization will proceed at room temperature with 1.1 equivalent of p-toluenesulfonic acid 
(p-TsOH). However, the rate at which condensation/cyclization occurs is not sufficient for 
practical use, and when the temperature was increased to 70 °C complete conversion to the 
desired indole was achieved (entry 1). Examining this transformation at lower temperatures, 
it was found that 50 °C led to the product indole cleanly in only two hours which was found 
to be independent of the presence of surfactant (entries 5, 6). As the Fisher indole synthesis 
is acid catalyzed, acid loading was decreased to 0.5 and 0.05 equivalents resulting in much 
slower conversion (entries 7, 8). Interestingly, ZnCl2 led only to the imine intermediate with 
cyclization only occurring in the presence of Brønsted acid (entries 9, 10). 
 
 
 
Figure 13. Condition screening for the Fisher indole synthesis from 21 and 2-pentanone. 
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Of course these preliminary experiments were only intended to understand the energy 
requirements for indole synthesis, and the actual desired transformation would require 
hydrolysis to liberate benzophenone from the aryl-hydrazone prior to indole synthesis. Focus 
then turned to examination of the same system from the corresponding hydrazone, 24, 
(Figure 14). First, in order to get a comparative reference, the reaction was conducted under 
standard literature conditions by refluxing in ethanol overnight in the presence of 1.1 
equivalents of p-TsOH affording an isolated yield of 82% (entry 1). Hydrolysis of the 
benzophenone was found to be quite difficult, affording no detectable product after 16 hours 
at 50 °C (entry 2). Increasing to 70 °C, indolization did occur, however these conditions 
required an extended reaction time of three days to afford only 73% conversion (entry 3). 
Similar to the findings in Figure 13, the use of Lewis acids offered no improvement with 
most systems being incapable of hydrolyzing the benzophenone hydrazone (entries 4-10).  
At this stage, it was considered that an alternate hydrazone could be used which would 
more readily undergo hydrolysis. In designing such a system, it was considered that 
substitution on the benzophenone scaffold would lead to hydrolysis at lower temperatures. 
Candidates were considered based on the IR C=O stretching frequencies, where a longer C-
O bond (lower wavenumber) suggests a weaker, more hydrolyzable bond. This hypothesis 
was met with success when the model reaction was conducted from four phenyl hydrazone 
derivatives at 70 °C with camphorsulfonic acid (CSA) affording quantitative conversion 
from the substrate bearing Michler’s Ketone hydrazone, 27 (Figure 15). The trend observed 
from the data in Figure 15 shows the direct correlation between resonantly donating groups 
and the extent of hydrolysis after ca. 13 hours. 
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Figure 14. Condition screening for the Fisher indole synthesis from 24 and 2-pentanone. 
 
 
 
Figure 15. Fisher indole synthesis in water from substituted N-phenylbenzopehone 
hydrazones. 
 
Showing that hydrolysis could be effected by the substitution of benzophenone 
hydrazone with Michler’s ketone hydrazone, the cross coupling of the parent hydrazone (28) 
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was investigated to prove its suitability as a nucleophile for the developed methodology. Not 
surprisingly, 28 was effectively coupled to 4-bromotoluene and 4-bromoanisole to afford the 
corresponding aryl hydrazones in good isolated yields (Scheme 9). It should be noted that 
these reactions were carried our prior to complete system optimization described above (e.g. 
catalyst loading and base screening), and these couplings should be carried out under those 
conditions which we believe will result in higher product yields.  
 
 
Scheme 9. Coupling procedure with Michler’s ketone hydrazone (28) as the nucleophile. 
 
In 2010, Fabis and co-workers described a method for the two step synthesis of 
substitruted 3-aminoindazoles from 2-bromobenzonitriles via Pd-catalyzed arylation of 
benzophenone hydrazone followed by an acid catalyzed cyclization sequence.38 As an initial 
attempt at accessing the 3-aminoindazole scaffold in one pot, 2-chlorobenzonitrile (31) was 
coupled with hydrazone 32, affording the corresponding aryl hydrazone in quantitative 
conversion (Scheme 10). p-TsOH (1.1 equiv) was then charged to the system and the 
mixture was allowed to stir at 70 °C overnight to deliver 3-aminoindazole 34 in 51% 
isolated yield. Again, it should be noted that this reaction was carried out prior to system 
optimization (as many of the hydrolysis experiments were carried out in parallel), so this 
example simply shows the capabilities of the system and it is believed that this product could 
be isolated in higher yields from the procedures described below. 
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Scheme 10. One pot synthesis of 3-amino indazole 34. 
 
The concept of developing a more hydrolyzable aryl hydrazone was originally pursued 
such that hydrolysis could occur at lower temperatures facilitating the one-pot 
transformation where heating of the system is minimized. Here, we are met with a trade-off 
between atom economy and energy input. While these systems may be desirable for  
temperature or acid sensitive substrates, it should be considered that for the synthesis of a N-
heteroaromatic scaffold, at most two nitrogens from the parent hydrazone are present in the 
final product (for pyrazoles and indazoles), or only one for the synthesis of indoles which 
simply translates to poor atom economy. Furthermore, the condensation/cyclization 
sequence may require additional energy input beyond what is required for hydrazone 
hydrolysis thus making this modification unnecessary.  
Because heating the system to 70 °C was already required for effective hydrolysis of 
Michler’s ketone, we had considered the use of higher loading of a stronger acid for the 
hydrolysis of benzophenone hydrazone. In addition to atom economy, this route was pursued 
on the basis of cost and availability. For example, the synthesis of 2 is simply achieved by 
refluxing hydrazine hydrate with benzophenone in EtOH from which the product is 
recrystallized in the reaction flask upon cooling. In comparison, synthesis of 28 is carried out 
in a bomb flask at 200 °C overnight requiring recrystallization in a separate step.39 Also, 2 is 
commercially available, relatively inexpensive, and unlike Michler’s ketone, benzophenone 
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is nontoxic.40 Furthermore, the use of an acid such as H2SO4 is significantly more cost 
effective than p-TsOH even when used in excess.  
Using 11 as a model substrate for the synthesis of N-heteroaromatic compounds, a few 
ketones were tested in the presence of 6.0 equivalents H2SO4 (Scheme 11). It was found that 
heating to 70 °C afforded products within short reaction times in quantitative conversion. It 
should be noted that this is the same temperature required for the most electron rich 
benzophenone hydrazone derivatives which required longer reaction times to reach 
completion. From these experiments, pyrazole 35 was produced in 99% isolated yield, where 
under the same conditions with 4-methylcyclohexanone afforded the corresponding indole 
(36) in quantitative conversion. Reaction of 11 with 2-acetylcyclohexanone under these 
conditions afforded pyrazoles 37 as a 72:28 mixture of regioisomers. 
 
 
Scheme 11. Representative examples of N-heteroaromatic synthesis in H2O. 
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The effect of reducing acid loading was investigated for the synthesis of 35. Figure 16 
shows the completion time for each loading, where 5.0 equivalents of H2SO4 afforded a 
parallel kinetic profile to the system with 6.0 equivalents. Full conversion was also achieved 
when acid loading was dropped to 3.0 equivalents, however, reaction completion required 5 
h. 
 
 
Figure 16. Kinetic profile of pyrazole 35 synthesis at different acid loadings. 
 
In addition to investigating the one-pot route to heterocycles, we envisioned a tandem N-
heteroaromatic synthesis followed by a sequential functionalization. As an example, 35 was 
synthesized from 11, and then submitted to bromination conditions. An initial attempt at this 
procedure showed only moderate conversion under previous conditions. It was found that the 
brominating reagent was being consumed by the excess ketone in the pot, undergoing α-
bromination. By reducing the ketone equivalents to 1.2 and increasing the bromination 
reagent equivalents to 1.5, it was found that high yields could be realized of the 
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corresponding brominated pyrazole (38) from N-bromosuccinimide (NBS), pyridinium 
tribromide, and BnNMe3Br3 (Figure 17). 
 
 
Figure 17. One-pot pyrazole cyclization/bromination from 11. 
6.5 Summary and Conclusions 
In conclusion, a method has been developed for the synthesis of aryl hydrazones via Pd-
catalyzed amination using benzophone hydrazones with aryl halides in water affording high 
yields within short reaction times. This system relies on Takasago’s ligand, cBRIDP, with 
[Pd(allyl)Cl]2, used under mild reaction conditions. Notable features of this method include 
the use of relatively low temperatures (rt to 45 °C) and Et3N, which is unprecedented for 
amination chemistry. Furthermore, this method allows for the one-pot synthesis of N-
heteroaromatics including pyrrazoles, indoles, and indazoles. Further exploiting these 
conditions for tandem operations, high yields were obtained for the synthesis of a pyrazole 
with subsequent bromination. Future development is nowunder way to expand the substrate 
scope to more electron rich aryl halides and the scope of N-heteroaromatic cyclizations. 
Additionally, we wish to investigate the hypothesis of disproportionation as it relates to the 
mode of reagent addition by synthesizing analogues of the PdCl(cBRIDP) pre-catalyst.  
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6.6 Experimental Procedures 
General Information 
A solution of 2 wt % TPGS-750-M/H2O solution was prepared by dissolving TPGS-750-
M in degassed HPLC grade water and was stored under argon. TPGS-750-M was made as 
previously described41 and is available from Sigma-Aldrich (catalog #733857). All 
commercially available reagents were used without further purification. Thin layer 
chromatography (TLC) was done using Silica Gel 60 F254 plates (Merck, 0.25 mm thick). 
Flash chromatography was done in glass columns using Silica Gel 60 (EMD, 40-63 μm). 
GC-MS data was recorded on a 5975C Mass Selective Detector coupled with a 7890A Gas 
Chromatograph (Agilent Technologies). A capillary column (HP-5MS cross-linked 5% 
phenylmethyl-polysiloxanediphenyl, 30 m x 0.250 mm, 0.25 micron, Agilent Technologies) 
was employed. Helium was used as the carrier gas at a constant flow of 1 mL/min. 1H and 
13C NMR were recorded at 22 °C on a Varian UNITY INOVA at 500 MHz. Chemical shifts 
in 1H NMR spectra are reported in parts per million (ppm) on the δ scale from an internal 
standard of residual CDCl3 (7.27 ppm) or the central peak of DMSO-d6 (2.50 ppm). Data are 
reported as follows:  chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, quin = quintet), integration, and coupling constant in Hertz (Hz). Chemical shifts in 
13C chemical spectra are reported in ppm on the δ scale from the central peak of residual 
CDCl3 (77.00 ppm) or the central peak of DMSO-d6 (39.51 ppm).  
Catalyst Screening with KOtBu as Base 
[Pd] (0.02 mmol), ligand (0.02 mmol), and degassed 2 wt % TPGS-750-M/H2O (1.0 mL) 
were sequentially charged to an argon purged microwave vial with Teflon-coated stir bar. 
The mixture was allowed to stir at 50 °C under argon for ca. 5 min. KOtBu (84.2 mg, 0.75 
mmol) was then charged to the reaction mixture followed by 4 (93.5 mg, 0.5 mmol) and 2 
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(107.9 mg, 0.55 mmol). The reaction was allowed to stir vigorously at 50 °C and monitored 
by TLC and GC-MS.  
Temperature and Concentration Screening  
[Pd(allyl)Cl]2 (0.9 mg, 0.0025 mmol), cBRIDP (3.5 mg, 0.01 mmol), and degassed 2 wt 
% TPGS-750-M/H2O were sequentially charged to an argon purged flask with Teflon-coated 
stirbar. The mixture was allowed to stir under argon for ca. 5 min. KOtBu (84.2 mg, 0.75 
mmol) was then charged to the reaction mixture followed by 4 (93.5 mg, 0.5 mmol) and 
benzophenone hydrazone (107.9 mg, 0.55 mmol). The reaction was allowed to stir 
vigorously for 2 h before analysis via GC-MS. 
Base Screening Procedures 
[Pd(allyl)Cl]2 (0.9 mg, 0.0025 mmol), cBRIDP (3.5 mg, 0.01 mmol), and degassed 2 wt 
% TPGS-750-M/H2O (1.0 mL) were sequentially charged to an argon purged microwave 
vial with Teflon-coated stir bar. The mixture was allowed to stir at 45 °C under argon for ca. 
5 min. Base was then charged to the reaction mixture followed by 6 (91.0 mg, 0.5 mmol) 
and 2 (107.9 mg, 0.55 mmol). The reaction was allowed to stir at 45 °C for ca. 24 h. The 
reaction was then extracted with 3 x 2 mL EtOAc, the organic extracts were combined, dried 
over anhydrous Na2SO4, filtered, concentrated, and purified by flash chromatography. 
[Pd(allyl)Cl]2 (0.9 mg, 0.0025 mmol), cBRIDP (3.5 mg, 0.01 mmol), and degassed 2 wt 
% TPGS-750-M/H2O (1.0 mL) and base were sequentially charged to an argon purged 
microwave vial with Teflon-coated stir bar. The mixture was allowed to stir at 45 °C under 
argon for ca. 5 min. 4 (93.5 mg, 0.5 mmol) or 8 (108.5 mg, 0.5 mmol) and 2 (107.9 mg, 0.55 
mmol) were then added. The reaction was allowed to stir at 45 °C and monitored by 
UPLC/MS.  
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Catalyst Screening Procedure with Et3N as Base 
[Pd] (0.01 mmol), ligand (0.01 mmol), and degassed 2 wt % TPGS-750-M/H2O (2.0 mL) 
were sequentially charged to an argon purged microwave vial with Teflon-coated stir bar. 
The mixture was allowed to stir at 45 °C under argon for ca. 5 min. Et3N (75.9 mg, 1.5 
mmol) was then charged to the reaction mixture followed by 10 (208.1 mg, 1.0 mmol) and 2 
(215.6 mg, 1.1 mmol). The reaction was allowed to stir at 45 °C for ca. 16 h. The reaction 
was then extracted with 3 x 2 mL EtOAc, the organic extracts were combined, dried over 
anhydrous Na2SO4, filtered, concentrated, and purified by flash chromatography. 
[Pd(allyl)Cl]2 and cBRIDP or PdCl(allyl)cBRIDP and degassed 2 wt % TPGS-750-
M/H2O (2.0 mL) were sequentially charged to an argon purged microwave vial with Teflon-
coated stir bar. The mixture was allowed to stir at 45 °C under argon for ca. 5 min. Et3N 
(75.9 mg, 1.5 mmol) was then charged to the reaction mixture followed by 12 (237.1 mg, 1.0 
mmol) and 2 (215.6 mg, 1.1 mmol). The reaction was allowed to stir at 45 °C for ca. 5 h. 
The reaction was then extracted with 3 x 2 mL EtOAc, the organic extracts were combined, 
dried over anhydrous Na2SO4, filtered, concentrated, and purified by flash chromatography. 
General Procedure 
 [Pd(allyl)Cl]2 (3.7 mg, 0.01 mmol), cBRIDP (7.0 mg, 0.02 mmol), and degassed 2 wt % 
TPGS-750-M/H2O (2.0 mL) were sequentially charged to an argon purged flask with Teflon-
coated stir bar. The mixture was allowed to stir at 45 °C under argon for ca. 5 min. Et3N 
(75.9 mg, 1.5 mmol) was then charged to the reaction mixture followed immediately by the 
aryl halide (1.0 mmol) and benzophenone hydrazone (215.6 mg, 1.1 mmol). The reaction 
was allowed to stir at 45°C until reaction completion by TLC. The reaction was then 
extracted with 3 x 2 mL EtOAc, the organic extracts were combined, dried over anhydrous 
Na2SO4, filtered, concentrated, and purified by flash chromatography. 
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Condition Screening for Fisher Indole Synthesis from Phenylhydrazine (21) 
21 (54.1 mg, 0.5 mmol), 2-pentanone (129.2 mg, 1.5 mmol), 2 wt % TPGS-750-M/H2O 
(1.0 mL), and acid were sequentially charged into a microwave vial Teflon-coated stir bar. 
The reaction was allowed to stir at a given temperature and analyzed by GC-MS. 
Condition Screening for Fisher Indole Synthesis from N-Phenyl Benzophenone 
Hydrazone (24) 
24 (136.2 mg, 0.5 mmol), 2-pentanone (129.2 mg, 1.5 mmol), 2 wt % TPGS-750-M/H2O 
(1.0 mL), and acid were sequentially charged into a microwave vial Teflon-coated stir bar. 
The reaction was allowed to stir at a given temperature and analyzed by GC-MS. 
Fisher Indole Synthesis Procedure from Substituted N-Phenyl Benzophenone 
Hydrazones 
Substituted N-Phenyl-benzophenone hydrazone (0.5 mmol), 2-pentanone (129.2 mg, 1.5 
mmol), 2 wt % TPGS-750-M/H2O (1.0 mL), and CSA (255.5 mg, 0.55 mmol) were 
sequentially charged a into microwave vial Teflon-coated stir bar. The reaction was allowed 
to stir at 70 °C for ca. 13 h and analyzed by GC-MS. 
One Pot Synthesis of 1H-indazol-3-amine (34) 
[Pd(allyl)Cl]2 (3.7 mg, 0.01 mmol), cBRIDP (7.0 mg, 0.02 mmol), and degassed 2 wt % 
TPGS-750-M/H2O (2.0 mL) were sequentially charged to an argon purged flask with Teflon-
coated stir bar. The mixture was allowed to stir at 45 °C under argon for ca. 5 min. Et3N 
(75.9 mg, 1.5 mmol) was then charged to the reaction mixture followed by the aryl halide 
(1.0 mmol) and benzophenone hydrazone (215.6 mg, 1.1 mmol). The reaction was allowed 
to stir at 45°C until reaction completion by TLC. The reaction was then extracted with 3 x 2 
mL EtOAc, the organic extracts were combined, dried over anhydrous Na2SO4, filtered, 
concentrated, and purified by flash chromatography. 
  323 
[Pd(allyl)Cl]2 (0.9 mg, 0.0025 mmol), cBRIDP (3.5 mg, 0.01 mmol), and degassed 2 wt 
% TPGS-750-M/H2O (1.0 mL) were sequentially charged to an argon purged flask with 
Teflon-coated stir bar. The mixture was allowed to stir under argon for ca. 5 min. KOtBu 
(84.2 mg, 0.75 mmol) was then charged to the reaction mixture followed by 31 (68.8 mg, 0.5 
mmol) and benzophenone hydrazone (107.9 mg, 0.55 mmol). The reaction was allowed to 
stir at 50 °C for ca. 16 h. The reaction was determined complete by GC/MS analysis and the 
mixture was neutralized with 1 M HCl. pTsOH (94.7 mg, 0.55 mmol) was transferred to the 
reaction and the temperature was increased to 70 °C. After ca. 15 h, saturated aqueous 
NaHCO3 was transferred to the reaction mixture and the crude product was extracted with 3 
x 2 mL EtOAc. Organic extracts were combined, dried over anhydrous Na2SO4, filtered, 
condensed, and purified by flash chromatography to afford 40.6 mg 34 (51% yield). 
Heterocycle Synthesis from 5-(2-(diphenylmethylene)hydrazinyl)quinolone (11) 
11  (80.85 mg, 0.25 mmol), ketone (1.5 mmol), 2 wt % TPGS-750-M/H2O (1.0 mL), 
and 6 M H2SO4 (0.25 mL, 1.5 mmol) were sequentially charged a microwave vial Teflon-
coated stir bar. The reaction was allowed to stir at 70 °C and analyzed by TLC and GC-MS. 
Acid Screening Procedure for the Synthesis of Pyrazole 35 
11  (80.85 mg, 0.25 mmol), acetylacetone (75.0 mg, 0.75 mmol), 2 wt % TPGS-750-
M/H2O (1.0 mL), and aqueous H2SO4 (0.25 mL, 1.5 mmol) were sequentially charged a 
microwave vial Teflon-coated stir bar. The reaction was allowed to stir at 70 °C until 
reaction completion as determined by TLC and GC-MS analysis. 
One Pot Pyrazole Synthesis/Bromination Procedure 
11  (80.85 mg, 0.25 mmol), acetylacetone (30 mg, 0.3 mmol), 2 wt % TPGS-750-
M/H2O (1.0 mL), and 5 M H2SO4 (0.25 mL, 1.25 mmol) were sequentially charged a 
microwave vial Teflon-coated stir bar. The reaction was allowed to stir at 70 °C until 
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reaction completion at ca. 4 h as determined by TLC and GC-MS analysis. The reaction was 
allowed to cool to 45 °C for ca. 30 min followed by the addition of the brominating reagent 
(0.75 mmol). Upon reaction completiong at ca. 30 minutes, saturated aqueous NaHCO3 was 
transferred to the reaction mixture and the crude product was extracted with 3 x 2 mL 
EtOAc. Organic extracts were combined, dried over anhydrous Na2SO4, filtered, condensed, 
and purified by flash chromatography. 
Synthesis of PdCl(allyl)(cBRIDP) 
Following the literature procedure,31a a flame-dried, argon-purged, 5 mL round bottom 
flask with a Teflon-coated stir bar, was charged [Pd(allyl)Cl]2 (109.8 mg, 3.0 mmol) and dry 
THF (1.5 mL) to give a clear yellow solution. cBRIDP (4, 15.0 g, 42.6 mmol, 2.1 equiv) was 
then added causing immediate precipitation of a pale yellow solid. The suspension was 
stirred for 2 h at 30 °C and n-heptane (5.5 mL) was added at the same temperature. The 
mixture was stirred for 2 h at 30 °C and filtered, triturated with n-heptane and dried under 
vacuum overnight to afford 300.0 mg PdCl(allyl)(cBRIDP) as a pale yellow solid (93%). 
 
 
Scheme 12. Preparation of substituted N-phenyl benzophenones. 
 
General Procedure for the Preparation of Substituted N-Phenyl Benzophenone 
Hydrazones.42 To an oven-dried 250 mL round bottom flask with Teflon coated stir bar and 
reflux condenser, argon was purged and benzophenone (3478.6 mg, 19.1 mmol), p-TsOH 
monohydrate (181.6 mg, 1.0 mmol), and EtOH (52 ml) were then added. Phenylhydrazine 
(1.9 mL, 19.1 mmol) was then transferred via syringe and the system was brought to reflux. 
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After ca. 4 h, the reaction mixture was removed from heating source and allowed to cool to 
rt and allowed to stand for ca. 16 h. The crystalline white solid was filtered and triturated 
with cold EtOH to afford pure benzophenone hydrazone 24 (4783.6 mg, 92%). 
 
 
Scheme 13. Preparation of hydrazone 32. 
 
(Bis(4-methoxyphenyl)methylene)hydrazine (32). Prepared following the literature 
prodedure:43 To an oven-dried 50 mL round bottom flask with Teflon coated stir bar and 
reflux condenser, bis(4-methoxyphenyl)methanone (5009.4 mg, 20.7 mmol), n-Bu (2.1 mL), 
and 86 % hydrazine hydrate (1.51 mL, 1.5 mmol) were transferred and the reaction was 
heated to 140 °C overnight. 20 mL MeOH was then transferred as the reaction cooled to rt. 
The mixture was set in the freezer overnight causing a large amount of precipitation. The 
solid was filtered, rinsed with cold EtOH and transferred to a 250 mL flask. The crude was 
then recrystallized from methanol to afford 32 as white crystals (4023.4 mg, 69%). 
 
 
Scheme 14. Preparation of Michler’s Ketone Hydrazone. 
 
Michler’s Ketone Hydrazone (28). Prepared following the literature prodedure:39 
Michler’s ketone (2.5 g, 9.3 mmol), 64% aqueous hydrazine (3.3 g, 66.1 mmol), and EtOH 
(1.7 mL) were heated to 200 °C in an autoclave (glass, applicable to 10 bar) for ca. 24 h. On 
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slow cooling and stirring, crystals deposited were separated by vacuum filtration and 
triturated with cold ethanol to afford pure 28 (2258.1 mg, 86%).  
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6.7 Compound Data 
Characterization of Products 
 
 
1-(4-Bromophenyl)-2-(diphenylmethylene)hydrazine (3). 72.2 mg (96%). 1H NMR 
(500 MHz, CDCl3) δ 7.62-7.56 (m, 4H), 7.52 (t, 1H), 7.42-7.24 (m, 7H), 7.06-6.99 (m, 2H). 
1H in agreement with previous reports of this compound.29 
 
 
1-(Diphenylmethylene)-2-(4-methoxyphenyl)hydrazine (5). 256.8 mg (85%). 1H 
NMR (500 MHz, CDCl3) δ 7.63-7.58 (m, 4H), 7.56-7.48 (m, 2H), 7.37-7.28 (m, 5H), 7.14 
(t, 1H), 6.80 (t, 1H), 6.58 (m, 1H), 6.43 (m, 1H), 3.83 (s, 3H). 1H in agreement with previous 
reports of this compound.44 
 
 
3-(2-(Diphenylmethylene)hydrazinyl)benzonitrile (7). 285.2 mg (96%). 1H NMR (500 
MHz, CDCl3) δ 7.67-7.56 (m, 6H), 7.44 (t, 1H), 7.41-7.29 (m, 6H), 7.22 (m, 1H), 7.11 (dt, J 
= 7.53, 1.30 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 146.33, 144.96, 137.63, 132.12, 
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129.75, 129.70, 129.50, 128.79, 128.54, 128.19, 126.64, 123.12, 119.05, 117.04, 115.78, 
112.88. 
 
 
5-(2-(Diphenylmethylene)hydrazinyl)quinolone (11). 314.3 mg (97%). 1H NMR (500 
MHz, CDCl3) δ 8.83 (dd, J=4.15, 1.30 Hz, 1H), 8.13 (s, 1H), 7.78 (dd, J = 7.27, 1.04 Hz, 
1H), 7.73-7.57 (m, 8H), 7.47-7.42 (m, 2H), 7.41-7.32 (m, 3H), 7.19 (dd, J = 8.56, 4.15 Hz, 
1H); 13C NMR (125 MHz, CDCl3) δ 149.81, 148.71, 147.01, 139.26, 137.75, 132.39, 
130.16, 129.75, 129.51, 128.83, 128.45, 128.17, 127.76, 126.66, 121.02, 119.42, 116.94, 
108.50.  
 
 
1-(Diphenylmethylene)-2-(2-methoxynaphthalen-1-yl)hydrazine (13). 325.8 mg 
(92%). 1H NMR (500 MHz, CDCl3) δ 9.18 (dd, 1H), 8.26 (s, 1H), 7.81 (dd, 1H), 7.69-7.64 
(m, 4H), 7.61-7.55 (m, 2H), 7.54-7.50 (m, 3H), 7.43 (m, 1H), 7.39-7.30 (m, 3H), 7.20 (d, 
1H), 3.81 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 146.62, 144.61, 138.42, 133.24, 130.22, 
129.48, 129.09, 129.03, 128.14, 127.88, 127.87, 126.61, 126.35, 125.18, 125.07, 123.84, 
122.61, 112.96, 56.88.  
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2-(2-(Diphenylmethylene)hydrazinyl)benzonitrile (14). 296.1 mg (99%). 1H NMR 
(500 MHz, CDCl3) δ 8.21 (s, 1H), 7.76 (dd, J=8.56, 0.52, 1H), 7.70-7.62 (m, 4H), 7.59 (m, 
1H), 7.53 (m, 1H), 7.42-7.36 (m, 6H), 6.85 (td, J=7.27, 1.04 Hz, 1H; 13C NMR (125 MHz, 
CDCl3) δ 148.23, 146.71, 137.49, 134.16, 132.10, 131.61, 129.90, 129.88, 128.86, 128.51, 
128.51, 128.26, 126.98, 119.32, 116.46, 113.52, 94.71. 1H and 13C NMR in agreement with 
previous reports of this compound.38 
 
 
1-(Diphenylmethylene)-2-(4-(trifluoromethyl)phenyl)hydrazine (15). 339.3 mg 
(94%). 1H NMR (500 MHz, CDCl3) δ 7.27 (s, 1H), 7.70-7.64 (m, 4H), 7.61 (tt, 1H), 7.56 (d, 
J=8.56 Hz, 2H), 7.44-7.36 (m, 5H), 7.18 (d, J=8.56 Hz, 2H; 13C NMR (125 MHz, CDCl3) δ 
147.06, 146.20, 137.87, 132.28, 129.74, 129.50, 128.93, 128.53, 128.24, 126.72, 126.54, 
126.51, 126.48, 126.45, 112.42. 1H and 13C NMR in agreement with previous reports of this 
compound.17a  
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1-(Diphenylmethylene)-2-(2-methyl-5-nitrophenyl)hydrazine (16). 323.5 mg (98%). 
1H NMR (500 MHz, CDCl3) δ 8.47 (d, J=2.34 Hz, 1H), 7.71-7.56 (m, 6H), 7.54 (s, 1H), 
7.41-7.35 (m, 5H), 7.11 (d, J=8.04 Hz, 1H), 1.91 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
147.74, 147.67, 142.98, 137.35, 132.30, 130.42, 129.79, 129.59, 128.71, 128.50, 128.25, 
127.20, 126.77, 113.90, 106.79, 16.57. 
 
 
1-(2-Chlorophenyl)-2-(diphenylmethylene)hydrazine (17). 264.0 mg (85%). 1H NMR 
(500 MHz, CDCl3) δ 8.16 (s, 1H), 7.84 (m, 1H), 7.72 (m, 2H), 7.65 (m, 2H), 7.58 (m, 1H), 
7.47-7.35 (m, 5H), 7.32 (m, 1H), 7.26 (m, 1H), 6.82 (m, 1H); 13C NMR (125 MHz, CDCl3) 
δ 146.51, 140.49, 137.97, 132.54, 129.66, 129.35, 128.91, 128.71, 128.34, 128.17, 127.83, 
126.69, 119.83, 117.32, 113.98. 1H and 13C NMR in agreement with previous reports of this 
compound.42 
 
 
4-((4-(2-(Diphenylmethylene)hydrazinyl)phenyl)sulfonyl)morpholine (18). 391.6 mg 
(93%). 1H NMR (500 MHz, CDCl3) δ 7.80 (s, 1H), 7.66-7.54 (m, 7H), 7.39-7.32 (m, 5H), 
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7.18 (d, 2H), 3.72 (t, 4H), 2.97 (t, 4H); 13C NMR (125 MHz, CDCl3) δ 148.08, 147.37, 
137.49, 131.92, 129.73, 129.60, 128.76, 128.19, 126.76, 124.53, 112.42, 65.96, 45.92.  
 
 
1-(Benzo[d][1,3]dioxol-5-yl)-2-(diphenylmethylene)hydrazine (19). 117.2 mg (37%). 
1H NMR (500 MHz, CDCl3) δ 7.62-7.55 (m, 4H), 7.55-7.49 (m, 1H), 7.42-7.25 (m, 6H), 
6.87 (d, 1H), 6.69 (d, 1H), 6.37 (dd, 1H), 5.91 (s, 2H); 13C NMR (125 MHz, CDCl3) δ 
148.43, 143.61, 141.27, 140.35, 138.34, 132.81, 129.65, 129.17, 129.12, 128.14, 127.86, 
126.35, 108.38, 104.74, 100.79, 95.80.  
 
 
5-Chloro-2-(2-(diphenylmethylene)hydrazinyl)-3-methylpyridine (20). 96.7 mg 
(60%). 1H NMR (500 MHz, CDCl3) δ 8.06 (d, 1H), 7.93 (s, 1H), 7.65-7.57 (m, 4H), 7.54 (tt, 
1H), 7.40-7.28 (m, 6H), 2.21 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 151.81, 148.08, 
143.73, 138.78, 137.64, 132.44, 129.77, 129.49, 119.30, 18.07.  
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3-Ethyl-2-methyl-1H-indole (23). 131.0 mg (82%). 1H NMR (500 MHz, CDCl3) δ 7.63 
(s, 1H), 7.57 (d, 1H), 7.29-7.26 (m, 1H), 7.17-7.10 (m, 2H), 2.76 (q, 2H), 2.39 (s, 3H), 1.27 
(t, 3H); 13C NMR (125 MHz, CDCl3) δ 135.23 130.06 128.46 120.76 118.92 118.03 113.90 
110.11 17.34 15.38 11.44. 1H and 13C NMR in agreement with previous reports of this 
compound.45  
 
 
1-(Diphenylmethylene)-2-phenylhydrazine (24). 4783.6 mg (92%). 1H NMR (500 
MHz, CDCl3) δ 7.63-7.58 (m, 4H), 7.54 (tt, 1H), 7.37-7.24 (m, 8H), 7.11-7.08 (m, 2H), 6.86 
(tt, 1H); 13C NMR (125 MHz, CDCl3) δ 144.60, 144.18, 138.37, 132.77, 129.66, 129.22, 
129.20, 129.15, 128.16, 127.98, 126.46, 120.04, 112.92. 1H and 13C NMR in agreement with 
previous reports of this compound.42 
 
 
1-((4-Methoxyphenyl)(phenyl)methylene)-2-phenylhydrazine (25). 2553.9 mg (88%). 
1H NMR (500 MHz, CDCl3) δ 7.63-7.50 (m, 3H), 7.36-7.22 (m, 7H), 7.13-7.05 (m, 4H), 
6.89-6.83 (m, 3H), 3.91+3.83 (2xs 13:87); 13C NMR (125 MHz, CDCl3) δ 164.48, 160.05, 
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144.65, 144.10, 138.69, 130.53, 129.58, 129.18, 1290.8, 128.11, 127.90, 127.82, 126.53, 
124.59, 119.91, 115.01, 113.59, 112.88, 112.77, 103.71, 103.70, 60.36, 55.34.  
 
 
1-(Bis(4-methoxyphenyl)methylene)-2-phenylhydrazine (26). 6552.0 mg (94%). 1H 
NMR (500 MHz, CDCl3) δ 7.55 (dt, 2H), 7.30-7.22 (m, 5H), 7.11-7.05 (m, 4H), 7.68 (dt, 
2H), 6.83 (tt, 1H), 3.91 (s, 3H), 3.83 (s, 3H).  
 
 
4,4'-((2-Phenylhydrazono)methylene)bis(N,N-dimethylaniline) (27). 1005.5 mg 
(74%). 1H NMR (500 MHz, CDCl3) δ 7.57-7.50 (m, 3H), 7.25-7.19 (m, 4H), 7.10-7.05 (m, 
2H), 6.86 (d, 2H), 6.79 (dt, 2H), 6.70 (d, 2H), 3.07 (s, 6H), 2.98 (s, 6H); 13C NMR (125 
MHz, CDCl3) δ 150.42, 150.26, 145.90, 145.37, 130.11, 129.04, 127.85, 120.23, 118.91, 
112.57, 112.49, 111.86, 40.45, 40.28.  
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4,4'-(Hydrazonomethylene)bis(N,N-dimethylaniline) (28). 2258.1 mg (86%). 1H 
NMR (500 MHz, CDCl3) δ 7.41 (dt, 2H), 7.21 (dt, 2H), 6.82 (dt, 2H), 6.65 (dt, 2H), 3.03 (s, 
6H), 2.97 (s, 6H). 1H in agreement with previous reports of this compound.39 
 
 
4,4'-((2-(p-Tolyl)hydrazono)methylene)bis(N,N-dimethylaniline) (29). 175.4 mg 
(86%). 1H NMR (500 MHz, CDCl3) δ 7.57 (d, 2H), 7.54 (s, 1H), 7.26 (dt, 2H), 7.09 (d, 2H), 
7.03 (d, 2H), 6.90 (dt, 2H), 6.74 (d, 2H), 3.09 (s, 6H), 3.02 (s, 6H), 2.33 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 150.30, 150.13, 145.28, 143.16, 132.06, 130.04, 129.46, 127.94, 
127.75, 127.69, 120.24, 112.51, 112.41, 111.77, 110.42, 40.36, 40.18, 39.96, 20.48.  
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4,4'-((2-(4-Methoxyphenyl)hydrazono)methylene)bis(N,N-dimethylaniline) (30). 
135.5 mg (70%). 1H NMR (500 MHz, CDCl3) δ 7.52 (dt, 2H), 7.41 (s, 1H), 7.22 (dt, 2H), 
7.03 (d, 2H), 6.90-6.79 (m, 4H), 6.74-6.66 (m, 2H), 3.78 (s, 3H), 3.06 (s, 6H), 2.98 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 193.90, 152.60, 150.33, 132.10, 130.08, 129.35, 127.67, 
126.20, 120.55, 120.35, 114.60, 113.79, 113.60, 112.46, 111.83 110.46, 55.68, 55.04, 40.02.  
 
 
2-(2-(Bis(4-methoxyphenyl)methylene)hydrazinyl)benzonitrile (33). 182.9 mg (99%). 
1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.71 (d, 1H), 7.58 (dt, 2H), 7.50 (m, 1H), 7.38 
(dd, 1H), 7.30 (td, 2H), 7.12 (td, 2H), 6.89 (td, 2H), 6.81 (td, 1H), 3.90 (s, 3H), 3.84 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 160.41, 160.27, 148.08, 146.98, 134.13, 132.18, 130.78, 
130.06, 128.53, 123.60, 118.88, 116.76, 115.14, 113.63, 113.45, 94.34, 55.31, 55.30, 55.29. 
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1H-Indazol-3-amine (34). 40.6 mg (51%). 1H NMR (500 MHz, CDCl3) δ 11.36 (s, 1H), 
7.67 (d, 1H), 7.27-7.16 (m, 2H), 6.89 (m, 1H), 5.30 (s, 2H). 1H in agreement with previous 
reports of this compound.38 
 
 
5-(3,5-Dimethyl-1H-pyrazol-1-yl)quinoline (35). 220.9 mg (99%). 1H NMR (500 
MHz, CDCl3) δ 8.92  (dd, 1H), 8.19 (dt, 1H), 7.18-7.73 (m, 2H), 7.51 (dd, 1H), 7.38 (dd, 
1H), 6.06 (s, 1H), 2.32 (s, 3H), 2.06 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 150.83, 149.28, 
149.27, 148.52, 141.33, 135.86, 131.98, 130.48, 128.37, 126.10, 125.38, 122.00, 105.77, 
13.49, 11.37.  
 
 
5-(4-Bromo-3,5-dimethyl-1H-pyrazol-1-yl)quinoline (39). 137.8 mg (91%). 1H NMR 
(500 MHz, CDCl3) δ8.96 (dd, 1H), 8.23 (dt, 1H), 7.80-7.76 (m, 2H), 7.51 (dd, 1H), 7.42 (dd, 
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1H), 2.34 (s, 1H), 2.09 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 151.09, 148.57, 148.02, 
139.54, 135.66, 131.67, 131.07, 128.43, 125.77, 125.48, 122.25, 95.55, 12.40, 10.91. 
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6.8 NMR Spectra 
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 1-(diphenylmethylene)-2-(4-methoxyphenyl)hydrazine_H1.esp
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 3-(2-(diphenylmethylene)hydrazinyl)benzonitrile_H1.esp
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 5-(2-(diphenylmethylene)hydrazinyl)quinolone_H1.esp
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 1-(diphenylmethylene)-2-(2-methoxynaphthalen-1-yl)hydrazine_H1.esp
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 2-(2-(diphenylmethylene)hydrazinyl)benzonitrile_H1.esp
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 1-(diphenylmethylene)-2-(4-(trifluoromethyl)phenyl)hydrazine_H1.esp
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 1-(diphenylmethylene)-2-(2-methyl-5-nitrophenyl)hydrazine_H1.esp
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 1-(2-chlorophenyl)-2-(diphenylmethylene)_H1.esp
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 4-((4-(2-(diphenylmethylene)hydrazinyl)phenyl)sulfonyl)morpholine_H1.esp
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 1-(benzo[d][1,3]dioxol-5-yl)-2-(diphenylmethylene)hydrazine_H1.esp
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 5-chloro-2-(2-(diphenylmethylene)hydrazinyl)-3-methylpyridine_H1.esp
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 3-ethyl-2-methyl-1H-indole_H1.esp
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 1-(diphenylmethylene)-2-phenylhydrazine_H1.esp
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 1-((4-methoxyphenyl)(phenyl)methylene)-2-phenylhydrazine_H1.esp
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 1-(bis(4-methoxyphenyl)methylene)-2-phenylhydrazine_H1.esp
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 4,4'-((2-(p-tolyl)hydrazono)methylene)bis(N,N-dimethylaniline)_H1.esp
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 4,4'-((2-(4-methoxyphenyl)hydrazono)methylene)bis(N,N-dimethylaniline)_H1.esp
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 2-(2-(bis(4-methoxyphenyl)methylene)hydrazinyl)benzonitrile_H1.esp
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 5-(3,5-dimethyl-1H-pyrazol-1-yl)quinoline_H1.esp
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 5-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)quinoline_H1.esp
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